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ABSTRACT 
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in Canada. 
Among non-traditional risk factors, plasma triglyceride (TG) concentration is re-
emerging as a significant risk factor. Patients with hypertriglyceridemia (HTG) – an 
archetypal complex phenotype defined by fasting plasma TG concentration >95
th
 
percentile – thus have significantly increased CVD risk, compounded by associated co-
morbidities such as obesity, metabolic syndrome and type 2 diabetes. However, the 
molecular pathways contributing to HTG susceptibility are incompletely defined. A 
better understanding of the genetic determinants that underlie the phenotypic spectrum of 
plasma TG and HTG susceptibility is necessary to identify novel genes and pathways that 
could be targeted to effectively lower plasma TG and improve cardiovascular risk. 
Accordingly, we sought to characterize the genetic architecture of HTG susceptibility and 
phenotypic heterogeneity using several modern genomic technologies, including high-
density microarray genotyping and high-throughput resequencing of candidate genes in 
HTG patients and healthy controls. We demonstrate that a broad allelic spectrum of 
common small effect variants and rare large effect variants is associated with HTG. 
Furthermore, we demonstrate that significant overlap exists between genes and variants 
that modulate plasma TG and increase HTG susceptibility. Taken together, we suggest 
that HTG susceptibility is the result of a genetic burden of TG-raising alleles in genes 
that modulate plasma TG concentration. These findings provide a breadth of novel targets 
for pharmaceutical development in hopes of reducing plasma TG concentration and 
improving cardiovascular risk in HTG patients. 
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KEYWORDS: cardiovascular disease, atherosclerosis, plasma triglycerides,  
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nucleotide polymorphisms, mutations, genome-wide association studies, rare variant 
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CHAPTER 1 
 
INTRODUCTION 
 
This chapter is based on material from the following publications: (1) Johansen CT and 
Hegele RA. (2009). Predictive genetic testing for coronary artery disease. Crit Rev Clin 
Lab Sci 46(5-6): 343-60; (2) Johansen CT, Lanktree MB, and Hegele RA. (2010). 
Translating genomic analyses into improved management of coronary artery disease. 
Future Cardiol 6(4): 507-21; (3) Johansen CT, Kathiresan S, and Hegele RA. (2011). 
Genetic determinants of plasma triglycerides. J Lipid Res 52(2): 189-206; and (4) 
Johansen CT and Hegele RA. (2011). Genetic bases of hypertriglyceridemic 
phenotypes. Curr Opin Lidiol 22(4): 247-53; and (5) Johansen CT and Hegele RA. 
(2011). Allelic and phenotypic spectrum of plasma triglycerides. Biochim Biophys Acta. 
Submitted. 
 
1.1 Cardiovascular disease 
Cardiovascular disease (CVD) is a broad term referring to diseases involving blood 
vessels and the heart. Ischemic CVD is defined by a pathological process called 
atherosclerosis, a chronic inflammatory-metabolic disease in which accumulation of 
plaque causes thickening of the arterial wall (Roy et al., 2009). Acute cardiovascular 
events occur when atherosclerosis is sufficiently advanced to result in complete arterial 
occlusion from either narrowing of the artery or plaque rupture and subsequent 
thrombosis, processes that both prevent delivery of oxygenated blood to cardiac and 
1
 
 
cerebral tissues, leading to ischemia and necrosis unless blood flow is restored. Coronary 
artery disease (CAD) refers to plaque formation specifically in the coronary arteries, 
which impairs cardiac blood flow causing chronic conditions such as angina pectoris or 
acute conditions such as myocardial infarction (MI). Cerebrovascular disease refers to 
occlusion of the carotid arteries, which impairs cerebral blood flow resulting in chronic 
conditions such as transient ischemic attacks and acute conditions such as stoke.  
 
According to the World Health Organization (WHO), CVD is the primary global 
cause of death (http://www.who.int/mediacentre/factsheets/fs317/en/index.html). In 2004, 
17.1 million people world-wide died from CVD (29% of deaths), including 7.2 million 
deaths resulting from CAD and 5.7 million deaths resulting from stroke. Projection of 
these statistics suggests that in the year 2030, ~23.6 million deaths will be caused by 
CVD. In Canada, the incidence of disease is equivalent to WHO rates, causing 1/3 of 
Canadian deaths and resulting in $22 billion in direct and indirect health care costs 
(Genest et al., 2009). Therefore, understanding of CVD susceptibility and identification 
of effective prevention strategies are essential to reduce the burden of this prevalent, 
asymptomatic and irreversible disease.  
 
1.1.1. Pathophysiology 
The formation of an atherosclerotic lesion is a complex pathophysiological process 
involving multiple cellular and molecular interactions between endothelial cells, 
monocytes, and smooth muscle cells (Wagenseil and Mecham, 2009). These cell types 
are found in distinct layers of the arterial wall, including the intima (inner layer), media 
2
 
 
(middle layer) and adventia (outer layer) (Figure 1.1). The intima is a layer of 
extracellular matrix composed of elastic fibers, proteoglycans and collagen. It is bounded 
by a monolayer of endothelial cells that form a selective barrier between arterial blood 
flow and subsequent layers of the artery wall. The media is composed of smooth muscle 
cells that regulate vascular tone through contraction and dilation in response to external 
signaling cues. The adventia is the strongest layer, composed predominantly of 
connective tissues such as collagen, which provide arterial structure and shape.  
 
Lesion formation begins with endothelial cell dysfunction (Figure 1.2). Physical forces 
such as fluid shear stresses resulting from blood flow lead to disruption of intercellular 
tight junctions between endothelial cells (Gimbrone, 1999). Dysregulation of the 
selective barrier allows passage of cholesteryl ester (CE)-rich low-density lipoprotein 
(LDL) into the intima-media space, which become retained, oxidized and capable of 
eliciting an immune response from endothelial cells (Lusis, 2000). Simultaneous 
exposure of endothelial cells to environmental stresses that accentuate endothelial 
dysfunction, including traditional risk factors such as dyslipidemia, hypertension, and 
dysglycemia, also stimulate endothelial cell expression of cell adhesion molecules that 
facilitate transmigration of monocytes from blood into the intima-media space (Libby and 
Theroux, 2005). Together, these processes recruit monocytes in the intima-media, which 
differentiate into macrophages in response to pro-inflammatory cytokines. Macrophages 
internalize lipoproteins via scavenger receptors on the cell surface and transform into 
metabolically-inactive lipid-loaded foam cells. It is the accumulation of foam cells in the 
intima-media which form a fatty streak, the initiation of an atherosclerotic plaque. 
3
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Simplified cross section of a normal artery. Endothelial cells provide a 
selective barrier between the capillary lumen and the arterial intima. The intima is a layer 
of extracellular matrix composed of elastic fibers, proteoglycans and collagen. The media 
is a layer of smooth muscle cells that regulate contractility and dilation. The adventitia is 
a strong layer of connective tissue that provides artery structure and shape. 
Atherosclerotic plaques develop between the intimal and medial layers of the artery wall. 
Figure adapted from (Lusis, 2000). 
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Accumulation of foam cells initiates a feed-forward loop of plaque progression 
involving cytokine secretion, monocyte recruitment and foam cell formation that 
progresses atherosclerotic lesion development. Eventually, the proinflammatory state of 
the developing atherosclerotic plaque stimulates migration of smooth muscle cells into 
the intima-media space, which proliferate and attempt to stabilize the growing lesion by 
secreting extra-cellular matrix proteins, including proteoglycans, collagen and fibronectin 
(Doran et al., 2008). These extra-cellular matrix components enhance retention of plasma 
lipoproteins and secretion of pro-inflammatory cytokines by smooth muscle cells. 
Recruitment of leukocytes such as T-cells leads to a chronic inflammatory state. Lipid-
laden foam cells at the center of an ischemic plaque eventually die and release cellular 
debris and crystalline lipid into the necrotic core of the atherosclerotic plaque (Libby and 
Theroux, 2005). Eventually, acute complications such as MI or stroke will occur, 
resulting from one of two mechanisms (Rader and Daugherty, 2008): 1) expansion of the 
atherosclerotic plaque until arterial blood flow is completely obstructed; or 2) plaque 
rupture causes release of cellular debris including tissue factor, which stimulates 
formation of an intra-arterial blood clot called a thrombus that obstructs blood flow.  
 
1.1.2. Traditional risk factors 
Many epidemiological studies have attempted to identify clinical and biochemical 
variables or “biomarkers” that accurately predict atherosclerosis susceptibility in large 
populations. These studies employ different statistical analyses to estimate the effect of 
each variable on CAD risk, such that risk prediction algorithms can calculate the 
likelihood of experiencing an acute coronary event within a 10-year period, based on 
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each patient’s individual data. Such risk prediction algorithms are used to stratify patients 
according to CAD risk to guide intensity of evidence-based treatments. For example, a 
low risk patient with a 10-year risk of CAD <5% would have a liberal target LDL 
cholesterol value and would likely not require any intervention for primary prevention of 
CAD in the short term. Conversely, a high-risk patient with a 10-year risk >20% would 
have strict target values for LDL cholesterol, blood pressure and glucose, requiring 
aggressive treatment to reduce risk through both therapeutic lifestyle changes and 
pharmacological intervention. Another emerging perspective includes implementation of 
‘lifetime’ risk prediction algorithms to stratify patients early in life according to their 
potential CAD risk. Such a strategy could help guide lifestyle and potentially 
pharmacological interventions to reduce a patient’s cumulative exposure to CAD risk 
factors over their lifetime, and presumably improve cardiovascular outcomes (Lloyd-
Jones, 2006). 
 
Risk prediction algorithms include the Framingham risk score (Wilson et al., 
1998), the Reynolds risk score (Ridker et al., 2007, Ridker et al., 2008), the Prospective 
Cardiovascular Munster (PROCAM) (Assmann et al., 2002), and the Atherosclerosis 
Risk in Communities (ARIC) Study Cardiovascular Risk Score (Morrison et al., 2007). 
These algorithms are very similar, differing mainly in details due to the populations in 
which they were derived. In both Canada and United States, the Framingham risk score is 
currently used to classify and treat patients according to their potential CAD risk as 
indicated by the 2009 Canadian Cardiovascular Society/Canadian guidelines for the 
diagnosis and treatment of dyslipidemia and cardiovascular disease in the adult (Genest et 
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al., 2009) and National Cholesterol Education Program (NCEP) Adult Treatment Panel 
III (ATP-III) guidelines (Expert Panel on Detection; Evaluation; and Treatment of High 
Blood Cholesterol in Adults, 2001), respectively. It is calculated using a patient’s age, 
gender, blood pressure, total cholesterol, high-density lipoprotein (HDL)-cholesterol, 
diabetes status, and smoking status. These variables are robustly associated with CAD 
across multiple epidemiological studies; however additional variables are occasionally 
implemented in other algorithms, including family history, additional lipid markers, 
apolipoproteins, and novel biomarkers such as high sensitivity C-reactive protein.  
 
Select CAD risk factors worth discussion are age, gender, dyslipidemia, 
hypertension, type 2 diabetes (T2D), and family history of CAD. Advanced age is a non-
modifiable risk factor for CAD, but the strongest predictor of cardiovascular events 
(Sniderman and Furberg, 2008). Direct effects of advanced age include increased 
stiffening of the artery walls, vascular calcification, endothelial cell dysfunction and cell 
adhesion molecule expression (Lee and Oh, 2010). Other traditional biochemical risk 
factors such as total cholesterol, blood pressure, body mass index and sex hormones are 
also correlated with increasing age, suggesting that indirect effects of advanced age may 
also increase cardiovascular risk (Jousilahti et al., 1999). 
 
 Gender is also a non-modifiable risk factor for CAD. Female sex appears to have 
a protective effect on atherosclerosis progression in pre-menopausal women compared to 
age-matched men; CAD onset appears to be delayed by approximately 10-years. This 
gender disparity has been attributed to the cardioprotective effects of estrogen. These 
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include antioxidant effects, improved lipid profiles including decreased LDL cholesterol 
and increased HDL cholesterol, and reduced vascular inflammation (Villablanca et al., 
2010). The mechanisms underlying the protective effect of estrogen are poorly 
understood, as cardioprotection is only observed in pre-menopausal women, while 
paradoxically hormone replacement therapy does not appear to reduce cardiovascular risk 
if initiated more than 10 years post-menopause  (Perez-Lopez et al., 2010).  
 
Dyslipidemia is the most well-established modifiable atherosclerosis risk factor 
(Kannel et al., 1979). Increased total cholesterol, increased LDL cholesterol and 
decreased HDL cholesterol all contribute significantly to elevated cardiovascular risk. 
Increased concentrations of LDL cholesterol have a direct role in atherosclerosis 
progression, as discussed above. Randomized controlled trials have demonstrated that 
pharmacological lowering of LDL cholesterol is an effective measure to prevent 
atherosclerosis, decreasing risk of CAD proportionally to the decrease in LDL cholesterol 
(Baigent et al., 2010, Baigent et al., 2005). By comparison, decreased concentrations of 
HDL cholesterol may impair effective reverse cholesterol transport, a process that 
effluxes unesterified cholesterol from peripheral tissues for delivery to the liver and 
subsequent excretion (Rader, 2007). HDL particles mediate the efflux of cholesterol from 
macrophages in atherosclerotic plaques; thus, HDL cholesterol concentration has a strong 
inverse relationship with intima-media thickness (Khera et al., 2011). Interestingly, 
pharmacological strategies used to increase HDL cholesterol would be expected to 
attenuate foam cell formation and confer atheroprotection in humans, however only 
modest evidence supporting a positive therapeutic effect for increasing HDL cholesterol 
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concentration currently exists (Singh et al., 2007). Future investigation of different 
pharmacological agents with various biological effects on components of the reverse-
cholesterol transport pathway may eventually reveal therapies with potential 
atheroprotective effects. 
 
 Other modifiable CAD risk factors including increased blood pressure and T2D 
also accentuate the metabolic dysfunction that perpetuates CAD. For instance, normal 
fluid dynamics cause shear stresses that disrupt intercellular tight junctions between 
endothelial cells. Thus, it is not surprising that high blood pressure (or hypertension) is 
also strongly associated with CAD (Vasan et al., 2001). Increased systolic blood pressure 
accentuates sheer stresses on the vascular endothelium, which stimulates a pro-adhesive 
endothelial cell phenotype causing greater recruitment of monocytes into growing 
atherosclerotic plaques (Malyszko, 2010). Similarly, impaired insulin signaling that 
accompanies increased plasma concentrations of glucose and insulin in T2D disrupts 
metabolic processes in multiple tissues that enhance conditions such as dyslipidemia, 
hypertension, arterial hardening, and endothelial dysfunction (Ginsberg, 2000). T2D is 
considered a CAD equivalent by the Canadian and ATP-III Guidelines, meaning that a 
patient with established T2D has a similar chance of experiencing an acute cardiovascular 
event as a patient without T2D who has already experienced an event (Juutilainen et al., 
2005). 
 
Interestingly, a very strong independent CAD risk factor not included in most risk 
prediction algorithms is a family history of CAD (Lusis et al., 2004). A family history of 
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premature CAD is thought to encompass several genetic variables that contributes to 
intermediate trait modulation and CAD susceptibility, including genetic variants, 
epigenetic factors, and higher-order gene-gene and gene-environment interactions that are 
essential for disease pathogenesis but would otherwise be difficult to directly implicate in 
disease susceptibility (Lanktree and Hegele, 2009). Many studies have shown that family 
history is an independent risk factor for CAD (Arnett et al., 2007, Lloyd-Jones et al., 
2004, Michos et al., 2005, Murabito et al., 2005, Taraboanta et al., 2008). Even in the 
Framingham Heart Study, family history was determined to be an independent risk factor 
for CAD, although due to a lack of thorough documentation for all study subjects, it was 
not included in the multivariate regression equation that gave rise to the Framingham risk 
score (Myers et al., 1990). Regardless, family history is still considered to be a major risk 
factor for CAD by the Canadian and ATP-III guidelines (Expert Panel on Detection; 
Evaluation; and Treatment of High Blood Cholesterol in Adults, 2001, Genest et al., 
2009); it is also included as a variable in the Reynolds risk score algorithm (Ridker et al., 
2007, Ridker et al., 2008). Similar associations continue to show that family history of 
CAD is a risk factor for disease even in multi-ethnic samples, and for various 
endophenotypes of cardiovascular disease, including coronary artery calcification, 
ischemic cerebrovascular disease, and carotid intima-media thickness (Choi et al., 2009, 
Nasir et al., 2007, Wang et al., 2003). 
 
1.1.3. Plasma triglyceride concentration as an emerging risk factor 
Traditional risk factors are well established in CAD susceptibility, however many novel 
or emerging risk factors have been proposed to contribute to atherosclerosis progression. 
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For instance, multiple lines of evidence suggest that plasma triglyceride (TG) 
concentration is another significant risk factor for CAD, independent of other plasma 
lipoproteins. Most historical studies have studied fasting plasma TG concentration as a 
risk factor, demonstrating that it is associated with an increased burden of both CAD 
(Cullen, 2000, Morrison and Hokanson, 2009) and ischemic stroke (Labreuche et al., 
2009). A longstanding estimate originating from meta-analysis of 17 studies including 
46,413 men and 10,864 women indicated that each 1 mM increase in fasting plasma TG 
concentration increased risk of CAD by 32% and 76%, respectively (Hokanson and 
Austin, 1996). More recently, investigations have demonstrated that nonfasting plasma 
TG concentration is additionally associated with cardiovascular events in women, 
increasing cardiovascular risk by 67% per 1 mM increase in plasma TG concentration, 
(Bansal et al., 2007). Similar associations have emerged from additional epidemiological 
studies in both men and women, reporting significant associations with increased risk of 
both CAD (Nordestgaard et al., 2007) and ischemic stroke (Freiberg et al., 2008). 
Together with historical data, these recent observations strongly underscore the re-
emergence of plasma TG concentrations as a risk factor for CAD.  
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1.2. Plasma triglycerides and triglyceride-rich lipoprotein metabolism 
 
1.2.1. Plasma lipids  
Three essential types of lipids are transported in plasma by lipoproteins: cholesterol, 
phospholipids and TG (Figure 1.3). Cholesterol has several important biological 
functions, including maintenance of fluidity in cell membranes, steroid synthesis in 
steroidogenic tissues, and synthesis of bile acids. It is a hydrophobic molecule primarily 
synthesized by the liver but also obtained exogenously from diet and transported through 
the plasma in lipoproteins to target organs. Phospholipids are amphipathic molecules 
composed of a 3-carbon glycerol molecule esterified to 2 hydrophobic fatty acids (FAs) 
and 1 hydrophilic phosphate group. Their amphipathic properties make them an essential 
component of cell membranes, lipoproteins and micelles. TG is an insoluble molecule 
comprised of three FAs esterified to a glycerol backbone. TG molecules serve multiple 
biological functions, including transport of high energy FAs to muscle cells for β-
oxidation and to adipocytes for storage in lipid droplets. TG-mediated sequestration of 
FAs is also necessary to protect cells from lipotoxicity due to their inherent detergent 
properties, and to regulate their action as energy sources, ligands and signaling 
molecules. TG is obtained primarily from our diet, although tissues such as adipose and 
muscle can synthesize TG de novo. 
 
1.2.2. Plasma lipoproteins 
Plasma lipids are primarily transported through plasma in specialized structures called 
lipoproteins (Figure 1.3). Conceptually, lipoproteins are spherical biochemical particles 
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Figure 1.3. Plasma lipids are transported through plasma in structures called 
lipoproteins. Plasma lipids including CE and TG are transported in the hydrophobic core 
of plasma lipoproteins, solubilized by amphipathic phospholipids and free cholesterol. 
Apolipoproteins embedded in the surface of lipoproteins mediate interactions of different 
lipoprotein species with specific cellular receptors and enzymes. This figure was created 
using Servier Medical Art. 
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of variable size that contain a hydrophobic core of non-polar lipids including TG or CE 
solubilized by an outer membrane of phospholipid and free cholesterol. Lipoproteins also 
contain accessory proteins called apolipoproteins embedded in their surface that modulate 
lipoprotein interactions with their environment. Depending upon their location of 
synthesis, target destination, apolipoprotein content and specific lipid composition, 
lipoproteins have a range of physiological roles mediated through interactions with 
different cell surface receptors and metabolizing enzymes.  
 
Importantly, biochemical measurement of plasma TG concentration is effectively 
an integrated measurement of TG-rich lipoprotein concentration, including intestinally-
synthesized chylomicrons in the post-prandial state and hepatically-synthesized very low-
density lipoproteins (VLDL) in the fasted state. Chylomicrons are composed of 80-95% 
TG obtained exogenously from diet, whereas VLDL is composed of 45-65% TG 
synthesized endogenously or recycled from chylomicron-remnants. 
 
1.2.3. Plasma lipoprotein metabolism 
TG metabolism can be considered as being compartmentalized into three separate 
processes: exogenous TG absorption and endogenous TG synthesis, intracellular TG-rich 
lipoprotein processing and circulating TG-rich lipoprotein metabolism (Figure 1.4). 
Exogenous dietary TG is catabolized by gastric lipases into glycerol and FA that are 
subsequently emulsified into mixed micelles by phospholipid, free cholesterol and bile 
salts (Iqbal and Hussain, 2009). From these structures, FAs are transported across the 
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intestinal brush border of the duodenum by passive diffusion and FA binding protein-
mediated mechanisms (Mansbach and Gorelick, 2007). Within the intestinal enterocytes, 
TG is re-synthesized from its components via progressive enzymatic reactions involving 
monoacylglycerol acyltransferase (MGAT) and diacylglycerol acyltransferase (DGAT) in 
the endoplasmic reticulum (ER) (Shi and Cheng, 2009).  
 
In parallel, dietary carbohydrate is converted into FA for esterification in TG and 
storage in adipose tissue in response to glucose and insulin signaling. Key hepatic genes 
involved in this process include the sterol regulatory element binding protein 1c 
(SREBP1), carbohydrate response element binding protein (CHREBP; also known as 
MLXIPL), and liver X receptor (LXR). SREBP1 is a transcription factor that mediates the 
effect of insulin by increasing expression of genes required for FA and TG synthesis 
including fatty acid synthase (FAS) and acetyl CoA carboxylase (ACC) (Dentin et al., 
2005). Similarly, CHREBP is a transcription factor that mediates the effects of glucose by 
increasing expression of lipogenic genes FAS and ACC, but also genes involved in 
glycolysis such as liver pyruvate kinase (Poupeau and Postic, 2011).  LXR is a master 
regulator of many genes required for lipid metabolism in response to cholesterol 
metabolites (Ducheix et al., 2011), including both SREBP1 (Repa et al., 2000) and 
CHREBP (Cha and Repa, 2007). Together, these three regulators of hepatic TG synthesis 
stimulate coordinated expression of genes required to convert glucose into acetyl-CoA 
for FA synthesis and further endogenous TG synthesis in the fed state, whereas FA flux 
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from TG stored in adipose tissue is used to synthesize endogenous hepatic TG in the 
fasted state (Barrows and Parks, 2006). 
 
Exogenous TG is subsequently packaged into chylomicrons in enterocytes, 
whereas endogenously synthesized TG is packaged into VLDL in hepatocytes for 
delivery to peripheral tissues (Iqbal and Hussain, 2009). This is accomplished by 
cotranslation of apolipoprotein (apo) B with the lipid loading action of the ER chaperone 
microsomal TG transfer protein (MTP) (Jiang et al., 2008). In enterocytes, the apo B-100 
backbone is truncated by an RNA editing enzyme called APOBEC1, which deaminates 
the full length APOB transcript encoding apo B-100 and introduces a stop codon at 48% 
of the full protein length to produce apo B-48 (Conticello, 2008). Apo B-48 is thus a 
smaller protein product lacking a crucial receptor binding domain. Hepatocytes do not 
express APOBEC1, and thus only synthesize apo B-100. Chylomicrons are secreted into 
lymph and reach systemic circulation via the thoracic duct and the superior vena cava, 
whereas VLDL is secreted directly into circulation. 
 
Within plasma, chylomicrons and VLDL acquire additional apolipoproteins from 
HDL that mediate their interaction with membrane receptors and other enzymes. 
Chylomicrons and VLDL are hydrolyzed by lipoprotein lipase (LPL) in capillaries of 
muscle and adipose tissue, where free FAs are delivered for oxidation or re-synthesized 
and storage, respectively. The process of hydrolysis is mediated by several proteins. First, 
glycosylphosphatidylinositol-anchored HDL binding protein 1 (GPIHBP1) facilitates 
interaction of the chylomicron with LPL (Beigneux et al., 2007). GPIHBP1 tethers 
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chylomicrons to the endothelial capillary lumen, binding both LPL and apo A-V, and 
allowing efficient TG hydrolysis by LPL. Apo C-II is a cofactor required for LPL 
activity, whereas apo C-III inhibits LPL activity. TG-rich lipoproteins eventually lose 
their apolipoproteins to HDL as hydrolysis alters lipoprotein surface area.  
 
TG-rich lipoproteins are metabolized into a heterogeneous spectrum of other plasma 
lipoproteins (Figure 1.5). Chylomicron-remnants largely depleted of TG are removed 
from circulation through the interaction of apo E with the hepatic LDL receptor (LDLR) 
and LDLR-related protein (LRP). Their remnant TG is reassembled into VLDL for 
secretion and redistribution to peripheral tissues in the fasted state. Conversely, VLDL is 
metabolized into intermediate density lipoprotein (IDL), which is either removed from 
circulation via interaction of apo B-100 with the LDLR or remodeled by the enzyme 
hepatic lipase (HL) into LDL. LDL is necessary to transport cholesterol to peripheral 
cells, but it is eventually cleared from plasma by interaction of apo B-100 with hepatic 
LDLR. 
 
 
1.2.4. TG-rich lipoproteins and atherosclerosis progression 
Multiple direct and indirect mechanisms have been proposed that could explain why 
plasma TG concentration is associated with increased cardiovascular risk (Botham et al., 
2007, Kannel and Vasan, 2009, Lopez-Miranda et al., 2007). It has been demonstrated in 
human subjects that lipoprotein remnants (including chylomicron-remnants and VLDL-
remnants 
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Figure 1.5. Spectrum of plasma lipoproteins. Intestinally-synthesized chylomicrons are 
the largest and least dense lipoproteins. Chylomicrons transport predominantly dietary 
TG; they are metabolized by LPL into chylomicron-remnants. Hepatically-synthesized 
VLDL transport endogenously synthesized TG; they are metabolized by LPL into IDL 
and further into LDL by HL. The size differences between lipoprotein subspecies are a 
result of relative CE and TG composition, in addition to time spent in circulation. HDL is 
atheroprotective and involved in efflux of cholesterol from peripheral tissues including 
macrophages. Chylomicrons are likely the only lipoprotein species that are unable to 
cross the selective endothelial cell barrier into the arterial wall, whereas their remnants 
and smaller lipoproteins are able to cross the barrier and contribute directly to 
atherogenesis (or cholesterol efflux for HDL). Figure courtesy of M. Beyea, adapted from 
(Vance and Vance, 2004). 
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are small enough to cross the arterial wall similar to LDL (Shaikh et al., 1991), where 
they can induce macrophage foam-cell formation without prior oxidation (as is required 
for LDL uptake by macrophages). Intestinally-derived chylomicrons are not likely 
capable of crossing the arterial wall without prior metabolism due to their relatively large 
size (Figure 1.5), however their remnants are small enough to pass through a damaged 
endothelium (Mamo et al., 1998). The CE-rich core of remnants, including IDL which 
has an equimolar ratio of TG to CE, makes them potently atherogenic. Furthermore, 
increased concentrations of plasma TG-rich lipoproteins may saturate LPL-mediated 
lipolysis resulting in prolonged residence of remnants in circulation, extending their 
opportunity to interact with the arterial wall and contribute to atherosclerosis.  
 
Another hypothesis is that elevated plasma concentrations of TG-rich lipoproteins 
could give rise to increased numbers of potently atherogenic small dense LDL (sdLDL) 
(Kannel and Vasan, 2009). Since VLDL is metabolized into LDL, elevated plasma 
concentration of TG-rich lipoproteins would give rise to increased concentrations of 
LDL. The increase in both TG-rich lipoproteins and LDL also result in competitive 
inhibition for LDLR binding sites, and thus prolonged residence in plasma. This increases 
their opportunity for interaction with the CE transfer protein (CETP), which exchanges 
CE in LDL and HDL for TG in TG-rich lipoproteins. Elevated concentrations of TG-rich 
lipoproteins cause greater exchange of CE/TG, and greater deposition of TG in LDL and 
HDL, resulting in increased remodeling by HL to deplete TG from the lipoprotein core, 
which produces sdLDL. The decreasing size of these LDL derivatives is thought to 
confer increased atherogenicity because they are less amenable to uptake by the LDLR, 
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more easily taken into the arterial wall and are more prone to oxidation. The same 
mechanism by which LDL is remodeled into sdLDL via CETP also causes depletion of 
CE from HDL, which enhances its clearance from plasma and subsequently attenuates 
the capacity for reverse cholesterol transport and resultant atheroprotection. Together, 
these mechanisms provide multiple hypotheses by which increased concentrations of 
plasma TG-rich lipoproteins could directly and indirectly increase cardiovascular risk. 
However, the true mechanism is likely a complex interaction of several variables that will 
be difficult to prove definitively. 
 
1.2.5 Clinical hypertriglyceridemia 
A severe clinical phenotype of elevated plasma TG concentration is hypertriglyceridemia 
(HTG). It is defined as an age and sex adjusted fasting plasma TG concentration >95
th
 
percentile (Yuan et al., 2007), corresponding generally to a plasma concentration >3.37 
mmol/L in the adult Canadian population (MacLean et al., 1992) (Figure 1.6). HTG can 
occur as a primary genetic disease or as a symptom secondary to associated conditions 
such as obesity, metabolic syndrome, T2D, excessive alcohol consumption, renal disease 
treatment with pharmacological agents, and exposure to estrogen either exogenously or 
endogenously in late pregnancy, which either result in over-production or improper 
catabolism of TG-rich lipoproteins. 
 
The greatest clinical consequence of HTG is increased cardiovascular risk 
resulting from significantly increased concentrations and prolonged residence of TG-rich  
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Figure 1.6. Frequency distribution of fasting plasma TG concentrations. White bars 
represent male subjects, black bars represent female subjects. Subjects with plasma TG 
concentration >3.37 mmol·L
-1
 are in the 95
th
 percentile, considered the threshold for 
HTG. The maximum plasma TG concentration in this sample was 45 mmol·L
-1
. Data 
were obtained from the Canadian Heart Health Survey, a cross-sectional population-
based study including >26,000 participants of multiple ancestries and ages 18-74, from 
metropolitan, urban and rural areas of Canada (MacLean et al., 1992). 
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lipoproteins in the plasma (Hopkins et al., 2003). Other visible clinical consequences 
include eruptive,
 
tuberous, and palmar crease xanthomas, lipemic plasma and lipemia 
retinalis, neurologic symptoms such as irritability, hepatosplenomegaly, and 
recurrent
 
epigastric pain associated with pancreatitis (Yuan et al., 2007). Xanthomas are 
CE engorged foam cells that deposit under the skin, observed in patients with severely 
elevated plasma TG >10 mmol/L. Eruptive xanthomas are small red papules that present 
on surfaces such as the back and neck. Tuberous xanthomas are larger yellowish nodules 
that tend to deposit on extensor surfaces. Palmar crease xanthomas are yellowish deposits 
within or adjoining the palmar creases. Lipemic plasma and lipemia retinalis are caused 
by the accumulation of TG-rich chylomicrons that become visible in plasma following 
blood sampling or when performing fundoscopy. Hepatosplenomegaly is the enlargement 
of both liver and spleen resulting from lipid accumulation in these tissues.  
 
Severe HTG is also sufficient to cause hypertriglyceridemic pancreatitis in ~10% 
of patients, although the precise mechanisms by which this occurs is poorly understood 
(Ewald et al., 2009). Pancreatitis refers to acute or chronic inflammation of the pancreas 
caused by abnormal secretion of digestive enzymes that damage pancreatic tissues 
causing nausea and epigastric pain. One proposed mechanism is that the abundance of 
free FA released from TG-rich lipoproteins is able to fully saturate plasma albumin, such 
that the detergent properties of unbound FA cause lipotoxicity that damages the 
pancreatic acinar cells causing ischemia and pancreatic injury. Alternatively, the 
increased viscosity of plasma rich in TG may cause ischemia and acidosis that damages 
the pancreas. Prevention of pancreatitis in HTG patients is accomplished by treatment 
30
 
 
with medications including fibrates, niacin, or fish oil, in addition to absolute restriction 
of dietary fat, refined carbohydrates and alcohol. 
 
Few effective pharmacologic interventions exist to reduce elevated plasma TG 
concentration. Available options include fibrates, niacin, and certain polyunsaturated 
fatty acids (Yuan et al., 2007). Fibrates are peroxisome proliferator-activated receptor 
alpha (PPARα) agonists. They activate a genetic program responsible for coordinated FA 
oxidation, which decreases VLDL secretion and increases TG-rich lipoprotein hydrolysis, 
effectively reducing plasma TG concentration by 50%. Fibrates are the most commonly 
used treatment option for patient with HTG. By comparison, niacin (nicotinic acid) can 
lower plasma TG to a comparable extent while simultaneously increasing HDL 
cholesterol, but with clinically significant side-effects including light-headedness, 
sweating, cutaneous flushing and pruritis. The mechanism through which niacin lowers 
plasma TG concentration is not well understood. Polyunsaturated FAs, particularly 
omega-3 FAs, are natural compounds that can lower TG concentrations by ~20%; 
however they are rarely effective as monotherapy. The mechanism whereby omega-3 
FAs lower plasma TG levels is not fully understood. Other pharmacotherapies including 
statins are effective at lowering plasma concentrations of LDL cholesterol in HTG 
patients with elevated cardiovascular risk, however they are not primarily indicated for 
prevention of plasma TG concentration in HTG patients (Drexel, 2009). Combination 
therapy with fibrates/niacin and statins are indicated for patients with plasma TG <5 
mmol/L for CAD prevention, whereas fibrate therapy becomes increasingly important for 
pancreatitis prevention when plasma TG exceeds 10 mmol/L.  
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Also, HTG often exists in the presence of other medical conditions such as poorly 
controlled diabetes, obesity, non-alcoholic steatohepatitis, certain autoimmune diseases, 
and chronic renal disease. Management of these conditions frequently helps to improve 
HTG. Further, certain medications such as corticosteroids, antihypertensive agents, and 
anti-rejection medications can raise TG in susceptible patients. Discontinuation or 
adjusting these treatments can also have beneficial effects on TG levels. 
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1.3. Genetic variation and human diseases 
 
1.3.1 Genetic variation 
The average human genome contains 3.1 billion base pairs of DNA, containing over 12 
million common sequence variants and 11,000 structural variants documented across 
world populations (Conrad et al., 2009, Frazer et al., 2007, Lander et al., 2001). 
Differences in DNA sequence between individuals are broadly encompassed by the term 
“genetic variation”. Human genetic variation can range from single base-pair differences 
to entire chromosome duplications or deletions (Figure 1.7).  
 
1.3.2. Single nucleotide variants 
Single nucleotide variants (SNVs) are DNA base pair substitutions that occur throughout 
the genome (Conrad et al., 2009, Frazer et al., 2009). They are the most abundant source 
of inter-individual variation, having the potential to alter metabolism either by changing 
patterns of gene expression or protein function. Nomenclature for SNVs is based on their 
allele frequencies. Rare variants have frequencies <1%, uncommon variants have 
frequencies 1%-5%, and common variants have frequencies >5%. Moreover, SNVs with 
frequencies >1% are often referred to as single nucleotide polymorphism (SNPs). SNPs 
are generally not damaging to protein function, meaning they have small effect sizes, and 
thus typically persist in the population with varying allele frequencies. SNVs with 
frequencies <1% are often referred to as mutations, especially when proven to attenuate 
protein function. Mutations often have significant functional impact leading to very large 
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Figure 1.7. Selected types of genetic variation found throughout the human genome. 
Variant size is indicated in base-pairs (bp). Single-nucleotide polymorphisms (SNPs) and 
mutations refer to changes in a single DNA base at a particular position in the genome. 
Structural variation includes inversions, translocations, and CNPs and CNVs, ranging 
from <1 kilobase to >1 megabase in size. Typically, any DNA segment is found once per 
chromosome, giving a copy number of 2. Deletions result in a copy number <2, and 
insertions result in a copy number >2. Inversions and translocation do not change DNA 
dosage, although they change the structural arrangement of a genome. 
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effect sizes that cause monogenic diseases. Due to evolutionary selection pressure, 
mutations are less likely to persist in the population at high frequency. Rare variants 
should only be referred to as mutations in situations where the SNV has a confirmed 
deleterious effect. 
 
SNVs that are associated with an intermediate trait or disease phenotype are not 
necessarily sufficient to cause disease in their carriers. This property is referred to as 
penetrance; the likelihood that carriers of a disease-causing allele will express the disease 
phenotype. This concept differs from expressivity which refers to variations in 
phenotypic expression or severity of a disease phenotype in variant carriers. For example, 
the penetrance of mutations causing monogenic diseases is virtually 100%. Carriers of a 
completely penetrant disease-causing mutation will manifest the disease, regardless of 
environmental or metabolic variables. The penetrance of common variants in complex 
diseases is comparably much lower and carriers do not necessarily express the disease 
phenotype. Alleles with low penetrance are much more likely to be affected by additional 
gene-gene or gene-environment interactions to result in phenotype expression. The 
penetrance of disease-causing alleles is thus related to SNV frequency and effect size, 
which is dependent upon the variant properties and gene product in question. 
 
Different types of SNVs are able to modulate intermediate phenotypes and 
disease susceptibility (Figure 1.8). For instance, SNVs in the protein coding sequence 
can introduce nonsynonymous amino acid substitutions (missense variants) into a 
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Figure 1.8. Types of SNVs. SNVs refer to individual sequence variations that occur 
between subjects. SNVs with frequency >1% generally have modest effects, whereas 
SNVs with frequency <1% generally have large effects on intermediate traits or disease 
susceptibility. Different types of SNVs have the capacity to influence gene and protein 
function. For instance, SNVs that occur in protein coding sequence are called non-
synonymous variants, which may introduce incorrect amino acids (missense variants) or 
premature stop codons (nonsense variants) into the protein sequence. Alternatively, they 
may not affect the amino acid sequence (synonymous variants) resulting in benign effects 
(silent variants) or affecting splicing or regulatory elements that occur in exons. SNVs 
that occur out of protein coding regions have the capacity to influence promoter activity, 
regulatory elements or intron-exon splicing patterns. 
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growing polypeptide that could potentially alter protein structure and function. These 
may have mild or severe deleterious effects, depending on the position of the mutation in 
the protein and the type of amino acid change. SNV can also introduce nonsense 
mutations into the coding sequence that can prematurely truncate the protein and likely 
alter its function. Similarly, small insertions or deletions that shift the reading frame of a 
protein can abnormally shorten or lengthen the product and likely alter its function. SNVs 
that border on intron-exon boundaries can interrupt the proper splicing pattern of a gene’s 
transcript, resulting downstream in an incorrectly synthesized protein, via exon skipping 
or intron retention. Finally, SNVs in regulatory elements that control gene expression, 
including promoters, enhancers, or repressors, can disrupt the proper dosage and 
expression patterns of genes whose products act in pathways that affect a phenotype. 
Ultimately, many genetic variants are also silent within the genome, as they occur in 
regions that presumably have no functional consequence. 
 
1.3.3. Functional evaluation of single nucleotide variants 
Rapid thorough functional evaluation of genetic variation is not always possible 
following discovery of disease-associated variants. Thus, in silico prediction algorithms 
are useful tools to evaluate the functional consequence of amino acid substitutions on 
protein products. Two commonly employed tools are SIFT (Sorting intolerant from 
tolerant) and Polyphen-2 (Polymorphism Phenotyping v2). SIFT (Kumar et al., 2009) and 
Polyphen-2 (Adzhubei et al., 2010) both predict the impact of amino acid substitutions on 
protein function by evaluating protein sequence homology, assessing amino acid 
conservation at the mutated residue throughout evolution. Polyphen-2 additionally 
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considers the impact of altered amino acid properties and position effects of substitutions 
based on known functional domains and protein modeling. These algorithms produce 
very straightforward interpretable results, using a composite score to indicate whether the 
variants are predicted to be benign or deleterious. These algorithms are quite effective at 
identifying functional from benign variants; however variant predictions ultimately 
require follow-up using functional assays in vitro to determine the true effects of variants 
on protein function. 
 
1.3.4. Structural variation 
Structural variants are also prevalent in the genome and can also influence disease 
susceptibility (Conrad et al., 2009). Structural variants are much larger in scale than 
SNVs, typically ranging from 1-5000 kilobases, encompassing copy number variants 
(CNVs), inversions and translocations (Hurles et al., 2008, Pollex and Hegele, 2007, 
Redon et al., 2006). They are found with varying frequencies, and thus have 
nomenclature similar to SNVs. CNVs have frequencies <1%, and copy number 
polymorphisms (CNPs) have frequencies >1%. CNVs change the quantity or dose of a 
section of a chromosome. A human diploid genome has 2 copies of each chromosome, 
but CNVs deviate from a copy number of 2: deletions reduce the DNA copy number to 1 
or 0, and duplications increase the copy number to 3 or even >4.  
 
Since structural variants are large, they can contain entire genes or cis-acting 
elements that have the capacity to alter gene dosage in carriers, which can result in 
clinical phenotypes (Hurles et al., 2008). Inversions and translocations are changes in the 
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organization of DNA, without changing copy number. Inversions change the orientation 
of a DNA segment without changing its position on the chromosome. Translocations 
change the physical position of a DNA segment; it is relocated onto another chromosome. 
All structural variants are able to disrupt the integrity of genes, and sometimes alter their 
function or expression. CNVs can further affect the proper dosage of genes, as they can 
contain entire genes or regulatory elements. However, while structural variation 
undoubtedly contributes to disease phenotypes, it is more difficult to detect with high 
resolution and prove statistical association with disease phenotypes (Kathiresan et al., 
2009a). As a result, few studies to date have investigated the impact of structural 
variation as a contributor to disease pathophysiology. Therefore, SNVs are the primary 
focus of this dissertation. 
 
1.3.5. Monogenic diseases 
Monogenic (or Mendelian) diseases are caused by highly penetrant mutations that are 
usually sufficient to cause disease. Such mutations attenuate gene function, disrupting 
normal metabolism so drastically that environmental influences have relatively negligible 
effects. Monogenic diseases are often inherited in an autosomal recessive manner, in 
which two loss-of-function mutations must be inherited to disrupt both alleles. However, 
monogenic diseases can also be inherited in an autosomal dominant or co-dominant 
manner, in which a single mutation causing haplo-insufficiency causes a disease 
phenotype, whereas two mutations cause a more severe phenotype. For instance, consider 
the genetic disease familial hypercholesterolemia in which plasma LDL concentration is 
>95
th
 percentile (Yuan et al., 2006). Autosomal recessive hypercholesterolemia is caused 
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by two mutations inherited in ARH (encoding the LDLR adapter protein). Abrogation of 
both ARH alleles is required to produce the disease phenotype, whereas a single mutation 
is insufficient to cause disease. Conversely, the related phenotype autosomal dominant 
familial hypercholesterolemia (ADH) is caused primarily by heterozygous mutations in 
LDLR, whereas disruption of both LDLR alleles produces a more severe phenotype 
(homozygous ADH) in which LDL cholesterol concentrations are doubled compare to 
heterozygous ADH. Mutations in multiple different genes that participate in the same 
metabolic pathway often cause the same monogenic phenotype, as in familial 
hypercholesterolemia where mutations in LDLR, APOB, PCSK9, and ARH may all 
contribute to disease pathophysiology. Studies of patients and families with familial 
hypercholesterolemia have been instrumental in the identification of genes and gene 
products with important physiological roles in LDL metabolism. 
 
1.3.6. Complex diseases 
Complex (or polygenic) disease phenotypes are the product of both genetic and 
environmental components, in which multiple low penetrance genetic variants in 
hundreds of genes contribute to the expressed phenotype. In contrast to monogenic 
disorders, no single genetic variant is necessary or sufficient to result in manifestation of 
a complex phenotype. Three genetic hypotheses have been proposed to explain familial 
inheritance of complex diseases, including the common-disease common-variant 
(CDCV) model, the common-disease rare-variant (CDRV) model, and the heterogeneity 
model. The CDCV model predicts that a spectrum of common variants in multiple genes, 
each with a subtle effects but high population allele frequency, additively contribute to 
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the manifestation of complex diseases (Reich and Lander, 2001). Alternatively, the 
CDRV model predicts that fewer rare variants with large effects and higher penetrance 
are the underlying cause of disease (Pritchard, 2001). Importantly, neither model suggests 
that the inheritance of any specific risk variant is deterministic of disease; rather they 
incrementally contribute to increased disease susceptibility. The heterogeneity model 
predicts that a combination of both common and rare variants contribute to complex 
phenotypes (Schork et al., 2009). The heterogeneity model seems to be emerging as a 
more accurate model that will explain larger proportions of genetic variation of discrete 
and quantitative traits (Altshuler et al., 2008). 
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1.4 Genetic investigation of monogenic and polygenic diseases 
 
1.4.1. Linkage analysis and autozygosity mapping 
Linkage analysis traces the cosegregation of genetic markers with a disease phenotype 
through large multi-generational families to identify regions of the genome that are 
statistically associated with disease susceptibility (Morton, 1955). For instance, 
restriction fragment length polymorphisms (RFLPs) were among genetic markers once 
used to map diseases; however technological advances and better understanding of the 
human genome have evolved such that predominantly SNP genotyping is now used to 
increase both statistical power and resolution of linkage analyses. Linkage analyses are 
used primarily to identify the basis of Mendelian disorders in large multi-generational 
pedigrees, where a single highly penetrant large effect mutation is the cause of disease 
(Belmont and Leal, 2005). Genetic and allelic heterogeneity are a source of confounding 
in linkage analyses of Mendelian traits. Linkage analyses are less powerful when 
examining multifactorial diseases because they require intact family units and are 
confounded by small effect sizes, genetic and allelic heterogeneity, and multiple different 
gene-gene and gene-environment interactions (Pollex and Hegele, 2005).  
 
Autozygosity mapping (also known as homozygosity mapping) is a type of 
linkage analysis used in autosomal recessive diseases in which consanguinity has been 
implicated in disease causation. It traces regions of the genome that are identical-by-
descent, having arisen from a single ancestor, becoming homozygous as the result of 
consanguinity. Homozygosity is identified across regions of the genome that are shared 
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by affected family members (Lander and Botstein, 1987). This is a powerful approach 
that functions well using small pedigrees with few affected family members, identifying 
strong associations with potentially causal loci. However, the limitations of general 
linkage analyses also pertain to autozygosity mapping. 
 
1.4.2. Candidate gene association studies 
Candidate gene association studies are based on a priori knowledge of genes involved in 
pathophysiology of complex diseases. Genetic variation is identified in a candidate gene, 
typically by resequencing in a subset of subjects, followed by genotyped in a large 
sample. Various different statistical analyses are employed to determine whether a 
genetic variant is associated with an intermediate trait or disease phenotype. Candidate 
gene studies were once used frequently to implicate candidate genes in disease processes, 
however they are notorious for failure to replicate in subsequent studies, likely due to 
confounding effects of population stratification, ethnicity, inadequate phenotyping, 
inadequate sample size, or inappropriate case-control matching (Hegele, 2002). 
Replication of study findings in independent cohorts is the gold standard for true positive 
association. Therefore, these challenges have limited the effectiveness of candidate gene 
studies over the years. 
 
1.4.3. Genome-wide association studies  
Unlike candidate gene studies, genome-wide association studies (GWAS) are a recently 
established unbiased technique capable of powerfully detecting reproducible associations 
between common genetic variants and complex quantitative or discrete phenotypes (Attia 
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et al., 2009a, b, c). Briefly, GWAS genotype millions of independent SNPs covering the 
entire genome in large populations and tests them each independently for association with 
a target phenotype (Figure 1.9). Either quantitative intermediate biochemical phenotypes 
such as plasma TG concentration or discrete clinical phenotypes such as CAD can be 
used in GWAS. The result is an estimate of effect and strength of association measured 
by a P-value for each SNP (adjusted for covariates and multiple testing). Statistically 
robust associations represent regions of the genome containing genes or regulatory 
elements in which common variation that modulate the target phenotype. The GWAS 
framework is an intricate part of analyses conducted for this dissertation. Accordingly, 
the following sections will review concepts and analyses integral to GWAS. 
 
1.4.3.1. Obtaining genotypes 
GWAS are enabled by inexpensive high-density microarray platforms that 
simultaneously genotype millions of known variants across the genome. For instance, the 
Affymetrix Genome-Wide Human SNP Array 6.0 is capable of simultaneously 
genotyping ~1.8 million markers representing ~900,000 SNPs and ~900,000 copy 
number probes, at positions strategically chosen across the genome. A variety of 
molecular techniques are used to segment, amplify and label genomic DNA for 
hybridization to the arrays. Affymetrix-based microarrays fluorescently-label sample 
DNA such that hybridization to a complementary probe, whose sequence and position on 
the array is known, allows genotype calling. For SNPs, probes are designed to target each 
allele of a known variant, such that fluorescence from either probe alone represents a 
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Figure 1.9. A path for discovery and translation of GWAS findings. 
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homozygote for either allele, whereas fluorescence from both probes represents a 
heterozygote for the target allele. For CNVs, signal intensities of each probe are 
compared to the average intensity across the genome to identify regions that have 
relatively increased or decreased signal, which correspond to changes in copy number. 
Advances in genome-wide genotyping now allow increased density, increased samples 
per chip, and custom design of targeted arrays to facilitate different experimental designs. 
However, these technologies are likely to become obsolete once next-generation 
sequencing becomes affordable and commonplace. 
 
1.4.3.2. Linkage disequilibrium and the HapMap project 
SNPs are chosen for inclusion on microarrays based on their position in haplotype blocks 
across each chromosome. Haplotype blocks are groups of SNPs that are inherited 
together on a chromosome (Figure 1.10). They have arisen historically in regions of the 
genome where homologous recombination has not occurred. As a result, SNPs within 
haplotype blocks have a non-random association among them known as linkage 
disequilibrium (LD), a feature that can be quantified and evaluated statistically using the 
metric r
2
, which ranges from 0 (complete linkage equilibrium) to 1 (complete LD). These 
properties of common variants allow sophisticated statistical analysis to estimate un-
genotyped SNPs with a high degree of accuracy based on panels of genotyped and 
patterns of LD in reference cohorts, a process known as imputation (Li et al., 2009). 
 
Patterns of human genetic variation have been thoroughly catalogued by the 
International HapMap Consortium, a large scale organization whose goal is to produce a  
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Figure 1.10. Illustration of LD and haplotype block structure. The axis below the 
“LD Plot” heading indicates where SNPs were genotyped by the International HapMap 
Consortium; each vertical black line indicates a SNP. The colour at the intersection points 
of two SNPs indicates the LD, or non-random association, between them. Red squares 
indicate high linkage, pink squares indicate moderate linkage, blue squares are 
uninformative markers, and white squares indicate no linkage. Large red blocks indicate 
extended regions of LD between multiple SNPs that form haplotype blocks which are 
likely inherited together on a chromosome. Single SNPs may be genotyped in haplotype 
blocks to effectively infer the genotype of surrounding SNPs. A limitation of this 
approach is that an association with a SNP in a haplotype block does not identify the 
precise functional variant mediating the association; it simply indicates the presence of a 
functional variant somewhere within that block. This figure is a screenshot of the 9p21 
locus modified from the International HapMap Consortium website. 
 
50
 
 
 
 
 
 
 
 
 
 
 
51
 
 
high resolution human haplotype map outlining the location of haplotype blocks and the 
LD within (International HapMap Consortium, 2003). The HapMap project has been 
invaluable to GWAS, allowing few “tagging” SNPs to be selected from within the 
haplotype block to serve as a surrogate for many more, such that modern microarrays can 
achieve maximally 90% coverage of the genome for testing association with disease traits 
(Altshuler et al., 2008). Imputation further increases power in large scale GWAS to detect 
associations between genotype and phenotypes. While effective at maximizing the 
likelihood of identifying significant associations, a limitation of this strategy is that 
statistically associated SNPs are rarely the specific variants that mediate a phenotypic 
effect; they simply indicate whether a haplotype block presumably containing a 
functional variant is associated with the phenotype. More recently, the 1000 Genomes 
Project was launched to more comprehensively characterize the majority of genetic 
variation in the studied population (Durbin et al., 2010). Next generation sequencing 
technologies were used to identify all variants with frequency >1% in European, East 
Asian and African populations. The project consisted of 3 phases, including low coverage 
(2-4X) sequencing of 180 subjects, moderate depth (30X) sequencing in 2 trios, and high 
depth (>50X) sequencing of 1000 genes in 900 samples. Data obtained by the 1000 
Genomes Project has been made available in the form of a genome browser and public 
databases, which have facilitated genetic analyses of both monogenic and complex 
diseases. 
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1.4.3.3. Statistics in GWAS 
Once typed and imputed genotypes are obtained, regression is commonly used to test for 
association between SNPs and quantitative or discrete phenotypes. Linear and logistic 
regression are often used to measure the effect of multiple independent variables, 
including SNP genotypes and other covariates, on the intermediate traits or discrete 
disease phenotypes, respectively. Generally, these analyses assume an additive model of 
risk alleles, meaning that each risk allele contributes additively to the phenotype. These 
analyses produce an effect size for each variant, measured by frequency ratios for discrete 
phenotypes, and a P-value representing the strength of association with the phenotype.  
 
The statistical analysis used to detect associations between genotype and 
phenotype in GWAS is relatively straightforward. However, the simultaneous analysis of 
millions of variants introduces a problem of multiple testing. Typically, statistical tests 
accept a false-positive rate of 5% (α=0.05), however this would correspond to an 
overwhelming 50,000 false positives occurring by chance in any particular GWAS that 
studied 1 million SNPs. A conservative approach to correct for multiple testing is the 
Bonferroni correction, which divides the accepted false positive rate by the number of 
independent tests. SNPs that surpass the accepted Bonferroni-corrected genome-wide 
significance threshold of P=5X10
-8
 are considered robustly associated with the target 
phenotype. 
 
GWAS also require implementation of other rigorous statistical analyses to 
prevent potentially confounding variables from identifying false positive associations. 
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One such confounding variable is population stratification. Population stratification refers 
to differences in allele frequencies that occur between different groups of subjects (Kraft, 
2011). These systematic differences in allele frequencies could be misconstrued as false 
positive associations if the sample distribution (e.g. cases and controls) is composed of 
unequal proportions of subjects from different geographical regions or ancestries. Two 
commonly employed statistical analyses are used to control population stratification, 
which include principal component analysis (Patterson et al., 2006, Price et al., 2006) and 
genomic control (Devlin and Roeder, 1999).  
 
An important concept in GWAS is statistical power. Power refers to the 
probability that a statistical test will reject the null hypothesis - that no association exists 
between genotype and phenotype – when no true association exists. In GWAS, power 
calculations are used to determine the sample size required to detect a given effect size; 
alternatively, they are used to determine the effect size that can be detected in a fixed 
sample size. Several variables affect statistical power in association studies, including 
sample size, effect size, allele frequency and threshold for false positive association. For 
example, a sample of 500 case patients and 1200 controls would have 100% power to 
detect associations with an effect size (measured by odds ratio [OR]) of 1.6 given an 
allele frequency of 30% (Figure 1.11). Decreasing allele frequencies reduce power to 
detect the same odds ratio, such that 100% power is achieved for an OR=1.8 at 20% 
allele frequency, OR=2.0 at 10% allele frequency, and OR=2.5 at 5% allele frequency. 
The experiments conducted for this dissertation have ~70% power to detect an OR=1.5 at 
an allele frequency of 10%, given a false positive rate of 5%. 
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Figure 1.11. Statistical power in genetic association studies. The plot above 
demonstrates the statistical power of a Fisher’s exact test to detect an association between 
genotype and phenotype at a false-positive rate of 5% (α=0.05), given various allele 
frequencies in a population of 500 case patients and 1200 healthy controls. 
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1.4.4. Resequencing studies 
Identification of rare variation is becoming increasingly important to explain the 
unattributed variation in complex phenotypes. Increasingly affordable high-throughput 
massively paralleled sequencing technologies permit identification of all genetic variants 
in a subject’s exome or whole genome (Metzker, 2010), however the recent introduction 
of these platforms has not allowed sufficient time for the development of robust 
analytical strategies (Bansal et al., 2010). Low frequency variants cannot be tested 
individually for association with a phenotype, given extremely limited power to detect a 
true association, especially given the need for multiple testing corrections. Hypothesis-
driven multi-locus grouping of rare variants is emerging as a standard approach to detect 
associations between groups of genes and a phenotype of interest, whereas gene-centric 
analyses facilitated by novel statistical analyses are quickly emerging to enhance the 
resolution of rare variant association studies (Neale et al., 2011, Price et al., 2010). 
However, rare variant analyses are a relatively novel avenue of investigation in genetic 
association studies resulting in few established analysis strategies or experimental 
designs. 
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1.5. Genetic architecture of plasma triglycerides and hypertriglyceridemia 
 
1.5.1 Common genetic determinants of plasma triglycerides 
Our understanding of the genetic architecture - that is the integrated contribution of all 
genetic variants that contribute to inter-individual variation – of plasma TG 
concentrations has increased substantially following the reports of GWAS in the 
literature. Fasting plasma TG is a stable biochemical analyte allowing GWAS to combine 
findings across multiple epidemiologic studies to identify associated genetic loci. Prior to 
the outset of the projects described in this dissertation, GWAS had identified association 
signals at 11 TG-associated loci (Table 1.1), containing both classically established 
genes and previously unknown genomic regions, as determinants of plasma TG 
concentration (Aulchenko et al., 2009, Kathiresan et al., 2008, Kathiresan et al., 2009b, 
Kooner et al., 2008, Sabatti et al., 2009, Wallace et al., 2008, Willer et al., 2008). 
However, the genes and functional variants at remaining newly-identified loci are mostly 
unknown. GWAS is not able to identify the specific genes or variants that mediate each 
association. Thus, the majority of genes associated with plasma TG by GWAS represent 
the most likely biological candidates for the association based on a priori functional 
evidence. These associations merely represent a starting point for subsequent functional 
characterization necessary to identify novel genes and pathways involved in modulation 
of TG-rich lipoprotein metabolism. Such discoveries could take many years to be 
validated, even with a novel straightforward mechanism without inherent biological 
complexities.  
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Table 1.1. Genetic variation associated with plasma TG concentration or HTG by 
GWAS or resequencing studies in January 2009. 
 Common variation - GWAS Rare variation - Sequencing 
 Normal TG Polygenic HTG Polygenic HTG Monogenic HTG 
APOA5 X X X X 
LPL X X X X 
APOC2   X X 
GPIHBP1    X 
LMF1    X 
GCKR X X   
TRIB1 X X   
MLXIPL X X   
APOB X    
NCAN X    
ANGPTL3 X X   
FADS1 X    
PLTP X    
XKR6 X    
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1.5.2. Rare genetic determinants of monogenic hypertriglyceridemia 
The genetic determinants of Mendelian HTG syndromes are fairly well defined. 
Characterization of these gene products has contributed significantly to our current 
understanding of TG metabolism. Monogenic HTG has a population frequency of <1:10
6
 
and follows autosomal recessive inheritance resulting from homozygous (or compound 
heterozygous) large-effect disease-causing mutations in genes that modulate plasma TG 
concentration. Most monogenic HTG patients have mutations in LPL leading to complete 
LPL deficiency (OMIM 238600). LPL hydrolyses TG molecules transported in TG-rich 
lipoproteins to liberate free FAs for TG re-synthesis and storage in adipose tissue or beta-
oxidation in skeletal muscle and heart (Kirchgessner et al., 1989). LPL is matured in the 
ER by LMF1 and transported to the capillary lumen by GPIHBP1. Thus, mutations in the 
N-terminal domain that attenuate LPL catalytic activity (Rahalkar et al., 2009), in 
addition to mutations in the C-terminal domain that prevent binding to GPIHBP1 (Voss 
et al., 2011), are sufficient to cause monogenic HTG. In total, >114 homozygous or 
compound heterozygous mutations have been shown to cause LPL deficiency in patients, 
including 72 missense mutations, 14 nonsense mutations, 13 small scale insertions and 
deletions, 9 splicing variants, 3 regulatory variants, and 3 large scale structural 
rearrangements (Figure 1.12a).  
 
 Interestingly, remaining genes that cause monogenic HTG are all essential for 
efficient activity, assembly or transport of LPL, which effectively block the lipolytic 
cascade (Figure 1.12b). For instance, APOC2 (encoding apo C-II) and APOA5 (encoding 
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Figure 1.12a. Homozygous and compound heterozygous mutations in LPL that 
cause Mendelian HTG. Mutations shown in red are nonsense mutations or frameshift 
mutations causing premature truncation of the protein product. 
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Figure 1.12b. Homozygous and compound heterozygous mutations in APOC2, 
APOA5, LMF1, and GPIHBP1 that cause Mendelian HTG. Mutations shown in red 
are nonsense mutations or frameshift mutations causing premature truncation of the 
protein product. 
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apo A-V) also cause monogenic HTG. Apo C-II is an essential LPL coactivator 
absolutely required for hydrolysis TG-rich lipoprotein hydrolysis (LaRosa et al., 1970), 
thus homozygous LOF mutations in APOC2 cause apo C-II deficiency (OMIM 207750) 
and monogenic HTG (Connelly et al., 1987). APOC2 mutations were first definitively 
shown to cause HTG through characterization at the amino acid level (Breckenridge et 
al., 1978). Since then, approximately 13 mutations have been identified that cause apo C-
II deficiency, including 4 nonsense mutations, 3 missense mutations, 1 splicing mutation, 
1 regulatory regions mutation, 1 gross deletion, 3 indels each causing a translational 
frameshift and predicted premature truncation of the protein product (Figure 1.12b). 
These variants result in complete absence of apo C-II from plasma, whereas missense 
mutations usually produced protein defective in LPL binding. Apo C-II variants cause 
significant increases in plasma TG concentration >10 mmol/L, accompanied by epigastric 
pain and pancreatitis, resulting from defective LPL activity. 
 
Apo A-V is also required for efficient lipolysis of TG-rich particles by LPL 
(Charlton-Menys and Durrington, 2005), however the precise mechanism by which it 
confers this activity is unknown. Apoa5 overexpression in mice has been demonstrated to 
decrease plasma TG concentrations, whereas Apoa5 knockout results in significantly 
increased plasma TG concentration in mice. Thus, it is logical to assume that APOA5 
deficiency (OMIM 144650) in humans would similarly cause HTG. However, 
surprisingly only 3 mutations have been associated with apo A-V deficiency, each a 
distinct glutamine to nonsense mutation (Marcais et al., 2005, Priore Oliva et al., 2008, 
Priore Oliva et al., 2005) (Figure 1.12b), although many heterozygous mutations have 
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been found in polygenic HTG patients. One monogenic patient with abdominal pain, 
hepatosplenomegaly and plasma TG concentration >40 mmol/L was a carrier of a 
glutamine to stop mutation at position 148 (Q148X) (Priore Oliva et al., 2005), which 
prematurely truncated the protein such that it lacked critical hydrophobic lipid binding 
domains and putative heparin-binding domains, although apo A-V was completely 
devoid from plasma. This truncation mutation cosegregated with increased plasma TG 
concentration in the proband’s family but without causing HTG. Another glutamine to 
stop mutation at position 139 (Q139X) was also identified in a HTG subject with 
recurrent pancreatitis, which was also identified as a heterozygous mutation in additional 
families (Marcais et al., 2005). Finally, a glutamine to stop mutation at position 97 
(Q97X) was identified in a male proband (Priore Oliva et al., 2008). This mutation 
resulted in complete absence of apo A-V from plasma, but interestingly his plasma TG 
was controlled greatly by a low-fat low-oligosaccharide diet (Priore Oliva et al., 2008). 
These variants were associated with increased plasma TG concentration but were not 
sufficient to cause HTG without the contribution of additional variants that attenuated TG 
metabolism in APOA5, APOC3, or APOE, or perhaps due to the contribution of 
environmental exposures not necessarily described by these studies (Calandra et al., 
2006). A more thorough understanding of the clinical consequences of apo A-V 
deficiency may eventually explain the incomplete penetrance of mutations in APOA5.  
 
Genes that are required for efficient assembly and transport of LPL, including 
LMF1 and GPIHBP1, were also recently shown to cause monogenic HTG. Only 2 
nonsense mutations have been identified in LMF1 (Figure 1.12b). One tyrosine to 
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nonsense (Y439X) mutation was identified in a HTG patient with recurrent pancreatitis, 
which resulted in a 93% reduction in post heparin plasma activity of LPL and plasma TG 
concentration of ~30 mmol/L (Peterfy et al., 2007). A tryptophan to nonsense (W464X) 
mutation identified in another patient also with recurrent pancreatitis was attributed to 
LPL activities of 76% causing a plasma TG concentration ~27 mmol/L
 
(Cefalu et al., 
2009). Similarly, only 6 mutations have been identified in GPIHBP1 that cause 
monogenic HTG (Figure 1.12b). Most of these LOF mutations have been identified in 
the cysteine-rich Ly6 domain, which is required for proper GPIHBP1 folding and 
interaction with LPL. These variants included compound heterozygotes for a cysteine to 
serine mutation at amino acid residue 65 (C65S) and a cysteine to glycine mutation at 
amino acid residue 68 (C68G) (Coca-Prieto et al., 2011, Franssen et al., 2010b, 
Olivecrona et al., 2010). Another patient was homozygous for a cysteine to tyrosine 
mutation also at residue 65 (C65Y) (Franssen et al., 2010a). These variants all result in 
plasma TG concentrations between 18 and 27 mmol/L. A homozygous glutamine to 
proline substitution at amino acid residue 115 (Q115P) was also identified in the Ly6 
domain, causing a plasma TG concentration ~38 mmol/L (Beigneux et al., 2009). Finally, 
a homozygous glycine to arginine mutation at residue 56 (G56R) was identified in two 
siblings with pancreatitis and plasma TG concentration >40 mmol/L (Wang and Hegele, 
2007). In vitro analyses did not show a specific defect affecting GPIHBP1 function (Gin 
et al., 2007), however the allele carrying this mutation cosegregated well with the HTG 
phenotype in affected family members. 
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1.5.3. Common genetic determinants of polygenic hypertriglyceridemia 
In contrast to monogenic HTG, the etiology of polygenic HTG was not well-defined. It 
was presumed to result from the deleterious effects of multiple low penetrance genetic 
variants combined with environmental and metabolic stressors (Ballantyne et al., 2000, 
Yuan et al., 2007). Prior to this dissertation, few replication studies had attempted 
replication of loci associated with population-based plasma TG concentrations (Table 
1.1) (Wang et al., 2008a, Wang et al., 2008b). However, these studies were conducted in 
relatively small sample sizes with poor power to detect biologically relevant associations. 
It was well established that common variants such as LPL D9N were significantly over-
represented in patients with HTG, whereas LPL S447X was less prevalent in HTG 
patients (Wang et al., 2008b). Similarly, both APOA5 S19W and -1131T>C variants were 
strong predictors of polygenic HTG, such that carriers of APOA5 S19W were >6 times 
more likely to be diagnosed with severe HTG than controls (Wang et al., 2008a).  
 
Rare variants were also weakly associated with polygenic HTG. Preliminary 
analyses that sequenced LPL, APOA5, and APOC2 revealed 9 heterozygous rare variants 
in 110 HTG patients, suggesting that large effect mutations may also contribute to 
increased disease susceptibility. However, a comprehensive and systematic analysis of 
the genetic determinants and genetic architecture of HTG had never been conducted for 
patients with polygenic HTG, mainly because severe disorders of TG metabolism are 
relatively rare in the general population, making it difficult to accrue samples with 
sufficient statistical power to elucidate the mechanisms of disease. 
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1.5.4. Phenotypic heterogeneity within polygenic hypertriglyceridemia 
Phenotypic heterogeneity among polygenic HTG patients is the result of qualitative and 
quantitative biochemical differences in plasma lipoproteins that form the basis of the 
WHO or Fredrickson hyperlipoproteinemia (HLP) phenotypes (Table 1.2). Five of six 
Frederickson phenotypes are defined by HTG; the exception is familial 
hypercholesterolemia (HLP type 2A) which most often results from mutations in LDLR 
encoding the LDL receptor (Rader et al., 2003). Among HLP phenotypes defined by 
HTG, there is one monogenic phenotype and four polygenic phenotypes. Monogenic 
HTG (HLP type 1) is defined by fasting chylomicronemia as described previously. The 
remaining polygenic familial phenotypes are adult phenotypes called combined 
hyperlipidemia (HLP type 2B), dysbetalipoproteinemia (HLP type 3), primary 
hypertriglyceridemia (HLP type 4) and mixed hyperlipidemia (HLP type 5), each differ 
in their plasma lipoprotein profile. Only one replication study assessing the association of 
GWAS-identified TG-associated loci in the Fredrickson phenotypes identified APOA5 as 
strongly associated with all phenotypes, whereas varying patterns of association were 
observed between remaining TG-associated loci and each phenotype (Hegele et al., 
2009). The genetic basis for the biochemically-defined Fredrickson phenotypes has never 
been characterized. 
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1.6. Summary 
Plasma TG concentration is re-emerging as a risk factor for CVD. HTG patients with 
plasma TG concentration >95
th
 percentile have significantly elevated cardiovascular risk, 
compounded by accompanying co-morbidities such as obesity, metabolic syndrome and 
T2D. However, the genetic architecture underlying HTG susceptibility is incompletely 
understood. Recent technological advances in genetic analyses now permit high-
throughput evaluation of common and rare genetic variation contributing to complex 
phenotypes. The overall hypothesis of experiments conducted in this dissertation is that 
modern genomic analyses strategies will be capable of elucidating the genetic 
determinants of HTG and the phenotypic heterogeneity therein. We sought to conduct a 
systematic and comprehensive analysis of polygenic HTG patients according to the 
following objectives: (1) conduct genome-wide genotyping and association to identify 
novel genes containing small effect common variants and genes associated with HTG; (2) 
conduct high-throughput resequencing of HTG-associated genes to identify containing 
large effect rare variants associated with HTG; and (3) conduct subgroup analyses within 
Fredrickson HLP phenotypes to evaluate the contribution of common and rare variants to 
the phenotypic heterogeneity among HTG patients. Together, these studies were able to 
identify specific variants associated with HTG and provide a model for the genetic 
architecture of HTG susceptibility and phenotypic heterogeneity. A long-term index of 
the success of this thesis will be its contribution to the discovery of biological pathways 
containing potential pharmacological targets capable of lowering plasma TG 
concentration and improving cardiovascular risk in HTG patients. 
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 CHAPTER 2 
 
COMMON GENETIC VARIATION IN TRIGLYCERIDE-ASSOCIATED GENES 
IS ASSOCIATED WITH HYPERTRIGLYCERIDEMIA AND ACCUMULATES 
IN PATIENTS VERSUS HEALTHY CONTROLS 
 
The work in this chapter originates from material in the following publications: (1) 
Johansen, CT, Wang, J, Lanktree, MB, et al. (2010). Excess of rare variants in genes 
identified by genome-wide association study of hypertriglyceridemia. Nat Genet 42(8): 
684-7; (2) Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, 
Koseki M, Pirruccello JP, Ripatti S, Chasman DI, Willer CJ, Johansen CT, et al. (2010). 
Biological, clinical and population relevance of 95 loci for blood lipids. Nature 
466(7307): 707-13. 
 
2.1. Introduction 
Plasma TG concentration is re-emerging as a risk factor for cardiovascular disease 
(CVD). Epidemiological evidence has suggested that prolonged exposure to elevated 
concentrations of triglyceride (TG)-rich lipoproteins, especially in the post prandial state, 
increases cardiovascular risk independent of other plasma lipoproteins (Bansal et al., 
2007, Cullen, 2000, Freiberg et al., 2008, Hokanson and Austin, 1996, Labreuche et al., 
2009, Morrison and Hokanson, 2009, Nordestgaard et al., 2007).Thus, patients diagnosed 
with clinical hypertriglyceridemia (HTG) likely also have significantly elevated CVD 
risk (Yuan et al., 2007). However, the pathways that modulate plasma TG concentrations 
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are incompletely understood, as indicated by the lack of very few effective therapies to 
lower plasma TG. Elucidation of the genes and genetic variants associated with plasma 
TG concentration can enrich our understanding of biochemical pathways involved in TG-
rich lipoprotein metabolism. Furthermore, identification of defects in patients with 
disordered TG metabolism could guide the development of therapeutic interventions to 
treat HTG and ameliorate CVD risk. 
 
HTG is a complex polygenic disease defined by plasma TG concentrations >95
th
 
percentile. Pediatric HTG is caused exclusively by homozygous loss-of-function (LOF) 
mutations in genes such as LPL (Havel and Gordon, 1960), APOC2 (Connelly et al., 
1987), APOA5 (Priore Oliva et al., 2005), LMF1 (Peterfy et al., 2007), and GPIHBP1 
(Beigneux et al., 2009, Wang and Hegele, 2007). Polygenic HTG has a much more 
complex etiology. As with other complex diseases, it is thought to result from the 
accumulation of genetic determinants associated with defective TG-rich lipoprotein 
hydrolysis (Plomin et al., 2009), combined with environmental and metabolic stressors 
such as alcohol, medications, renal disease, nonalcoholic fatty-liver disease, pregnancy, 
obesity, metabolic syndrome, and type 2 diabetes (T2D) (Yuan et al., 2007). Both 
common and rare genetic variation in genes known to modulated plasma TG 
concentration have been associated with HTG (Hegele et al., 2009, Wang et al., 2008, 
Wang et al., 2007), however the majority of phenotypic variation underlying HTG 
susceptibility remains unattributed (Hegele, 2009).  
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Genome-wide association studies (GWAS) are a class of recently developed 
genomic tools capable of identifying regions of the genome containing genetic variation 
associated with a complex trait (Altshuler et al., 2008). Briefly, a GWAS tests for 
association between common genetic variants with frequencies >1% in the population 
(called single nucleotide polymorphisms [SNPs]) and quantitative or discrete traits, 
enabled by modern microarray technologies and statistical genetic techniques. SNPs 
included on microarrays are strategically chosen to “tag” additional variants by virtue of 
blocks of linkage disequilibrium (LD), which cover large regions of the genome and 
often contain multiple genomic elements including variants, genes, and regulatory 
elements. GWAS cannot directly ascribe causation to a particular gene or variant 
underlying an association, although it can implicate new genomic regions for further 
study, irrespective of prior direct biological plausibility or knowledge of variant function. 
Thus, GWAS is an unbiased method that surveys the entire genome to identify novel 
genomic elements, such as genes or regulatory elements, involved in biological processes 
and disease susceptibility.  
 
GWAS have proven effective at identifying association signals containing both 
classically established genes and previously unknown genomic regions as determinants of 
plasma TG concentration. For example, before the start of our study, population-based 
studies had identified 30 loci associated with quantitative lipid traits, including 11 loci 
associated with plasma TG concentration (Kathiresan et al., 2009b). Here, we sought to 
comprehensively characterize the contribution of common genetic variation to HTG 
susceptibility. Our main objective was to perform a GWAS of patients with HTG in order 
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to identify novel genes and common variants associated with HTG. Our secondary 
objective was to extend associations between common variants in recently identified TG-
associated loci to our HTG cohort in a collaborative effort with the Global Lipids 
Genetics Consortium (GLGC). Our final objective was to assess the combined impact of 
common variation across multiple TG-associated loci on HTG susceptibility. We 
demonstrate that loci containing common variation associated with HTG are the same 
loci associated with plasma TG concentration in population-based studies, and that these 
common variants also accumulate in HTG patients compared to healthy controls. 
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2.2. Methods 
 
2.2.1. Study subjects 
This study was approved by the ethics boards at all collaborating institutions. All subjects 
provided informed consent for blood sampling, DNA analysis, and collection of clinical, 
biochemical and other demographic data. The GWAS of HTG included 463 HTG 
patients and 1197 controls after removal of subjects due to non-European ancestry or 
genotyping failure. HTG patients were defined as having untreated 12 h fasting plasma 
TG concentrations >3.4 mmol/L on at least two occasions. They were unrelated European 
subjects diagnosed with Fredrickson hyperlipoproteinemia (HLP) phenotypes 2B (MIM 
144250), 3 (MIM 107741), 4 (MIM 144600) or 5 (MIM 144650), ascertained primarily 
from a single tertiary referral lipid clinic (92% of patients) in London, Ontario, Canada, 
or from a tertiary referral lipid clinic in Amsterdam, Netherlands. Controls were subjects 
with familial hypercholesterolemia (4% of controls) obtained from a single tertiary 
referral lipid clinic in London, Ontario, Canada, or normal healthy controls obtained from 
population-based studies including the Study of Health Assessment and Risk in Ethnic 
Groups (Anand et al., 2000) (18%) or the Myocardial Infarction Genetics Consortium 
(Kathiresan et al., 2009a) (78%). Controls had plasma TG concentration <2.3 mmol/L to 
exclude potentially undiagnosed HTG, but were otherwise not phenotypically-selected. 
Subjects with familial hypercholesterolemia were included as negative controls to 
counterbalance the increased cholesterol phenotype that is observed in patients with 
HTG. Biochemical analyses were conducted separately in each cohort, as previously 
described (Anand et al., 2000, Hegele et al., 2009, Kathiresan et al., 2009a). The 
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replication cohort used for analyses conducted in conjunction with the GLGC included a 
subset of GWAS patients that were available when collaboration began, including 344 
HTG patients and 144 healthy population-based. 
 
2.2.2. Genotyping and imputation 
All subjects were genotyped using Affymetrix Genome-Wide Human SNP Array 6.0 
(Affymetrix, Santa Clara, CA) according to protocols of the London Regional Genomics 
Centre or the Broad Institute. Genotypes were called using Affymetrix Genotyping 
Console, setting quality control thresholds for subject call rate (>90%), SNP call rate 
(95%), Hardy-Weinberg equilibrium (P>0.0001) and minor allele frequency (>1%). 
Imputation was conducted using HapMap CEU phased haplotypes in MACH (Li and 
Abecasis, 2006). Imputed genotypes were also filtered for minor allele frequency >1%, 
Hardy Weinberg P>0.0001, and 95% call rate, in addition to imputation quality r
2
>0.4. 
Microarray probe intensity cluster plots were manually verified to ensure robust genotype 
calling within the cohort for all significant associations. 
 
2.2.3. Statistical analysis 
Identity-by-state calculations, multi-dimensional scaling, and association testing were 
conducted as implemented in PLINK (Purcell et al., 2007). Identity-by-state calculations 
and multidimensional scaling were performed using freely available HapMap CEU 
(European ancestry), CHB/JPT (Asian ancestry) and YRI (African ancestry) subjects in 
order to demonstrate the relative ancestry of study participants (Figure 2.1). Subjects  
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Figure 2.1. Axes of genetic variation in the study sample. Identity-by-state and 
multidimensional scaling analyses were used to illustrate the relative genetic similarity 
between subjects, represented as closer relative distance on the plot above. HTG cases 
(blue diamonds) and controls (red squares) are predominantly of European ancestry, 
assessed by clustering with HapMap CEU subjects of European ancestry (green 
triangles), and distance from HapMap YRI subjects of African ancestry (purple X's) and 
CHB/JPT subject of East Asian ancestry (blue X's). Potential confounding effects of 
population stratification were minimized by removal of extreme ancestral outliers (orange 
circles); outliers were arbitrarily selected by x-axis values exceeding 0.05. Remaining 
population substructure was corrected using 10 principal components of ancestry as 
generated by Eigenstrat to adjust for potential differences in allele frequency arising from 
differences in ancestry among study subjects 
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exceeding an arbitrary x-axis value of 0.05 (14 HTG patients and 14 controls) were 
excluded from subsequent analyses, in order to remove subjects deviating from the 
cluster of European subjects, while maximizing inclusion of study participants. Principal 
component analysis was used to correct for remaining population substructure, as 
implemented by Eigenstrat (Patterson et al., 2006, Price et al., 2006). Association was 
tested using an additive multiple logistic regression model, with case or control status as 
the dependent variable. Genome-wide significance was pre-specified as a Bonferroni-
corrected threshold P<5X10
-7
. This threshold was selected to maximize our ability to 
identify novel loci. Statistical significance for replication of TG-associated SNPs was 
P<0.05, as all loci were previously implicated in TG metabolism. Covariates entered into 
all analyses included sex, BMI, T2D and 10 principal components of ancestry as 
generated by Eigenstrat (Patterson et al., 2006, Price et al., 2006). Explained variation 
calculations were performed using multiple logistic regression without a predefined 
modeling strategy. Case or control status was modeled as the dependent variable, entering 
clinical variables (age, sex, BMI, and T2D), and TG-raising risk alleles at 7 HTG-
associated loci (APOA5, GCKR, LPL, APOB, MLXIPL, TRIB1, ANGPTL3) as 
independent variables. 
 
Genetic risk scores were constructed as the sum of TG-raising alleles at all 32 
TG-associated loci identified by the GLGC (Teslovich et al., 2010). Two risk scores were 
constructed: (1) unweighted risk scores composed of the raw number of TG-raising 
alleles; or (2) weighted risk scores composed of the weighted sum of TG-raising alleles 
each multiplied by their corresponding population-based effect estimate, as generated by 
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the GLGC (Teslovich et al., 2010). Units were initially reported as mg/dl but converted 
here to mmol/L (conversion factor 88.6 mg/dl = 1 mmol/L). All loci were included in risk 
score analysis regardless of statistical association in the replication phase. Frequency 
distributions (for both unweighted and weighted risk scores) were constructed by: (1) 
dividing the range of risk scores into equal bins; and (2) plotting the number of HTG 
patients or controls in each bin relative to total number of HTG patients or controls in the 
sample. Forest plots were generated by: (1) ranking all weighted risk scores from lowest 
to highest; (2) dividing risk scores into 4 bins of equal numbers of subjects; and (3) 
comparing the number of HTG patients to controls in each bin to the lowest risk score 
bin, which served as the referent group. The significance of increasing HTG 
susceptibility with increasing risk score bin was assessed using the Cochrane-Armitage 
test for trend. 
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2.3 Results 
 
2.3.1 Study sample 
Baseline clinical attributes of the 463 HTG patients and 1197 population-based controls 
are shown in Table 2.1. Generally, clinical attributes of HTG patients were less 
favourable than those of controls. HTG patients had increased BMI, increased plasma 
total cholesterol, decreased plasma HDL cholesterol and increased prevalence of T2D. 
Plasma TG concentrations were most greatly increased, with a mean of 14.3 mmol/L in 
HTG patients versus 1.1 mmol/L in healthy controls. Clinical attributes of the subset of 
HTG patients and controls used in the GLGC replication phase were essentially identical 
to the full cohort (Table 2.2). 
 
2.3.2 Genome-wide association study of hypertriglyceridemia 
The HTG phenotype was tested for association with >2.1 million genotyped and imputed 
SNPs using an additive multiple logistic regression model. Four loci were significantly 
associated with HTG at genome-wide significance levels (P<5X10
-7
): APOA5, GCKR, 
LPL and APOB (Figure 2.2). Multiple SNPs at each locus were associated with HTG; 
however repeat analyses conditioned on the lead SNP at each locus attenuated each 
association signal, suggesting that only a single association signal was present at each 
locus. Finally, we determined that covariates entered into this model, which included sex, 
body mass index, diabetes status and 10 principal components of ancestry, appropriately 
adjusted for potential confounding effects of stratification as the genomic inflation factor 
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Table 2.1. Baseline clinical attributes of full GWAS cohort. 
Characteristic HTG Controls 
Number 463 1197 
Female 30.7% 40.4% 
Diabetes 25.7% 0.4% 
Age (years) 50.9 ± 13.0 47.8 ± 11.1 
Body mass index (kg/m
2
) 29.9 ± 4.9 26.4 ± 4.6 
Plasma total cholesterol (mmol/L) 8.2 ± 3.9 5.3 ± 1.3 
Plasma HDL cholesterol (mmol/L) 0.9 ± 0.3 1.4 ± 0.4 
Plasma LDL cholesterol (mmol/L) - 3.4 ± 1.2 
Plasma TG (mmol/L) 14.3 ± 19.8 1.1 ± 0.7 
GWAS, genome-wide association study; HDL, high-density lipoprotein; HTG, hypertriglyceridemia; LDL, 
low-density lipoprotein; TG, triglycerides. Values are mean ± standard deviation. LDL cholesterol is not 
accurately calculated using the Friedewald equation for HTG patients when plasma TG concentration 
exceeds 4.5 mmol/L.  
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Table 2.2. Baseline clinical attributes of the replication cohort. 
Characteristic HTG Controls 
Number 344 144 
Female 33.7% 52.1% 
Diabetes 27.0% 3.5% 
Age (years) 50.2 ± 13.1 45.3 ± 20.0 
Body mass index (kg/m
2
)  29.9 ± 4.4 26.9 ± 5.6 
Plasma total cholesterol (mmol/L) 8.4 ± 4.0 6.2 ± 2.3 
Plasma HDL cholesterol (mmol/L) 0.9 ± 0.3 1.3 ± 0.4 
Plasma LDL cholesterol (mmol/L) - 4.3 ± 1.9 
Plasma TG (mmol/L) 12.1 ± 16.5 1.2 ± 0.5 
GWAS, genome-wide association study; HDL, high-density lipoprotein; HTG, hypertriglyceridemia; LDL, 
low-density lipoprotein; TG, triglycerides. Values are mean ± standard deviation. LDL cholesterol is not 
accurately calculated using the Friedewald equation for HTG patients when plasma TG concentration 
exceeds 4.5 mmol/L.  
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was reduced from λ = 1.25 to λ = 1.07. Residual inflation was further reduced upon 
removal of those SNPs most significantly associated with HTG (Figure 2.3). 
 
The HTG-associated loci ranged in strength of effect and association (Table 2.3). 
APOA5 was the strongest associated locus (P=5.4X10
-24
); each minor risk allele 
corresponded to a 3.3-fold increase in HTG susceptibility. The lead SNP at this locus is 
located in a block of LD containing several genes that are central in lipoprotein 
metabolism, including APOA5, APOA4, APOC3 and APOA1, making it difficult to 
determine the precise genomic element containing variation associated with HTG. 
However, APOA5 is known to be involved in both TG metabolism and HTG 
susceptibility, strongly suggesting that it is underlying the association with HTG. GCKR 
was second most strongly associated with HTG (P=6.5X10
-9
); each minor allele increased 
HTG susceptibility 1.8-fold. The lead SNP at this locus causes a proline to leucine amino 
acid substitution in GCKR at residue 446 (P446L), suggesting that this functional variant 
may mediate increased HTG susceptibility. The LPL locus was less strongly associated 
with HTG compared to the preceding loci (P=2.0X10
-7
), however each risk allele 
increases HTG susceptibility ~3.1-fold. Although the lead SNP is downstream of LPL, it 
is in a block of LD containing only LPL. Furthermore, LPL is well established in TG 
metabolism and HTG susceptibility, suggesting that common variants in this gene are 
underlying the GWAS association. APOB was associated with HTG with similar strength 
to LPL (P=2.0X10
-7
), although each risk allele only increased susceptibility by 1.7-fold. 
This variant was located ~122-kb upsteam of APOB in a block of LD spanning the APOB 
promoter. While APOB is the only gene at this locus, the position of the associated 
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Figure 2.3. Quantile-quantile plot of regression P-values. Deviation of P-values from 
the null is caused predominantly by significant associations with HTG (top), which is 
eliminated when significantly associated loci are removed from analysis (bottom). Both 
plots show minimal residual inflation of association test statistics. Association P-values 
displayed here were visualized using WGAViewer (Ge et al., 2008). 
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variant does not allow for common variation in genomic elements that regulate APOB 
expression to be ruled out. 
 
The loci identified by our study had recently been identified by a GWAS of 
normal plasma TG concentrations in healthy controls (Kathiresan et al., 2009b). This 
GWAS of normolipidemic plasma TG concentrations conducted in ~40,000 healthy 
controls had identified 11 TG-associated loci. In addition to the 4 loci identified by our 
study, they identified associations with common variation in MLXIPL, TRIB1, ANGPTL3, 
NCAN, FADS1, and PLTP. We hypothesized that the same loci associated with 
population-based plasma TG concentration could also mediate HTG susceptibility. We 
reasoned that the strength of association at these loci likely precluded detection at our 
genome-wide significance threshold, given smaller effect sizes and allele frequencies. 
Thus, we tested for association between lead SNPs at these loci and HTG in the full 
GWAS cohort of HTG patients. Associations were replicated at only three loci using a 
significance threshold of P<0.05, including MLXIPL, TRIB1, and ANGPTL3, increasing 
HTG susceptibility by 1.4-fold to 2.3-fold (Table 2.3). Positive replication of these TG-
associated loci, combined with trends towards significance at FADS1-FADS2-FADS3 
(P=0.05) and NCAN-CILP2-PBX4 (P=0.07), suggested that additional TG-modulating 
loci may also be involved in HTG pathophysiology.  
 
Finally, we sought to determine what proportion of variation was explained by 
clinical and genetic variants in HTG patients versus healthy controls. Together, clinical 
and genetic variables explained 40.5% of variation in HTG diagnoses: clinical variables 
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(age, sex, BMI and T2D) explained 19.7%, whereas genetic variables at 7 HTG-
associated loci (APOA5, GCKR, LPL, APOB, MLXIPL, TRIB1, and ANGPTL3) explained 
an additional 20.8%. It is likely that additional genetic variants in TG-associated loci 
would explain more variation in case status. 
 
2.3.3. Replication of TG-associated loci from the GLGC 
While conducting the GWAS above, we simultaneously engaged in collaboration with 
the GLGC. Their meta-analysis of >100,000 healthy controls identified 95 loci associated 
with plasma lipid and lipoprotein traits, including 32 loci associated with plasma TG 
concentrations. Our contribution was to validate the clinical significance of TG-
associated loci in patients with extreme levels of plasma TG. However, when we entered 
that collaboration only a subset of our sample was available for replication, which 
included 344 HTG patients and 144 healthy controls (Table 2.2). The baseline clinical 
characteristics of this subset of patients were virtually indistinguishable from the full 
GWAS cohort. 
 
We first attempted to replicate associations at 32 TG-associated loci identified by 
the GLGC (Table 2.4). In total, 10 loci were associated with HTG at a significance 
threshold of P<0.05. The strongest associated loci were those identified by our initial 
GWAS of HTG (APOA5, GCKR and LPL) with similar allele frequencies and effect 
sizes. However, an association was not identified with APOB rs1042034. Investigation of 
this discrepancy revealed that the two variants were separated by ~180-kb and were not 
in LD (r
2
=0). Re-analysis of each association using multiple logistic regression 
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Table 2.4. Replication of 32 TG-associated loci from the GLGC in HTG patients. 
CHR, chromosome; HTG, hypertriglyceridemia; GLGC, Global Lipids Genetics Consortium; GWAS, 
genome-wide association study; MAF, minor allele frequency; OR, odds ratio; SNP, single nucleotide 
polymorphism. Loci were replicated from the GLGC GWAS meta-analysis of >100,000 population-based 
TG concentrations (Teslovich et al., 2010), using a significance threshold of P<0.05. Association was tested 
using an additive multiple logistic regression model, entering sex, body mass index, diabetes status, and 10 
principal components of ancestry as covariates. This analysis included 344 HTG patients and 144 healthy 
controls. Risk allele is the TG-raising allele identified by the GLGC. 
Locus CHR SNP 
Minor allele 
(risk allele) 
HTG 
MAF 
Control 
MAF OR P 
APOA5 11 rs964184 G (G) 0.32 0.14 2.75 4.7E-07 
GCKR 2 rs1260326 T (T) 0.53 0.36 2.05 5.7E-06 
LPL 8 rs12678919 G (A) 0.04 0.10 0.37 0.0013 
ANGPTL3 1 rs2131925 G (T) 0.28 0.35 0.59 0.0017 
TRIB1 8 rs2954029 T (A) 0.35 0.43 0.62 0.0031 
MLXIPL 7 rs17145738 T (C) 0.07 0.13 0.49 0.0040 
TYW1B 7 rs13238203 T (C) 0.02 0.04 0.28 0.0062 
GALNT2 1 rs4846914 G (G) 0.42 0.35 1.55 0.0088 
ZNF664 12 rs4765127 T (G) 0.34 0.27 1.48 0.020 
KLHL8 4 rs442177 G (T) 0.35 0.41 0.71 0.041 
APOE 19 rs439401 T (C) 0.31 0.34 0.72 0.10 
PINX1 8 rs11776767 C (C) 0.39 0.35 1.24 0.17 
CAPN3 15 rs2412710 A (A) 0.02 0.01 2.12 0.17 
LIPC 15 rs1532085 A (A) 0.39 0.35 1.22 0.20 
JMJD1C 10 rs10761731 T (A) 0.41 0.38 1.21 0.22 
FRMD5 15 rs2929282 T (T) 0.06 0.05 1.49 0.24 
TIMD4 5 rs6882076 T (C) 0.34 0.40 0.84 0.26 
IRS1 2 rs2972146 G (T) 0.31 0.33 0.84 0.28 
COBLL1 2 rs10195252 C (T) 0.38 0.40 0.85 0.30 
NAT2 8 rs1495741 G (G) 0.24 0.22 1.20 0.33 
FADS1 11 rs174546 T (T) 0.39 0.36 1.16 0.34 
MAP3K1 5 rs9686661 T (T) 0.24 0.19 1.20 0.35 
HLA 6 rs2247056 T (C) 0.23 0.25 0.87 0.41 
MSL2L1 3 rs645040 G (T) 0.20 0.23 0.86 0.42 
CILP2 19 rs10401969 C (T) 0.05 0.07 0.79 0.42 
CYP26A1 10 rs2068888 A (G) 0.48 0.52 0.89 0.43 
PLTP 20 rs6065906 C (C) 0.18 0.18 1.15 0.47 
LRP1 12 rs11613352 T (C) 0.21 0.25 0.89 0.52 
APOB 2 rs1042034 C (T) 0.19 0.23 0.91 0.63 
KLF12 13 rs9592961 G (A) 0.01 0.01 0.69 0.69 
CETP 16 rs3764261 A (C) 0.33 0.37 0.96 0.82 
ACSS2 20 rs11546155 A (G) 0.15 0.16 1.03 0.88 
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conditioned upon the other SNP revealed negligible changes in strength of association. 
We confirmed that the three additional sub-threshold APOB variants identified in our 
initial GWAS were all in moderate LD with our lead SNP rs4635554 (r
2
 from 0.35 to 
0.51); furthermore, they were not affected by conditioning on the population-based TG-
associated SNP APOB rs1042034, whereas conditioning upon our lead SNP rs4635554 
completely ablated their associations with HTG. This totality of evidence suggested that 
the HTG-derived APOB signal and the population-based APOB signal likely represent 
two independent associations.  
 
Replication was also successful but less robust at loci including MLXIPL, TRIB1, 
and ANGPTL3 (Table 2.4), with allele frequencies and effect sizes similar to those 
observed in the full GWAS cohort. Additional replications were observed at 4 newly 
identified loci including TYWIB, GALNT2, ZNF664, and KLHL8. These variants ranged 
in effect, increasing HTG susceptibility by 1.4-fold to 3.6-fold. However, only ~1/3 of all 
variants were statistically associated with HTG (P<0.05). Interestingly, there was an 
over-representation of TG-raising risk alleles at 29/32 loci with directions of effect 
concordant with population-based studies (P=1.2X10
-6
), suggesting that additional loci 
likely contribute to increased HTG susceptibility, but again small effect sizes likely limit 
their detection. Given the small sample size of this subset of our GWAS cohort, we did 
not assess the additional variation explained by newly discovered TG-associated loci. 
  
We next compared the genetic burden of common TG-associated variants in HTG 
patients versus healthy controls. We hypothesized that common variants may accumulate 
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in HTG patients given that the same loci associated with population-based TG 
concentrations were also associated with increased HTG susceptibility. Unweighted TG 
risk scores were increased in HTG patients versus controls (Figure 2.4). Comparison of 
the number of HTG patients and healthy controls in each risk score bin revealed a 
striking trend towards increased proportions of HTG patients compared to healthy 
controls with increasing risk scores. The mean unweighted risk score was clearly 
increased in HTG versus controls, with 36.2 ± 0.2 risk alleles versus 33.6 ± 0.3 risk 
alleles (P=6.2X10
-15
), respectively. 
 
Weighted TG risk scores were also significantly increased in HTG patients versus 
controls (Figure 2.5). The relative frequency distribution was clearly shifted towards 
increased scores in HTG patients versus controls: 0.99±0.01 mmol/L versus 0.88±0.01 
mmol/L (P=4.7X10
-32
), respectively. Furthermore, weighted TG risk scores were an 
important predictor of HTG susceptibility (Figure 2.6). Increasing bins of HTG risk 
score were distinctly associated with increasing HTG susceptibility (Ptrend<0.001), such 
that subjects in the highest risk score bin were 7.16 (95% CI: 3.86-13.2) times more 
likely to be an HTG patient than a healthy control compared to subjects in the lowest risk 
score bin (P=8.5X10
-14
). Together, these data strongly suggested that an increase burden 
of common population-based TG associated loci is characteristics of patients with HTG. 
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Figure 2.4. Distribution of unweighted TG risk scores in HTG patients and healthy 
controls. Unweighted TG risk scores were constructed as the sum of raw TG-raising 
alleles at 32 TG-associated loci identified by the GLGC (Teslovich et al., 2010). All loci 
were included in risk score analysis regardless of statistical association in the replication 
phase. The figure was constructed by counting the proportion of HTG patients (n=344) to 
healthy controls (n=144) in each risk score bin. 
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Figure 2.5. Relative frequency distribution of weighted TG risk scores in HTG 
patients and healthy controls. Weighted TG risk scores constructed as the sum of TG-
raising alleles at all 32 TG-associated loci, each multiplied by the corresponding 
population-based effect estimate, as generated by the GLGC (Teslovich et al., 2010). 
Units were initially reported as mg/dl but converted here to mmol/L (conversion factor 
88.6 mg/dl = 1 mmol/L). All loci were included in risk score analysis regardless of 
statistical association in the replication phase. The frequency distributions was 
constructed by dividing the range of risk scores into equal bins, and plotting the number 
of HTG patients (n=344) or controls (n=144) in each bin relative to total number of HTG 
patients or controls in the sample.  
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Figure 2.6. Increasing TG risk score is associated with increased HTG susceptibility. 
Forest plots were generated by ranking all weighted risk scores in the combined sample 
of HTG patients (n=344) and healthy controls (n=144) from lowest to highest, dividing 
risk scores into 4 bins of equal numbers of subjects; comparing the number of HTG 
patients to controls in each bin to the reference bin using Fisher’s exact test. The 
significance of increasing HTG susceptibility with increasing risk score bin was assessed 
using the Cochrane-Armitage test for trend. 
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2.4 Discussion 
We have conducted the first GWAS evaluating subjects at the extremes of a lipid 
phenotype distribution conducted to date. Using a case-control design comparing 463 
HTG patients and 1197 healthy population-based controls, we showed genome-wide 
significant associations with APOA5, GCKR, LPL and APOB, and replicated associations 
at MLXIPL, TRIB1, ANGPTL3. Trends towards significance were also observed at NCAN 
and FADS1. Furthermore, we demonstrated that TG-raising alleles at 29/32 TG-
associated loci identified by the GLGC were over-represented in HTG patients compared 
to healthy controls, suggesting that loci that modulate plasma TG concentration in the 
general population also underlie HTG susceptibility. Furthermore, TG-raising risk alleles 
appear to accumulate in HTG patients rather than healthy controls, suggesting that an 
increased genetic burden of common TG-associated variants could be a characteristic of 
HTG susceptibility. Together, common variants at 7 HTG-associated loci explain ~21% 
of variation in HTG diagnoses. 
 
A common feature that has emerged from GWAS studies, including our GWAS 
of HTG patients, is the identification of both known and novel genes involved in the 
target phenotype. For instance, LPL (lipoprotein lipase) and APOA5 (apolipoprotein A-V) 
were already appreciated as involved in monogenic and polygenic HTG phenotypes. LPL 
has long been recognized as the fulcrum for hydrolysis of plasma TG-rich lipoproteins 
(Havel, 2010). It hydrolyses TG-rich lipoproteins in tissues requiring fatty acids for TG 
re-synthesis in adipose tissue or beta-oxidation in muscle (Kirchgessner et al., 1989). 
APOA5 is also a crucial determinant of TG-rich lipoprotein metabolism. It enhances LPL 
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activity, likely by affecting the distribution of apo C-III molecules on VLDL, thus 
promoting TG-rich lipoprotein lipolysis (Qu et al., 2007). Rare LOF variants in both LPL 
and APOA5 are also associated with both monogenic and polygenic HTG (Hegele, 2009).  
 
However, GCKR and APOB are newly implicated players in HTG susceptibility. 
GCKR encodes an allosteric regulator of glucokinase (GK) called the glucokinase 
regulatory protein (GKRP), which allows rapid mobilization of GK in response to 
increased cellular glucose concentrations (Agius, 2008). The P446L functional variant in 
GKRP is known to attenuate ligand-dependent GK inhibition (Beer et al., 2009, Orho-
Melander et al., 2008), in turn promoting glucose uptake and mobilization, thus 
attenuating fatty acid oxidation and promoting de novo TG synthesis (Beer et al., 2009). 
APOB encodes the defining structural component of TG-rich lipoproteins called a B-100, 
traditionally implicated in extreme phenotypes involving plasma LDL-C, such as familial 
hypercholesterolemia and familial hypobetalipoproteinemia. Preliminary analyses of 
APOB association signals from population-based studies suggest that the functional 
variant affects an expression quantitative trait locus (QTL) that modulates transcript 
levels of both APOB and a novel noncoding RNA BU630349, in addition to being a QTL 
for plasma apo B concentrations (Haas et al., 2011). Although the precise contribution of 
common variation in GCKR and APOB to increased HTG susceptibility remains to be 
elucidated, these associations provide new leads and hypotheses that can be evaluated to 
better understand the biology and biochemistry of TG metabolism and HTG 
susceptibility. 
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Further examination of SNPs below our threshold for significance (i.e. between 
P=5X10
-7
 and P=5X10
-6
) revealed 82 additional associations localizing predominantly to 
APOA5, LPL, APOB, and MLXIPL. Otherwise, only two potentially novel associated 
SNPs were found in the LHFPL3 (P=5.7X10
-7
) and TSC1 (P=3.0X10
-6
) genes. LHFPL3 
is a poorly characterized gene, annotated as a homolog of LHFP; mutations in the latter 
were identified by mapping of non-syndromic deafness (Longo-Guess et al., 2005). 
While somewhat better characterized, mutations in TSC1 have been associated with 
tuberous sclerosis (Sampson, 2003), and some cancers. Neither locus is thus a credible a 
priori candidate for involvement in HTG susceptibility or TG-metabolism. 
 
A particularly important novel insight provided by our study is that the genetic 
determinants of plasma TG concentration also contribute to increased HTG susceptibility. 
For example, the lead variants at APOA5 and GCKR are identical between both GWAS 
of HTG and population-based studies, and the lead variant in LPL is in the same block of 
LD between both studies. Furthermore, we successfully replicated TG-associated loci 
from population-based studies at MLXIPL, TRIB1, and ANGPTL3, and we demonstrated 
that 29/32 loci have similar directions of effect as those reported in the GLGC. Our 
interpretation of this trend is that, given sufficient power, the same loci that modulate 
plasma TG in population-based subjects will be shown also to modulate HTG 
susceptibility.  
 
We also demonstrated that genetic risk scores composed of TG-associated risk 
alleles were increased in HTG patients versus controls. Whether unweighted or weighted 
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by population-based effect estimates, TG-raising alleles accumulated more often in HTG 
patients. This suggests that a genetic burden of TG-raising alleles may be important in 
HTG pathophysiology. However, the significant overlap between risk score distributions 
in HTG patients and healthy controls suggests that common variation contributes only in 
part to HTG susceptibility; our current estimate being ~21%.  
 
Future studies will require larger sample sizes and different study designs to 
complement our analyses and elucidate remaining genetic determinants of HTG. 
Replication and risk score analyses of the 32 TG-associated loci identified by the GLGC 
are required in a larger HTG cohort to determine whether the hypotheses generated by 
our study are correct. Furthermore, a more exhaustive survey of genetic variation at 
HTG-associated loci, obtained by complete resequencing in many subjects, will be 
required to uncover additional genetic variation underlying HTG susceptibility. 
 
In summary, we used a GWAS of HTG and replication of TG-associated loci to 
demonstrate that the same genetic determinants of plasma TG concentration are 
associated with increased HTG susceptibility. Furthermore, TG-raising alleles tend to 
accumulate in HTG patients, suggesting that a genetic burden of TG-associated risk 
alleles is characteristic of HTG. Common variation in TG-associated genes only explains 
~21% of variation in HTG diagnoses, meaning that additional genes and genetic variants 
need to be identified to fully understand the complex nature of HTG pathophysiology. 
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CHAPTER 3 
 
RARE GENETIC VARIATION IN TRIGLYCERIDE-ASSOCIATED GENES 
ACCUMULATES IN PATIENTS WITH HYPERTRIGLYCERIDEMIA 
 
The work in this chapter originates from material in the following publications: (1) 
Johansen CT, Wang J, Lanktree MB, et al. (2010). Excess of rare variants in genes 
identified by genome-wide association study of hypertriglyceridemia. Nat Genet 42 (8): 
684-7; and (2) Johansen CT, Wang J, McIntyre AD, et al. (2011). Excess of rare variants 
in non-GWAS candidate genes in patients with hypertriglyceridemia. Circ Cardiovasc 
Genet. Submitted. 
 
3.1 Introduction 
Genome-wide association studies (GWAS) have reliably identified novel and known loci 
associated with population-based plasma lipid concentrations (Aulchenko et al., 2009, 
Kathiresan et al., 2008, Kathiresan et al., 2009, Sabatti et al., 2009, Teslovich et al., 2010, 
Willer et al., 2008). Despite the robustness of these associations, the proportion of 
variability explained by GWAS-identified loci is relatively modest, <10% in most studies 
(Aulchenko et al., 2009, Kathiresan et al., 2009, Teslovich et al., 2010), and <20% in our 
study of hypertriglyceridemia (HTG) (Johansen et al., 2010). While vastly expanded 
GWAS sample sizes continue to reveal new associations, each newly associated variant 
has an incrementally smaller effect size and contributes only marginally to the cumulative 
variation of each lipid phenotype (Manolio et al., 2009). This suggests that GWAS of 
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population-based subjects may be reaching their limits to explain heritability of complex 
traits.  
 
The source of ‘missing heritability’ in complex traits is a topic of intense 
speculation (Manolio et al., 2009). One hypothesis is that additional forms of genetic 
variation may explain some unattributed variation. Rare variants of individually large 
effect are suspected to account for a large proportion of such variation. Furthermore, 
gene-gene and gene-environment interactions involving both common and rare variants 
could also contribute to the unexplained variation. Another explanation is that GWAS-
identified genes represent only a fraction of all genes that contribute to complex traits. 
For instance, important disease-associated genes may not contain common variation, or 
common variants may have minute effect sizes, that would cause such genes to elude 
detection even in epidemiologically-sized GWAS (Johansen et al., 2011a). Regardless, 
such non-GWAS loci may harbour rare genetic variants that contribute to disease 
susceptibility. For instance, several non-GWAS genes have been implicated in 
triglyceride (TG) metabolism by pre-genome-era biochemical studies of patients with 
Mendelian HTG syndromes and naturally-occurring or genetically-engineered mutants 
causing HTG in mice, including LPL, APOC2, APOA5, GPIHBP1, and LMF1 (Hegele, 
2009). Extensive re-sequencing of such genes and evaluation of rare variant accumulation 
could help identify the contribution of additional genes and variation to polygenic HTG.  
 
High-throughput resequencing studies are effective at detecting rare variant 
accumulation in case-control studies of complex disease (Bansal et al., 2010). Using 
124
  
 
missense-accumulation analysis in genes defined a priori as likely to contain rare 
variants, a burden of mutations can be quantified statistically in subjects with severe 
phenotypes (Bansal et al., 2010). However, clear hypotheses are necessary to focus 
analyses towards a subset of genes and variants with increased a priori probability of 
determining the disease phenotype. One hypothesis is that genomic loci containing 
common small effect variants identified by GWAS also harbour rare variants that are 
associated with disease (Manolio et al., 2009). While the mechanistic basis for the 
association between lipid traits and most common variants discovered in GWAS is still 
largely unknown, it remains possible that rare variants in GWAS-identified genes may 
contribute significantly to lipid phenotypes and may help to identify specific disease-
associated genes.  
 
Studying subjects at the extremes of a quantitative phenotype distribution has 
proven useful to identify functional rare variants (Cohen et al., 2004, Nejentsev et al., 
2009, Plomin et al., 2009, Romeo et al., 2007, Wang et al., 2007). In primary HTG, 
resequencing of TG-modulating candidate genes has implicated both common and rare 
variants in HTG disease pathophysiology (Hegele et al., 2009, Wang et al., 2008, Wang 
et al., 2007). Thus, our objectives were to resequence coding regions of candidate genes 
in 1) loci reaching genome-wide significance by GWAS of HTG; and in 2) non-GWAS 
candidate genes established in TG metabolism by mouse models and Mendelian 
syndromes of HTG, to evaluate the burden of rare variants in HTG patients compared 
with controls. We also sought to determine whether rare variants contribute additionally 
to the explained variation in HTG case status. 
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3.2 Methods 
 
3.2.1 Study subjects 
This study was approved by the University of Western Ontario Institutional Review 
Board (protocol #07920E), and ethics boards at collaborating institutions. All subjects 
provided informed consent for blood sampling, DNA analysis, and collection of clinical, 
biochemical and other demographic data. All subjects in this study were unrelated and of 
self-declared European ancestry. In total, 437 HTG patients and 326 population-based 
controls were included in these studies. HTG patients were clinically diagnosed with 
Fredrickson hyperlipoproteinemia (HLP) phenotypes 2B (MIM 144250), 3 (MIM 
107741), 4 (MIM 144600) or 5 (MIM 144650), ascertained primarily from a single 
tertiary referral lipid clinic in London, Canada. HTG patients had plasma TG 
concentrations >95
th
 percentile (3.37 mmol/L). Population-based controls were 
ascertained through the Study of Health Assessment and Risk in Ethnic Groups (Anand et 
al., 2000), as previously described. Control subjects with fasting plasma TG 
concentration >2.3 mmol/L were excluded from analyses due to potentially undiagnosed 
HTG, but were otherwise not phenotypically-selected, preventing the selection of 
potentially protective variants that might be expected in super-normal controls. The 
majority of subjects are common between both resequencing studies, including 421 HTG 
patients and 324 controls. Biochemical analyses of lipoprotein traits were conducted 
separately in each cohort, as previously described (Anand et al., 2000, Hegele et al., 
2009). 
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3.2.2 Gene selection 
Two distinct hypotheses were tested in this chapter: (1) GWAS-identified genes would 
harbour an excess of rare variants in HTG patients versus controls; and (2) candidate 
genes identified by mouse and human models of HTG would harbour an excess of rare 
variants in HTG patients versus controls. GWAS-identified genes were selected from 
HTG-associated loci as the most probable gene to be involved in HTG pathophysiology 
(Hegele et al., 2009, Johansen et al., 2010), including APOA5, GCKR, LPL, and APOB. 
There were multiple genes at the APOA5 locus with possible involvement in HTG 
pathophysiology, however only the APOA5 gene was present in the HTG-associated 
block of linkage disequilibrium. Furthermore, homozygous rare variants in the APOA5 
gene have been established as causative for pediatric Mendelian HTG (Priore Oliva et al., 
2005). The remaining GWAS-identified genes were the closest genes to each GWAS 
association signal.  
 
Non-GWAS candidate genes were selected for sequencing based on mouse 
models and Mendelian syndromes of HTG. APOC2 was selected based on knowledge 
that homozygous mutations in humans cause pediatric Mendelian HTG (Connelly et al., 
1987). Heterozygous mutations in APOC2 have also been identified in subjects with 
polygenic forms of HTG (Wang et al., 2007). GPIHBP1 and LMF1 were each selected as 
human genes orthologous to knockout mouse models characterized by HTG (Beigneux et 
al., 2007, Peterfy et al., 2007). Functionally characterized homozygous mutations in 
GPIHBP1 (Beigneux et al., 2009, Franssen et al., 2010, Olivecrona et al., 2010) have also 
been reported in patients with pediatric Mendelian HTG.  
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Two novel HTG candidate genes were also sequenced in this study, including 
CREB3L3 and ZHX3, both genes identified by novel mouse models of HTG. Zhx3 was 
initially identified as a candidate gene for high-density lipoprotein (HDL) cholesterol 
concentration by a systems genetics analysis of HDL metabolism. It is a member of a 
family of three transcription factors, of which Zhx2 has previously been shown to 
regulate both TG and cholesterol levels (Gargalovic et al., 2010). A linkage analysis of 
HDL cholesterol concentration and gene expression patterns in liver and adipose was 
used to identify candidate HDL-associated loci in the progeny of a cross between two 
inbred mouse strains differing vastly in their metabolism of HDL (CAST/EiJ and 
C57BL/6J) (Figure 3.1). Zhx3 was directly under the linkage peak and exhibited a strong 
expression quantitative trait locus (eQTL) associated with HDL levels. Association of 
Zhx3 with TG levels has also been observed in human genome-wide expression scans 
(Gargalovic et al., 2010).  
 
Creb3l3, encoding the transcription factor Creb-h, was hypothesized to be an 
important regulator of nutrient and energy metabolism in mice (Lee et al., 2011). Recent 
studies demonstrated that Creb-h was involved in regulation of phosphoenolpyruvate 
carboxykinase 2 and glucose-6-phosphatase in vivo, and that Creb3l3 expression is 
modulated by fasting and insulin resistant states (Lee et al., 2010). Studies aimed at 
elucidating the in vivo function of Creb3l3 pursued the creation of a knockout mouse 
strain, which revealed a fasting HTG phenotype. The human orthologous gene CREB3L3 
was therefore suspected as a candidate gene for HTG susceptibility. A manuscript based 
on this work was recently published (Lee et al., 2011).  
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3.2.3 Sequencing and rare variant definition 
All genes were bidirectionally sequenced in individual samples using an ABI 3730 
Automated DNA Sequencer and called using automated software (Applied Biosystems, 
Foster City, CA). Our main goal was the identification of protein coding variants, thus all 
exonic DNA was sequenced including ~50-bp of flanking intronic DNA; however only 
exons 26 and 29 of APOB (67.8% of protein sequence; corresponding to the receptor 
binding domain of apo B) were sequenced. Variants were manually curated, and 
confirmed by repeat analysis. Subjects missing sequencing data in any gene were 
removed from the study prior to analysis.  
 
Variant frequency thresholds were calculated based on frequencies in healthy 
controls for GWAS genes, whereas variant frequency thresholds were calculated based 
on frequencies in the combined dataset for candidate genes. These methodological 
differences in rare variant definition reflect our evolving understanding of analyses in 
rare variants studies (as hypotheses were not tested simultaneously) that will be addressed 
in the overall discussion of this dissertation (Chapter 5). These differences in rare variant 
definition have virtually no difference on the results presented here (Johansen et al., 
2011b). Rare variants were defined by frequency <1%, uncommon variants were defined 
by frequency ≥1% to <5%, and common variants were defined by frequency ≥5%. 
Nonsynonymous variants refer to sequence variations causing amino acid substitutions 
(missense variants) or introducing premature protein truncations (nonsense variants). 
Synonymous variants refer to DNA sequence variants that do not change protein coding 
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sequence (silent variants) or do not affect protein coding sequence (variants in noncoding 
variants).  
 
3.2.4 Statistical analysis 
Rare variant accumulation across all genes was compared between HTG patients and 
controls using Fisher’s exact test, defining nominal significance as a 2-sided P<0.05, 
using SAS v.9.2 (Cary, NC, USA). Comparison of plasma TG concentrations between 
carriers and non-carriers of rare variants in nuclear families was conducted using the 
Wilcoxon signed-rank test for non-parametric data, defining nominal statistical 
significance as a 2-sided P<0.05. Mutation accumulation analyses compared either the 
number of observed rare alleles, or the number of rare variant carriers, between HTG 
patients and healthy controls, as indicated. Carriers were defined as having ≥1 rare 
variant. Enrichment for rare variants with high probability of function effects was 
attempted using two different strategies, where indicated: (1) filtration enriching for 
‘exclusive’ variants not identified in controls; and (2) filtration enriching for variants 
predicted in silico to have deleterious functional effect. Exclusive variants were defined 
as rare variants found exclusively in HTG patients or controls (not both), deliberately 
excluding variants previously reported without demonstrated functional compromise. 
Filtration of rare variants using in silico prediction of deleterious effect was conducted 
using established software, including Polyphen-2 (Polymorphism Phenotyping v2) 
(Adzhubei et al., 2010) and SIFT (Sorting Intolerant from Tolerant) (Kumar et al., 2009) 
for variants resulting in amino acid substitutions at the protein level. Nonsense mutations 
were ranked as analogous to having 2 predictions of deleterious effect. 
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Rare variant accumulation was assessed across individual genes using Fisher’s 
exact test and three additional permutation-based analyses of genetic burden (general 
case-control comparison, C-alpha, and the variable threshold approach) as implemented 
in PlinkSeq (http://atgu.mgh.harvard.edu/plinkseq). No single proposed test statistic has 
been proposed for rare variant accumulation studies; therefore we chose 3 distinct 
independent analyses for further post hoc evaluation of our dataset. The general burden 
test was chosen as a method that was parallel to Fisher’s exact test, and could compare 
the number of alternate alleles between HTG patients and healthy controls using a 
permutation-based approach. The C-alpha test statistic was chosen because it was a 
recently proposed analysis to measure genetic burden across a locus considering variants 
with a mixture of protective and deleterious directions of effect (Neale et al., 2011). The 
variable threshold analysis was chosen as an analysis strategy that increases the weight of 
very rare variants, such as those likely to be functionally significant (Price et al., 2010). 
Empirical P-values were calculated in parallel for all statistical tests using 10,000 or 
1,000,000 permutations, as indicated. 
 
Summary statistics are displayed as mean ± standard deviation. Identity-by-state 
calculations, multi-dimensional scaling and association testing were conducted as 
implemented in PLINK (Purcell et al., 2007) and PlinkSeq. Identity-by-state calculations 
and multidimensional scaling were performed using freely available HapMap CEU 
(European ancestry), CHB/JPT (Asian ancestry) and YRI (African ancestry) subjects in 
order to demonstrate the relative ancestry of study participants. Association was tested 
between common variants and HTG using an additive multiple logistic regression model, 
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adjusted for clinical covariates age, sex, body mass index (BMI) and type 2 diabetes 
(T2D) where indicated. Statistical significance for association was defined as a nominal 
P<0.05. Statistical significance for association was defined as a nominal P<0.05. All 
variants were in Hardy-Weinberg equilibrium (P>0.05). Explained variation calculations 
were performed using multiple logistic regression without a predefined modeling 
strategy. Case or control status was modeled as the dependent variable, entering clinical 
variables (age, sex, BMI, and T2D), and common variants at 7 HTG-associated loci (0, 1 
or 2 TG-raising alleles) as independent variables. Subjects included in the explained 
variation analysis were common to both GWAS (Chapter 2) and resequencing cohorts, 
including 346 HTG patients and 205 healthy controls. Independent variables included 
clinical covariates age, sex, BMI and T2D status as either continuous or discrete 
variables, common variants as continuous variables of HTG risk associated alleles at each 
of the 7 HTG-associated loci, and rare variants as a continuous variable including the 
number of rare variants carried by each subject.  
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3.3 Results 
 
3.3.1. Study subjects 
Baseline clinical attributes of the 437 HTG patients and 326 population-based controls 
are shown in Table 3.1. Generally, clinical attributes of HTG patients were less 
favourable than controls. HTG patients had increased BMI, increased plasma total 
cholesterol, decreased plasma HDL cholesterol and increased prevalence of T2D. Plasma 
TG concentration was most greatly increased, with a mean of 12.8 mmol/L in HTG 
patients versus 1.2 mmol/L in healthy controls. In subjects with whole genome 
genotyping data available, including 346 HTG patients and 205 healthy controls, we 
confirmed their European ancestry using identity-by-state calculations and 
multidimensional scaling (Figure 3.2). 
 
3.3.2. Rare variant accumulation in GWAS-identified HTG-associated genes 
Our first hypothesis was that rare variants related to HTG disease causation would 
accumulate in genes containing common variation associated with HTG by GWAS. The 
protein-coding sequences of APOA5, GCKR, LPL and exons 26 and 29 (67.8%) of APOB 
were resequenced in individual subjects as regions most likely to harbour protein-
compromising mutations. Across the 4 genes, 80 distinct heterozygous rare variants were 
identified (Table 3.2; Figure 3.3). Only 29/80 (36%) rare variants were annotated in 
public databases such as dbSNP or 1000 Genomes Project. The strength of association 
between HTG and GWAS-associated loci did not predict the mutation accumulation in 
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Table 3.1. Baseline clinical attributes of study sample. 
Characteristic HTG Controls 
Number 437 326 
Female 33.0% 54.6% 
Diabetes 27.9% 1.9% 
Age (years) 51.4 ± 13.1 49.7 ± 15.1 
Body mass index (kg/m
2
) 30.0 ± 4.9 26.7 ± 4.5 
Plasma total cholesterol (mmol/L) 8.4 ± 3.9 4.9 ± 0.8 
Plasma HDL cholesterol (mmol/L) 0.9 ± 0.3 1.3 ± 0.4 
Plasma LDL cholesterol (mmol/L) - 3.2 ± 0.9 
Plasma TG (mmol/L) 12.8 ± 16.4 1.2 ± 0.4 
The majority of study subjects were common among both sequencing projects, including 421 HTG patients 
and 324 healthy controls. Values are shown for the GWAS cohort, but are virtually identical between 
cohorts. Values are mean ± standard deviation. LDL cholesterol is not accurately calculated using the 
Friedewald equation for HTG patients when plasma TG concentration exceeds 4.5 mmol/L. GWAS, 
genome-wide association study; HDL, high-density lipoprotein; HTG, hypertriglyceridemia; LDL, low-
density lipoprotein; TG, triglyceride. 
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Figure 3.2. Confirmation of European ancestry within the study sample. Identity-by-
state and multidimensional scaling analyses were used to illustrate the relative genetic 
similarity between study subjects, represented by closer relative distance on the plot 
above. HTG cases (diamonds) and healthy controls (squares) are all of European 
ancestry, assessed by clustering with HapMap CEU subjects of European ancestry (green 
triangles), and distance from HapMap YRI subjects of African ancestry (purple X's) and 
CHB/JPT subject of East Asian ancestry (blue X's). Rare variant carriers are shown as 
orange symbols to illustrate that they do not deviate from European ancestry. This 
analysis only included subjects for whom both sequencing and whole genome genotyping 
data were available, which included 346 HTG patients and 205 healthy controls. 
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Figure 3.3. Rare variants identified by resequencing GWAS-identified genes in HTG 
patients and healthy controls. Variants above gene maps were identified in HTG 
patients and variants below gene maps were identified in controls. Rare variants are 
coloured according to their identification in control subjects or previous identification in 
subjects of unknown clinical status (black), exclusivity to HTG patients or controls 
(blue), or proven biological dysfunction or truncation (red). Nomenclature refers to 
functional protein sequences. Only exons 26 and 29 were resequenced in APOB. Gene 
maps are roughly to scale, although differ in scale between genes. GWAS, genome-wide 
association study; HTG, hypertriglyceridemia; TG, triglyceride. 
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resequenced genes. LPL harboured the largest relative proportion of rare variants, 
followed by GCKR, APOB and APOA5, with 30.9, 10.7, 9.3, and 4.5 rare variants per 
kilobase of coding sequence in HTG patients, whereas the same genes harboured 5.6, 2.7, 
4.3 and 0.9 rare variants per kilobase of coding sequence in controls. Among these 
variants, 20 were identified in both HTG patients and controls, 50 were identified 
exclusively in HTG patients, and 10 exclusively in controls. The vast majority of rare 
variants were singletons (54/80), compared to doubletons (9/80), tripletons (2/80) or 
variants with other frequencies (15/80). 
 
Overall, a significant accumulation of rare variants was identified in HTG patients 
(Table 3.3): 154 rare variant occurrences were observed among 437 HTG patients 
compared to 53 rare variant occurrences observed among 326 healthy controls, 
corresponding to a 2.4-fold (95% CI: 1.72-3.34) increase in rare variants in HTG patients 
(P=6.2X10
-8
). There was also a significant increase in rare variant carriers in HTG 
patients versus controls: 28.1% of HTG patients and 15.3% in controls carried ≥1 rare 
variant, corresponding to a 2.2-fold (95% CI: 1.50-3.12) increased in carrier frequency 
(P=2.6X10
-5
). Although the majority of subjects carried only 1 rare variant, subjects with 
multiple rare variants were also significantly over-represented in HTG patients (6.6% 
HTG carriers versus 0.9% control carriers; P=3.7X10
-5
).  
 
A more restricted analysis enriching for rare variants with potentially functional 
effects based on exclusivity in either HTG patients or controls, similarly revealed a 
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significant burden of 47 rare variant occurrences  in HTG patients compared to 9 rare 
variant occurrences in controls (Table 3.3). This corresponded to a 4.1-fold (95% CI: 
1.98-8.35) increase in exclusive variants in HTG patients (P=2.4X10
-5
). Similarly, there 
was a significantly increased carrier frequency of exclusive variants, as 10.3% of HTG 
patients and 2.8% of controls carried ≥1 exclusive variant, corresponding to a 4.0-fold 
(95% CI: 1.95-8.40) increase in HTG patients versus healthy controls (P=4.4X10
-5
). HTG 
carriers’ fasting plasma TG concentrations ranged from 3.10–88.5 mmol/L, whereas 
control carriers’ fasting plasma TG concentrations ranged from 0.45–1.93 mmol/L. No 
discernable patterns were observed between such attributes as the gene, mutation type or 
mutation position with plasma TG concentration or HTG phenotype. 
 
Finally, we conducted a post hoc analysis to determine whether rare variant 
accumulation could be detected in any specific genes. Using Fisher’s exact test, a 
significant excess of rare variants was detected in HTG patient versus healthy controls in 
LPL, GCKR, and APOB. LPL had a 4.3-fold enrichment (95% CI: 2.00-9.13; P=2.47X10
-
5
), GCKR had a 3.0-fold enrichment (95% CI: 1.13-8.12; P=0.024), APOB had a 1.7-fold 
enrichment (95% CI: 1.14-2.51; P=7.99X10
-3
). We could not detect a statistically 
significant increase in rare variants in APOA5 (OR=3.8; P=0.25), although the relative 
magnitude of this accumulation was second only to LPL in comparison to other genes. 
We repeated the analysis above considering carriers versus non-carriers, confirming 
statistical association between rare variant accumulation and HTG in only LPL and 
GCKR. LPL had a 4.3-fold enrichment (95% CI: 2.00-9.37; P=2.9X10
-5
), and GCKR had 
a 2.9-fold enrichment (95% CI: 1.08-7.91; P=0.035). However, we were no longer able to 
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detect an accumulation of rare variants in APOB (OR=1.56; P=0.054), likely because the 
magnitude of the accumulation was attenuated by carriers of multiple APOB rare 
variants. 
 
We repeated the gene-centric association analysis using three recently proposed 
permutation-based statistical analyses designed for rare variant accumulation studies. We 
employed 3 different analyses to differently assess rare variant accumulation in 
individual genes post hoc, including a general test of burden, a recently proposed 
variance-based analysis using the C-alpha test statistic (Neale et al., 2011), and a recently 
proposed variable-threshold analysis (Price et al., 2010), all of which employed 
permutation-based analyses to obtain empirical P-values for variant accumulation. The 
three statistical analyses used to assess genetic burden varied in their ability to detect rare 
variant accumulation in HTG patients versus healthy controls in various genes (Table 
3.4). A significant accumulation of rare variants was confirmed empirically across all loci 
by the general burden test (P=7.0X10
-7
), the C-alpha test statistic (P=0.002), and the 
variable threshold approach (P=4.1X10
-6
). Among individual genes, rare variant 
accumulation was detected in LPL, APOB, and GCKR using the general burden test 
(P=1.1X10
-5
, P=0.0092, and P=0.013, respectively) and the variable threshold approach 
(P=1.5X10
-5
, P=0.023, and P=0.014, respectively). These analyses did not detect rare 
variant accumulation in APOA5 using the burden test (P=0.11) or the C-alpha test 
(P=0.97), although a trend toward significance was observed using the variable threshold 
approach (P=0.071). C-alpha could only detect rare variant accumulation in LPL 
(P=0.0014). 
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3.3.3. Rare variant accumulation in non-GWAS candidate genes 
Our second hypothesis was that rare variants related to HTG disease causation would 
accumulate in candidate genes identified by mouse models and Mendelian syndromes of 
severe HTG. Re-sequencing of HTG-associated candidate genes in 437 HTG patients and 
326 healthy controls identified 49 distinct missense or nonsense variants in HTG patients 
and healthy controls (Table 3.5), including 43 heterozygous rare variants (minor allele 
frequency [MAF] <1%), 3 heterozygous uncommon variants (MAF 1-5%) and 3 
common variants (MAF >5%). Only 6/43 (14%) rare variants were annotated in public 
databases such as dbSNP or 1000 Genomes Project, whereas all common and uncommon 
variants had been previously identified. APOC2 had the largest number of rare variants 
relative to size, followed by LMF1, CREB3L3, GPIHBP1, and ZHX3, harbouring 
respectively 19.8, 9.4, 8.0, 7.2 and 5.6 variants per kilobase sequenced in HTG patients, 
and 0, 2.9, 0.7, 3.6 and 2.8 variants per kilobase sequenced in controls. Among these 
variants, 6 were identified in both HTG patients and controls, 30 were identified 
exclusively in HTG patients, and 7 exclusively in controls (Figure 3.4). The vast 
majority of rare variants were again singletons (30/43), as opposed to doubletons (6/43), 
tripletons (3/43) or variants with other frequencies (4/43). 
 
Rare nonsynonymous variants were found to be in large excess among HTG 
patients (Table 3.6). In total, we found 53 rare variant occurrences among 437 HTG 
patients and 16 rare variant occurrences among 326 controls, corresponding to a 2.3-fold 
increase in variants found in HTG patients (P=0.0050). Only 6 HTG patients and 1 
healthy control were carriers of 2 rare variants, which had virtually no effect on the  
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Figure 3.4. Rare variants identified in HTG patients and healthy controls by 
resequencing candidate genes from mouse and human models of HTG. Variants 
above gene maps were identified in HTG patients and variants below gene maps were 
identified in controls. Rare variants are coloured according to their identification in both 
HTG patients and controls (black), exclusivity to HTG patients or controls (blue), or 
proven biological dysfunction or truncation (red). Nomenclature refers to functional 
protein sequences. Gene maps are roughly to scale, although differ in scale between 
genes. HTG, hypertriglyceridemia. 
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observed accumulation (OR=2.3, P=0.0046). These associations were maintained when 
uncommon variants with MAF <5% were included in the analysis (Table 3.6). At a 5% 
allele frequency threshold, 96 variant occurrences were observed among HTG patients 
and 41 variant occurrences were observed among healthy controls, corresponding to a 
1.8-fold increase in variants among HTG patients (P=0.0060). We identified 17 HTG 
patients and 6 healthy controls carrying 2 rare variants, which again had a minimal effect 
on the observed accumulation (OR=1.7; P=0.019). Rare variant accumulation was robust 
to potential sampling or technical biases in our cohort as no differences were observed 
between HTG patients and healthy controls in terms of benign synonymous and 
noncoding variants at either frequency threshold (1%: P=0.37; 5%: P=0.26).  
 
We next hypothesized that enrichment for rare nonsynonymous variants with 
increased likelihood of full penetrance would accentuate the effect size of variants that 
accumulate in HTG patients. Accordingly, we assessed rare variant accumulation in HTG 
patients and healthy controls using predictions of deleterious effect using SIFT and 
Polyphen-2. The excess of rare variants in HTG patients was increased when 
nonsynonymous variants were filtered by prediction of deleterious effects in silico (Table 
3.7). There were 32/43 distinct rare variants predicted by ≥1 algorithm to have a 
deleterious effect in silico, including 37 variant occurrences in 437 HTG patients 
compared to 9 variant occurrences in 326 controls, which corresponded to a 3.1-fold 
increase in variants found in HTG patients (P=0.0018). Furthermore, 17/43 distinct rare 
variants were predicted by both algorithms to have deleterious effects in silico, including  
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16 variant observations in HTG patients and 3 variant observations in healthy controls, 
corresponding to a 4.0-fold increase in variants found in HTG patients (P=0.019). The 
accentuated accumulation of rare variants was essentially lost when considering variants 
with frequency <5% (Table 3.7). There were 35/43 distinct uncommon variants predicted 
by ≥1 algorithm to have deleterious effect in silico, including 80 variants observed among 
HTG patients and 34 variants observed among healthy controls, corresponding to a 1.8-
fold increase in variants observed in HTG patients (P=0.01). The subset of variants with 2 
predictions of deleterious effect in silico was identical under both 1% and 5% frequency 
thresholds.  
 
We conducted a post hoc analysis to determine whether rare variant accumulation 
could be detected in any one specific gene. Using Fisher’s exact test, a significant excess 
of rare variants was detected in HTG patients versus healthy controls in CREB3L3 and 
APOC2. CREB3L3 had an 8.4-fold enrichment (95% CI: 1.08-64.4; P=0.016), and 
APOC2 had a 9.9-fold enrichment (95% CI: 0.56-176.3; P=0.040). No evidence for rare 
variant accumulation was observed for LMF1 (OR=2.3; p=0.11), ZHX3 (OR=1.42; 
P=0.52) or GPIHBP1 (OR=1.13; P=1.0). However, such experiments have relatively low 
power to detect associations. Accordingly, we sought to assess the individual burden of 
rare variants accumulation in specific genes among HTG patients and controls using the 
recently proposed permutation-based analyses designed for rare variant accumulation 
studies. Again, these three statistical analyses varied in their ability to detect rare variant 
accumulation in HTG patients versus healthy controls in several genes (Table 3.8). A 
significant accumulation of rare variants was confirmed empirically across all loci by the  
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general burden test (p=0.0010) and the variable threshold approach (P=0.0029), but no 
differences were observed using the C-alpha test statistic (P=0.19). Virtually identical 
results were observed for a frequency threshold of <5%, as a significant accumulation 
was detected using the general burden test (P=0.0027) and the variable threshold 
approach (P=0.0066), but not with the C-alpha test statistic (P=0.11). Among individual 
genes, rare variant accumulation was detected in LMF1, CREB3L3, and APOC2 using the 
general burden test (P=0.047, P=0.0056, and P=0.018, respectively) and the variable 
threshold approach (P=0.021, P=0.0041, and P=0.019, respectively). These analyses did 
not detect significant rare variant accumulation in either GPIHBP1 (P=0.36-0.50) or 
ZHX3 (P=0.21-0.30). The C-alpha test statistic could not detect significant rare variant 
accumulation in any particular gene. 
 
Next, we sought to determine whether rare variants in non-GWAS genes showed 
evidence for cosegregation with HTG in nuclear families. Lipoprotein profiles of nuclear 
families related to 4 probands carrying either the CREB3L3 E245Kfs397X (245fs) or 
W46X nonsense mutations were ascertained (Figure 3.5). Within all pedigrees, probands 
had the highest plasma TG concentration of all subjects, whereas non-proband carriers all 
had somewhat elevated plasma TG concentrations. Overall, mean plasma TG 
concentrations were significantly elevated across 11 nonsense variant carriers versus 5 
non-carrier first degree relatives (9.67±4.70 vs. 1.66±0.55 mmol/L, P=0.021). 
Interestingly, the father related to the W46X proband was also a carrier, but had normal 
plasma TG concentrations, whereas the mother related to the W46X proband who did not 
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Figure 3.5. Cosegregation of the CREB3L3 K245Efs374X (245fs) and W46X variants 
with HTG through four pedigrees. Symbols for males and females are squares and 
circles, respectively. Small symbols are subjects not genotyped in our study. Symbols 
with a strike-through represent deceased subjects. White filled symbols are non-carriers; 
half-filled symbols are heterozygous carriers, black-filled symbols are homozygous 
carriers (none in this pedigree). Arrows indicate probands referred for tertiary referral. 
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carry the variant, had elevated plasma TG concentration. These data suggest that the 
penetrance of heterozygous CREB3L3 variants is incomplete, and that rare variants are 
individually insufficient to cause HTG, likely requiring additional environmental and 
genetic factors to significantly alter TG metabolism. 
 
Finally, we hypothesized that variants with frequency >1% in HTG-associated 
candidate genes could also mediate increased susceptibility to HTG. Using logistic 
regression, we tested uncommon and common variants for association with HTG (Table 
3.9). Only the uncommon variant P562R in LMF1 was modestly associated with HTG, 
corresponding to a 3.8-fold increase in disease susceptibility (P=0.04), which was robust 
to covariate adjusted analysis (OR=4.2; P=0.03). However, given the 1.2% MAF of 
P562R and modest association P-value, we believe that this variant is likely a false 
positive association that would not sustain a Bonferroni-corrected significance threshold. 
The common variant G36D in LMF1 was also modestly associated with HTG (P=0.02), 
although this association was not robust to a covariate adjusted analysis (P=0.13). 
Generally, the relatively poor representation of common variation in these genes may 
provide a putative explanation for their lack of detection by large-scale GWAS of HTG 
or plasma TG concentration. 
 
3.3.4. Combined analysis of all sequenced genes 
As another post hoc experiment, we conducted a combined analysis of all rare variants 
identified in our resequencing studies. Not surprisingly, a significant accumulation of rare 
variants was again identified in HTG patients (Table 3.10). In total, 120 distinct 
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Table 3.10. Combined post hoc analysis of rare variants observed in HTG patients 
and healthy controls. 
 
Hypothesis Gene Distinct variants HTG Control 
GWAS APOA5 5 5 1 
 GCKR 12 20 5 
 LPL 13 18 3 
 APOB 46 84 38 
     
Non-GWAS APOC2 3 5 0 
 CREB3L3 7 11 1 
 GPIHBP1 6 5 2 
 LMF1 12 15 5 
 ZHX3 16 15 8 
     
Post hoc Total 120 178 63 
Rare variants were defined by a combined frequency <1%. Both the number of distinct variants and total 
occurrences in 421 HTG patients and 324 healthy controls are shown. GWAS, genome-wide association 
study; HTG, hypertriglyceridemia. 
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heterozygous variants were observed, including 178 variants in 421 HTG patients and 63 
variants in 324 healthy controls, corresponding to an overall 2.1-fold (95% CI: 1.53-2.91) 
increase in rare variant carriers in HTG patients versus healthy controls (P=3.40X10
-6
). 
The majority of subjects carried only 1 rare variant, however subjects carrying multiple 
rare variants were also significantly over-represented in HTG patients, including 8.6% of 
HTG patients versus 2.4% of healthy controls, corresponding to a 3.5-fold (95% CI: 1.60-
7.62) increase in carriers of multiple rare variants in HTG patients versus healthy controls 
(P=8.0X10
-4
). Gene-centric association tests were not different from above, although the 
multi-locus association test detected a significant accumulation of variants in HTG 
patients versus controls using all three statistical analyses including the general burden 
test (P=6.7X10
-5
), C-alpha (P=0.049), and the variable threshold approach (P=1.0X10
-6
). 
 
Finally, we assessed the contribution of different genetic and clinical variables to 
the total variation in HTG diagnosis, in subjects common between GWAS and 
resequencing cohorts. A comprehensive logistic regression model including clinical 
variables and both common and rare genetic variants explained maximally 41.6% of total 
variation in HTG diagnosis: clinical variables explained 19.7%, common genetic variants 
in 7 HTG-associated loci (from Chapter 2) explained 20.6% and rare genetic variants 
across 4-GWAS identified genes explained 1.3%. Interestingly, there was virtually no 
difference when rare variants from HTG-associated candidate genes were added to these 
calculations, contributing only 0.07% to the unattributed variation. Inclusion of a 
combined variable including any rare variant identified in either a GWAS or non-GWAS 
gene similarly explained only 1.3% of variation in HTG diagnoses. 
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3.4. Discussion 
The principal finding of this chapter is that a significant excess of rare variants was 
identified in patients with polygenic adult-onset HTG. Extensive re-sequencing of 
GWAS-identified candidate genes and non-GWAS HTG-associated candidate genes 
selected based on mouse models and Mendelian syndromes of HTG identified a 2-fold 
increase in rare variants in HTG patients versus controls, including 178 variants in HTG 
patients and 63 variants in controls. Importantly, our study also provides valuable insight 
into the genetic architecture of complex diseases including HTG, demonstrating that: (1) 
GWAS-identified genes harbouring small effect common variants associated with 
complex disease also harbour rare variants that contribute additionally to disease 
susceptibility; and (2) non-GWAS candidate genes lacking common variation associated 
with complex diseases may harbour rare variants that significantly increase disease 
susceptibility.  
 
In GWAS-identified genes, 80 distinct heterozygous missense and nonsense rare 
variants were identified across APOA5, GCKR, LPL, and APOB in 437 HTG patients and 
326 healthy controls, corresponding to a 2.4-fold increase in rare variants in HTG 
patients (P=6.2X10
-8
). Enrichment for variants with increased likelihood of mechanistic 
effect using exclusivity in HTG patients or controls enhanced this association: a 4.1-fold 
increase in exclusive variants was observed in HTG patients (P=2.4X10
-5
). Post hoc 
analyses of genetic burden further implicated specific genes in polygenic HTG 
pathophysiology, including LPL, APOB, and GCKR. In HTG-associated candidate genes, 
43 distinct heterozygous missense and nonsense rare variants were identified across 
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GPIHBP1, LMF1, CREB3L3, APOC2, and ZHX3 in 437 HTG patients and 326 healthy 
controls, corresponding to a 2.5-fold increase of variants in HTG patients (P=0.001). 
Enrichment for variants with increased likelihood of mechanistic effect based on in silico 
predictions of deleterious effect accentuated this accumulation: variant enrichment in 
HTG patients was increased by 3.0- and 4.0-fold with 1 or 2 predictions of deleterious 
effect, respectively. Post hoc analyses of genetic burden assessed among individual genes 
suggested that rare variant accumulation was greater in LMF1, APOC2 and CREB3L3, 
rather than in GPIHBP1 or ZHX3. Together, these analyses suggest that rare variation in 
HTG-associated candidate genes is strongly associated with polygenic HTG 
susceptibility and the rare variants incrementally contribute to the unexplained variation 
in HTG susceptibility. 
 
The burden of rare variants identified in HTG patients is very likely to increase 
HTG susceptibility. This is supported by several lines of evidence: (1) Genetic variants 
causing premature truncations that likely attenuate protein function were observed in 14 
(3.2%) HTG patients versus 1 (0.30%) healthy control; (2) large effect singleton variants 
(that are only observed in 1 subject) were observed in 67 (15.3%) HTG patients versus 17 
(5.2%) in healthy controls; (3) rare frameshift variants cosegregate with increased plasma 
TG concentration through families; and several bonafide deleterious mutations identified 
in HTG patients have been characterized in the literature and in preliminary studies in our 
laboratory (unpublished data). Furthermore, enrichment for rare variants with increased 
likelihood of fully penetrant deleterious effects shows an increase in effect size and 
significance of association. This filtering step seemed to increase specificity for 
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deleterious, potentially functional rare variants in HTG patients and reduce the noise 
contributed by benign variants in controls. In fact, the effect of likely deleterious rare 
variants more closely approximated the impact of carrying one APOA-V S19W variant 
(OR=5.35) (Hegele et al., 2009), which is the best single genetic marker so far reported 
for polygenic HTG. Filtration based on predicted dysfunction also reduced the 
contribution of any single gene to the overall rare variant tally and ensured a more 
uniform signal arising from all genes selected under our initial hypothesis. Interestingly, 
enrichment for exclusivity most greatly accentuated the accumulation observed in HTG 
patients (Figure 3.6), supporting the hypothesis that variants absent from healthy controls 
are large effect variants that contribute to disease susceptibility. Conversely, including 
uncommon variants with MAF between 1% and 5% attenuated the estimated effect of 
rare variants on HTG susceptibility. This suggests that alleles with higher frequency are 
less likely to contribute to increased HTG susceptibility.  
 
Rare variants in HTG patients may also contribute to the phenotypic 
heterogeneity characterized by the Fredrickson HLP phenotypes. For instance, the APOB 
p.R3500W variant causes hypercholesterolemia (Gaffney et al., 1995), but was found in a 
HTG patient with HLP phenotype 2B, defined by both plasma TG and total cholesterol in 
excess of the 95
th
 percentile. For this individual case, APOB p.R3500W is more likely 
contributing to the elevated total cholesterol phenotype, but the mutation is part of the 
genetic background of this patient that led to his ascertainment through the lipid clinic. 
This patient exemplifies our working model that both common and rare genetic 
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Figure 3.6. Filtration of rare variants based on predictions of deleterious effect 
accentuates rare variant accumulation in HTG patients versus controls. Data 
presented are reflective of variants in genome-wide association study (GWAS)-identified 
genes APOA5, GCKR, LPL, and APOB, including 154 variants in 437 HTG patients and 
53 variants in healthy controls. Deleterious effects were predicted using ≥1 in silico 
prediction algorithm (SIFT or Polyphen-2) or exclusivity in HTG patients or controls. 
Bars represent the number of rare variants among HTG patients and healthy controls (left 
y-axis); the corresponding odds ratio for rare variant accumulation is shown (right y-
axis). Bars around odds ratios represent 95% confidence intervals. 
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determinants in TG-associated genes together contribute to the phenotypic heterogeneity 
underlying HTG. 
 
Our study provides a proof-of-principle that rare variant accumulation analyses 
can help implicate individual genes in complex phenotypes without prior identification 
by GWAS. Multi-locus association tests that group rare variants from many genes 
together provide increased power to detect an association with disease phenotypes, 
however they are unable to identify the contribution of specific genes to the overall 
association. We first conducted  multi-locus association tests to evaluate our main 
hypotheses that GWAS-identified and non-GWAS candidate genes would harbour an 
excess of rare variants in HTG patients. We next conducted post hoc gene-centric 
analyses using three different methods to empirically implicate specific genes in HTG 
susceptibility. These latter analyses were of particular interest for non-GWAS genes, and 
specifically the 2 recently identified genes CREB3L3 and ZHX3.  
 
Both the general test of burden and the variable threshold approach were most 
successful at identifying rare variant accumulation in LPL, APOB, GCKR, LMF1, 
CREB3L3 and APOC2 as being associated with HTG susceptibility, whereas C-alpha 
only identified a specific burden in LPL. These differences in performance between 
statistical analyses are probably related to their respective designs and also to the 
distribution of variants in our sample. For instance, the variable threshold approach 
provides increased weight to very rare variants, which in retrospect was a favorable 
weighting scheme for our samples, since the majority of rare variants identified in these 
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studies were singletons. In contrast, C-alpha seems designed to detect genetic burden 
when genes have numerous rare variants, and when opposing directions of effect on 
phenotype are suspected for particular variants. C-alpha appears inadequately adapted to 
analyze numerous singleton variants in cases versus controls; recurrent rare variants seem 
to be optimal for this analysis. Thus, the general test of burden and the variable threshold 
approach seem to have been best suited to identify rare variant accumulation within our 
study. 
 
Interestingly, rare variants in GWAS-identified and non-GWAS candidate genes 
explained only an additional ~1.1% of HTG diagnoses. However, we believe that this is 
likely an underestimate of the true biological effect of rare variants. In regression 
equations, the effect attributable to carrying a rare variant is estimated from the relative 
occurrence of variants in HTG patients versus controls, which essentially treats all 
variants as having an equal effect. More precise attribution of variation - weighting - to 
rare variants requires knowledge of whether they are truly benign or deleterious. 
Generation of an appropriate weighting scheme will require functional genomic analyses 
both in vitro and in vivo. Alternatively, surrogate weighting schemes, based on inverse 
allele frequencies for instance, may also prove useful in the interim. Such a weighting 
strategy will effectively minimize the contribution of benign variants identified in 
controls, and maximize the effect of pathogenic variants identified in HTG patients, 
allowing regression equations to accurately estimate the variation attributable to disease 
causing rare variants in HTG diagnoses. However, rare variants will probably not explain 
very large proportions of HTG diagnoses, even when their effects are large enough to 
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completely account for the disease pathophysiology. Such variants are rare and 
cumulatively affect very few HTG patients, which will limit the total proportion of 
variation attributable to rare variants.  
 
Ultimately, our study provides evidence that rare variants contribute 
incrementally to the unexplained variation underlying HTG and that GWAS-identified 
and non-GWAS candidate genes in HTG pathophysiology, specifically LPL, GCKR, and 
APOB, CREB3L3, APOC2, and LMF1. LPL encoding lipoprotein lipase is well-
established in TG metabolism, and both polygenic and monogenic forms of HTG. 
However, GCKR and APOB are more recently implicated players in HTG susceptibility. 
GCKR encodes an allosteric regulator of glucokinase (GK) called the glucokinase 
regulatory protein (GKRP), which allows rapid mobilization of GK in response to 
increased cellular glucose concentrations (Agius, 2008). The lead single nucleotide 
polymorphism (SNP) in GCKR, a common proline to leucine (P446L) functional variant 
in GCKR attenuates ligand-dependent GK inhibition (Beer et al., 2009, Orho-Melander et 
al., 2008), in turn promoting glucose uptake and mobilization, thus attenuating fatty acid 
oxidation and promoting de novo TG synthesis (Beer et al., 2009). APOB encodes 
apolipoprotein B-100, the backbone of TG-rich and other atherogenic lipoproteins, which 
was earlier implicated in phenotypes involving plasma low density lipoprotein (LDL) 
cholesterol concentrations, such as familial hypercholesterolemia (FH) and familial 
hypobetalipoproteinemia (Hegele, 2009). Furthermore, our study demonstrates that 
heterozygous rare variants in HTG candidate genes also contribute to HTG susceptibility. 
Most notably, we found that the recently identified CREB3L3, associated with TG 
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metabolism, is also significantly associated with increased HTG susceptibility. CREB3L3 
was recently implicated in TG metabolism as a transcription factor that regulates 
expression of cofactors required for TG-rich lipoprotein metabolism including APOC2, 
APOA5 and APOA4 (Lee et al., 2011), but has never identified in a pure Mendelian form 
of HTG. In contrast, APOC2 and LMF1 are established genes in TG metabolism: APOC2 
encodes an essential lipoprotein lipase (LPL) cofactor required for hydrolysis of TG-rich 
lipoproteins (Hegele et al., 1991); whereas LMF1 encodes a maturation factor required 
for LPL activity (Peterfy et al., 2007).  
 
Importantly, our findings cannot exclude the potential contribution of genetic 
variation in APOA5, GPIHBP1 or ZHX3 to HTG susceptibility, since these genes have 
been implicated in lipoprotein pathophysiology through other means. For instance, 
APOA5 appears to play a focal role in hydrolysis of TG-rich lipoproteins by enhancing 
LPL activity (Charlton-Menys and Durrington, 2005), and has been implicated in HTG 
by Apoa5 knock-out mice (Pennacchio et al., 2001) and human HTG patients 
homozygous for rare LOF mutations in APOA5 (Marcais et al., 2005). GPIHBP1 encodes 
a cell-surface scaffold required for transendothelial LPL transport (Beigneux et al., 2007), 
which is absolutely necessary for TG-rich lipoprotein metabolism. Functionally 
characterized heterozygous mutations in GPIHBP1 (Beigneux et al., 2009, Franssen et 
al., 2010, Olivecrona et al., 2010) have been reported in patients with HTG. It is probable 
that we were unable to show a significant accumulation of rare variants in APOA5 and 
GPIHBP1, due to small gene size, and relatively low power to detect increased genetic 
burden on an individual gene basis. Conversely, given the abundance of rare variants in 
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ZHX3 found in both HTG patients and healthy controls, statistical power was likely not 
an issue in this gene and any association with the HTG phenotype would be tenuous at 
best. ZHX3 encodes a protein homologous to ZHX2, a developmental regulator of lipid 
metabolism (Gargalovic et al., 2010), although perhaps rare variants in this gene do not 
largely contribute to polygenic HTG susceptibility.  
 
In summary, our results indicate the importance of framing hypotheses and 
selecting analytic strategies that apply not only for Sanger re-sequencing projects, but 
also for future exome and targeted resequencing studies, particularly in the absence of 
prior GWAS association signals for complex phenotypes. Specifically, re-sequencing 
four genes associated with HTG by GWAS and resequencing five HTG candidate genes 
identified by mouse models and Mendelian syndromes of HTG has helped to identify an 
accumulation of rare nonsynonymous variants in polygenic adult-onset HTG patients 
compared to normolipidemic population-based controls. Functional analyses may more 
accurately define the extent of dysfunction of rare variants identified in HTG patients and 
their role in disease causation, while higher level analyses including gene-gene and gene-
environment interactions will determine the combined impact of multiple genetic variants 
on plasma TG concentration in patients with HTG.  These findings support a cumulative 
burden of rare variants in both known and novel genes in human polygenic HTG that 
incrementally contribute to the unexplained variation in HTG. These studies foreshadow 
the importance of testing predefined hypotheses and provide a framework for whole-
exome and genome resequencing studies of complex traits. 
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CHAPTER 4 
 
AN INCREASED BURDEN OF COMMON AND RARE LIPID-ASSOCIATED 
RISK ALLELES CONTRIBUTES TO THE PHENOTYPIC SPECTRUM OF 
HYPERTRIGLYCERIDEMIA 
 
This chapter is based on the following publication: Johansen, CT, Wang, J, Lanktree, 
MB, et al. (2011). An increased burden of common and rare lipid-associated risk alleles 
contributes to the phenotypic spectrum of hypertriglyceridemia. ATVB, 31(8): 1916-26. 
 
4.1. Introduction 
Plasma triglyceride (TG) concentration is an independent risk factor for cardiovascular 
disease (CVD). Both fasting and post-prandial plasma TG concentrations are 
determinants of CVD (Bansal et al., 2007, Cullen, 2000, Hokanson and Austin, 1996), 
increasing risk of both myocardial infarction and ischemic stroke (Freiberg et al., 2008, 
Nordestgaard et al., 2007). Thus, patients with hypertriglyceridemia (HTG) defined by 
plasma TG concentrations >95
th
 percentile have significantly elevated CVD risk (Hegele 
and Pollex, 2009, Yuan et al., 2007), which is frequently exacerbated by concomitant 
pro-atherogenic co-morbidities such as obesity, metabolic syndrome, and type 2 diabetes 
(T2D) (Yuan et al., 2007).  
 
Recently, the genetic architecture of HTG has become clearer. However, the 
genetic determinants underlying the phenotypic heterogeneity among HTG patients 
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remain less well defined. Phenotypic heterogeneity among HTG patients is defined by 
qualitative and quantitative biochemical differences in plasma lipoproteins that form the 
basis of the World Health Organization or Fredrickson hyperlipoproteinemia (HLP) 
phenotypes. The HLP phenotypes defined by HTG (HLP-HTG) include one monogenic 
pediatric phenotype called chylomicronemia (HLP type 1), and four polygenic familial 
phenotypes called combined hyperlipidemia (HLP type 2B), dysbetalipoproteinemia 
(HLP type 3), primary hypertriglyceridemia (HLP type 4) and mixed hyperlipidemia 
(HLP type 5). HLP type 1 is usually caused by homozygous loss-of-function mutations in 
genes such as LPL (Havel and Gordon, 1960), APOC2 (Connelly et al., 1987), APOA5 
(Priore Oliva et al., 2005), LMF1 (Peterfy et al., 2007), and GPIHBP1 (Beigneux et al., 
2009, Wang and Hegele, 2007). However, the genetic architecture underlying 
predisposition to the polygenic HLP-HTG is not known (Hegele, 2009).  
 
Candidate gene studies and genome-wide analyses have established that genetic 
variants associated with unfavourable plasma TG concentration in populations are also 
associated with susceptibility to clinical HTG (Hegele et al., 2009, Johansen et al., 2010, 
Wang et al., 2008a, Wang et al., 2008b, Wang et al., 2007). Both common and rare TG-
associated variants accumulate in HTG patients, and account for a large proportion of 
explained variation among HTG patients (Chapters 2-3). However, corresponding 
analyses have not yet been performed in the HLP-HTG phenotypes.  
 
Earlier surveys of few isolated genetic determinants suggested to a first 
approximation that TG loci were associated with multiple different HLP phenotypes, 
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suggesting that a shared genetic architecture may underlie the biochemically-defined 
HLP-HTG phenotypes (Wang et al., 2008a, Wang et al., 2008b). Here, we provide a 
comprehensive analysis of the genetic etiology of the HLP-HTG phenotypes in a much 
larger sample of HTG patients and healthy controls to assess this hypothesis. Further, we 
include all GWAS-identified genetic determinants of lipid metabolism recently identified 
by the Global Lipids Genetic Consortium (GLGC) (Teslovich et al., 2010), to assess the 
contribution of common variants associated with concentrations of TG, high-density 
lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) to both 
HTG susceptibility and HLP-HTG phenotypic heterogeneity. Finally, we have integrated 
rare variants into the analyses of HLP phenotypes. We demonstrate a shared genetic 
architecture of common and rare TG-associated variants as the genetic foundation across 
HTG patients, and provide evidence that accumulation of pleiotropic TG-associated, 
HDL-C-associated and LDL-C-associated variants may together dictate susceptibility to 
the polygenic HLP phenotypes. 
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4.2. METHODS 
 
4.2.1. Study subjects 
This study was approved by the University of Western Ontario Institutional Review 
Board (protocol #07920E), and ethics boards at collaborating institutions. Study subjects 
provided informed consent for collection of clinical data, DNA extraction and analysis. In 
total, 504 HTG patients and 1213 population-based controls were studied. HTG patients 
were European subjects ascertained through tertiary referral lipid clinics in London, 
Canada, and Amsterdam, Netherlands. HTG patients were clinically diagnosed with one 
of four familial polygenic HLP-HTG phenotypes prior to ascertainment for this study and 
without genetic information (see Table 1.5 in Chapter 1); these patients are now referred 
to as having HLP-HTG case status. Population-based controls were European subjects 
ascertained through the Study of Health Assessment and Risk in Ethnic Groups (Anand et 
al., 2000) and the Myocardial Infarction Genetics Consortium (Kathiresan et al., 2009), 
as previously described. Control subjects with fasting plasma TG concentration >2.3 
mmol/L were excluded from analyses due to potentially undiagnosed HTG. Biochemical 
analyses of lipoprotein traits were conducted separately in each cohort, as previously 
described (Anand et al., 2000, Hegele et al., 2009, Kathiresan et al., 2009). The study 
sample consisted of all subjects genotyped in Chapter 2 (most of which were sequenced 
in Chapter 3) with the addition of few recently ascertained subjects.  
 
4.2.2. Genotyping and sequencing 
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Genotyping was conducted using Affymetrix Genome-Wide Human Single Nucleotide 
Polymorphism (SNP) Array 6.0, as previously described (Johansen et al., 2010). 
Imputation was conducted using HapMap2 European phased haplotypes (Li and 
Abecasis, 2006), only imputing SNPs with r
2
>0.4. Genotypes were subsequently 
extracted for lipid-associated loci identified by the GLGC (Teslovich et al., 2010). 
Functional variants in APOE (rs7412 and rs429358) were genotyped using validated 
TaqMan assays on an ABI Prism 7900HT Sequence Detection System and automated 
software (Applied Biosystems, Foster City, CA). Rare variants in APOA5, GCKR, LPL 
and exons 26 and 29 of APOB were defined as nonsense or missense mutations with 
allele frequency <1%, as previously described in Chapter 3. The list of variants identified 
by this study is located in Chapter 3. 
 
4.2.3. Statistical analysis 
Data management, linkage disequilibrium (LD) calculations, association testing and risk 
score calculations were conducted as implemented in PLINK (Purcell et al., 2007). 
Association was tested using an additive multiple logistic regression model with clinical 
covariates age, sex, body mass index (BMI), T2D and 10 principal components of 
ancestry (Patterson et al., 2006, Price et al., 2006). Statistical significance for association 
was defined as concordant direction of effect and P<0.05, as all SNPs have a priori 
evidence for association with lipid metabolism.  
 
Each subject’s genetic risk index (or genetic risk score) was determined by 
summing risk (TG-raising, LDL-raising, and HDL-lowering) alleles at 32 TG-associated 
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SNPs, 47 HDL-C-associated SNPs, or 37 LDL-C-associated SNPs, as identified by the 
GLGC (Teslovich et al., 2010). Genetic risk indices were measured using either 
unweighted scores or weighted scores, where indicated. Unweighted scores were created 
by summing the raw number of risk alleles carried by each subject. Weighted risk scores 
were created by summing risk alleles after being multiplied by their population-based 
effect size calculated by the GLGC (Teslovich et al., 2010). Units were initially reported 
as mg/dl, but converted here to mmol/l; conversion factors for TG and HDL-C/LDL-C 
were 0.0113 and 0.0258, respectively. All SNPs were included in the risk score 
regardless of statistical significance in the replication phase. Where SNPs were associated 
with multiple lipid phenotypes, they were included in each risk score, although weighted 
by the appropriate lipid-specific effect estimate. Pleiotropy was assessed by comparing 
risk scores constructed using SNPs exclusively associated with HDL-C or LDL-C, or 
jointly associated with HDL-C or LDL-C plus plasma TG concentration (Teslovich et al., 
2010). Frequency distributions were plotted by dividing the range of risk scores into 
equal bins, and plotting the relative number of HTG patients or controls in each bin. 
Forest plots were generated by comparing the number of HTG patients in each of 7 risk 
score bins to the median risk score bin or the lowest risk score bin, as indicated. 
Summary statistics, risk score comparisons, rare variant accumulation and explained 
variation calculations were conducted in SAS v9.2 (SAS Institute, Cary, NJ). Summary 
statistics are displayed as mean ± standard deviation. Significance of increasing risk score 
in forest plots was determined using Cochrane-Armitage test for trend. Comparison of 
risk scores among HLP-HTG phenotypes was assessed using one-way ANOVA and post 
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hoc pairwise comparisons using Tukey’s test. In figures, values are mean ± standard 
error; means sharing letters are not statistically different.  
 
Rare variant accumulation was compared between HLP-HTG phenotypes and 
controls with Fisher’s exact test, using a two-sided P<0.05 as the threshold for statistical 
significance. Differences in number of rare variants in each HLP-HTG phenotype was 
assessed using a 2X4 contingency table (number of variants in carriers versus non-
carriers for each phenotype); differences in distribution of rare variants among genes in 
each HLP-HTG phenotype was assessed using a 4X4 contingency table (number of 
variants in each gene for each phenotype).  
 
A logistic regression model using case or control status as the dependent variable 
was used to calculate the proportion of variation explained by clinical and genetic 
variables. The proportion of variation explained by the coefficient of determination (R
2
) 
in linear regression does not have a straightforward analogue in logistic regression. 
Therefore, we used a likelihood-based pseudo-R
2
 metric for logistic regression as 
implemented in SAS-v9.2, which compares the increase in information provided by a 
model fitted with predictors over a null model. We used incremental changes in this 
metric to assess how well each variable improves model fit, thus comparing the relative 
contribution of variables between models. Here, to facilitate comprehension, we describe 
successive increases in model fit (R
2
) with progressive introduction of each variable as 
the proportion of variation explained by each variable. These analyses only included 
subjects for whom both genome-wide genotyping and resequencing data were available, 
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which comprised 346 HTG patients and 205 controls. Forward modeling was used to 
systematically enter clinical variables (age, sex, BMI, and T2D), common variants at TG-
associated loci (0, 1 or 2 TG-raising alleles as each locus), the number of rare variants 
identified in HTG-associated genes (APOA5, GCKR, LPL, and APOB as a composite 
score) (Johansen et al., 2010), and APOE genotype (copies of ɛ2/ɛ3/ɛ4 isoform) into the 
model. These analyses were conducted including all HTG patients, and subsequently 
using HLP phenotype subgroups, in comparison to the same group of healthy controls. 
This analysis serves only as a relative comparison of variables contributing to the model 
within our cohort, and should be considered only within the context of our study. 
  
188
  
 
4.3. Results 
 
4.3.1. Study subjects 
Baseline clinical characteristics of the 504 HTG patients and 1213 population-based 
controls are shown in Table 4.1. Generally, HTG patients had less favourable clinical 
profiles than controls. HTG patients had increased BMI, increased plasma total 
cholesterol, decreased plasma HDL-C and increased prevalence of T2D. HLP type 5 had 
the least favourable clinical profile across all traits, including fasting plasma TG 
concentration >99
th
 percentile.  
 
4.3.2. Replication of lipid-associated loci 
First, we sought to replicate the genetic determinants of plasma lipoprotein metabolism 
from the GLGC (Teslovich et al., 2010) in our HTG cohort. For TG-associated loci 
(Table 4.2a-e), we replicated many loci previously associated with HTG (Johansen et al., 
2010), and additionally replicated recently identified loci KLHL8 (OR=1.36; P=1.5X10
-3
) 
and CYP26A1 (OR=1.29; P=5.9X10
-3
). Generally, there was a trend towards significance 
at additional loci, as 29/32 loci had directions of effect concordant with estimates from 
the GLGC, significantly more than would be expected by chance (P=1.15X10
-6
). Most 
TG-associated loci showed different patterns of association with the HLP-HTG 
phenotypes (Table 4.2 a-e), however there were again more concordant directions of 
effect than would be expected by chance (HLP 5, P=0.007; HLP 4, P=0.01; HLP 3, 
P=0.007; HLP 2B, P=0.0002). Taken together, these data extend the concept that
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Table 4.2a. Replication of TG-associated loci in all HLP-HTG phenotypes. 
CHR Gene SNP 
Minor allele/ 
modeled allele 
All HTG (n=504) 
OR (95% CI) P-value 
11 APOA5 rs964184 G/G 3.43 (2.72-4.31) 1.12X10
-25
 
2 GCKR rs1260326 T/T 1.64 (1.36-1.97) 1.97X10
-7
 
8 LPL rs12678919 G/A 2.21 (1.52-3.22) 3.5X10
-5
 
8 TRIB1 rs2954029 T/A 1.50 (1.24-1.81) 3.8X10
-5
 
1 ANGPTL3 rs2131925 G/T 1.51 (1.23-1.85) 1.0X10
-4
 
7 MLXIPL rs7811265 G/A 1.63 (1.25-2.13) 3.3X10
-4
 
4 KLHL8 rs442177 G/T 1.36 (1.13-1.64) 1.5X10
-3
 
10 CYP26A1 rs2068888 A/G 1.29 (1.08-1.55) 5.9X10
-3
 
19 CILP2 rs10401969 C/T 1.72 (1.16-2.54) 6.8X10
-3
 
2 APOB rs1042034 C/T 1.28 (1.02-1.61) 0.032 
5 TIMD4 rs1553318 G/C 1.21 (1.00-1.46) 0.054 
11 FADS1 rs174546 T/T 1.20 (1.00-1.45) 0.054 
16 CETP rs7205804 A/G 1.20 (1.00-1.45) 0.056 
2 IRS1 rs2943645 C/T 1.20 (0.99-1.46) 0.061 
6 HLA rs2247056 T/C 1.21 (0.98-1.50) 0.076 
1 GALNT2 rs1321257 G/G 1.16 (0.96-1.40) 0.12 
5 MAP3K1 rs9686661 T/T 1.19 (0.95-1.48) 0.12 
15 LIPC rs261342 G/G 0.84 (0.68-1.05) 0.13 
15 CAPN3 rs2412710 A/A 1.50 (0.87-2.59) 0.14 
2 COBLL1 rs10195252 C/T 1.13 (0.94-1.36) 0.19 
12 LRP1 rs11613352 T/C 1.11 (0.89-1.40) 0.35 
7 TYW1B rs13238203 T/C 1.30 (0.65-2.60) 0.47 
8 NAT2 rs1495743 G/G 1.07 (0.87-1.33) 0.52 
3 MSL2L1 rs645040 G/T 1.06 (0.85-1.33) 0.58 
16 CTF1 rs11649653 G/C 1.05 (0.87-1.27) 0.59 
20 PLTP rs4810479 C/C 1.06 (0.85-1.32) 0.60 
19 APOE rs439401 T/C 0.95 (0.74-1.21) 0.68 
22 PLA2G6 rs5756931 C/T 1.04 (0.86-1.25) 0.70 
12 ZNF664 rs12310367 G/A 0.97 (0.81-1.17) 0.77 
15 FRMD5 rs2929282 T/T 1.06 (0.69-1.64) 0.79 
10 JMJD1C rs10761731 T/A 1.00 (0.83-1.20) 1.00 
8 PINX1 rs11776767 C/C 1.00 (0.83-1.21) 1.00 
CHR, chromosome; CI, confidence interval; HLP, hyperlipoproteinemia; HTG, hypertriglyceridemia; Mb, 
megabases; NC, not calculated; OR, odds ratio; SNP, single nucleotide polymorphism; T2D, type 2 
diabetes mellitus; TG, plasma triglyceride. The modeled allele is the TG-raising allele in the combined 
HTG cohort.  
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Table 4.2b. Replication of TG-associated loci in patients with HLP type 5. 
CHR Gene SNP 
Minor allele/ 
modeled allele 
HLP type 5 (n=180) 
OR (95% CI) P-value 
11 APOA5 rs964184 G/G 5.65 (3.92-8.14) 1.81X10
-20
 
2 GCKR rs1260326 T/T 1.60 (1.19-2.15) 1.9X10
-3
 
8 LPL rs12678919 G/A 2.79 (1.43-5.44) 2.7X10
-3
 
8 TRIB1 rs2954029 T/A 1.43 (1.06-1.92) 0.019 
1 ANGPTL3 rs2131925 G/T 1.85 (1.31-2.61) 4.7X10
-4
 
7 MLXIPL rs7811265 G/A 1.70 (1.10-2.62) 0.017 
4 KLHL8 rs442177 G/T 1.36 (1.02-1.82) 0.038 
10 CYP26A1 rs2068888 A/G 1.44 (1.08-1.92) 0.013 
19 CILP2 rs10401969 C/T 2.29 (1.18-4.43) 0.014 
2 APOB rs1042034 C/T 1.19 (0.84-1.70) 0.32 
5 TIMD4 rs1553318 G/C 1.14 (0.85-1.54) 0.39 
11 FADS1 rs174546 T/T 1.19 (0.88-1.59) 0.25 
16 CETP rs7205804 A/G 1.37 (1.01-1.85) 0.046 
2 IRS1 rs2943645 C/T 1.20 (0.89-1.61) 0.24 
6 HLA rs2247056 T/C 1.29 (0.92-1.80) 0.13 
1 GALNT2 rs1321257 G/G 1.27 (0.95-1.70) 0.11 
5 MAP3K1 rs9686661 T/T 1.04 (0.73-1.47) 0.84 
15 LIPC rs261342 G/G 0.91 (0.64-1.28) 0.58 
15 CAPN3 rs2412710 A/A 1.66 (0.74-3.72) 0.22 
2 COBLL1 rs10195252 C/T 1.00 (0.75-1.33) 0.98 
12 LRP1 rs11613352 T/C 1.51 (1.04-2.19) 0.030 
7 TYW1B rs13238203 T/C 0.75 (0.30-1.9) 0.54 
8 NAT2 rs1495743 G/G 0.92 (0.65-1.31) 0.65 
3 MSL2L1 rs645040 G/T 0.92 (0.66-1.27) 0.61 
16 CTF1 rs11649653 G/C 0.86 (0.64-1.14) 0.29 
20 PLTP rs4810479 C/C 1.27 (0.91-1.79) 0.16 
19 APOE rs439401 T/C 0.91 (0.62-1.34) 0.64 
22 PLA2G6 rs5756931 C/T 0.97 (0.73-1.30) 0.85 
12 ZNF664 rs12310367 G/A 1.17 (0.86-1.59) 0.31 
15 FRMD5 rs2929282 T/T 0.93 (0.46-1.89) 0.84 
10 JMJD1C rs10761731 T/A 1.01 (0.76-1.35) 0.94 
8 PINX1 rs11776767 C/C 0.98 (0.73-1.33) 0.92 
CHR, chromosome; CI, confidence interval; HLP, hyperlipoproteinemia; HTG, hypertriglyceridemia; Mb, 
megabases; NC, not calculated; OR, odds ratio; SNP, single nucleotide polymorphism; T2D, type 2 
diabetes mellitus; TG, plasma triglyceride. The modeled allele is the TG-raising allele in the combined 
HTG cohort.  
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Table 4.2c. Replication of TG-associated loci in patients with HLP type 4. 
CHR Gene SNP 
Minor allele/ 
modeled allele 
HLP type 4 (n=128) 
OR (95% CI) P-value 
11 APOA5 rs964184 G/G 3.71 (2.56-5.39) 4.9X10
-12
 
2 GCKR rs1260326 T/T 1.79 (1.29-2.48) 5.3X10
-4
 
8 LPL rs12678919 G/A 5.78 (2.10-15.9) 7.0X10
-4
 
8 TRIB1 rs2954029 T/A 1.37 (0.99-1.89) 0.059 
1 ANGPTL3 rs2131925 G/T 0.98 (0.70-1.39) 0.93 
7 MLXIPL rs7811265 G/A 2.09 (1.25-3.49) 4.8X10
-3
 
4 KLHL8 rs442177 G/T 1.19 (0.86-1.64) 0.29 
10 CYP26A1 rs2068888 A/G 1.02 (0.75-1.40) 0.88 
19 CILP2 rs10401969 C/T 1.53 (0.79-2.95) 0.20 
2 APOB rs1042034 C/T 0.88 (0.61-1.28) 0.50 
5 TIMD4 rs1553318 G/C 1.22 (0.88-1.69) 0.24 
11 FADS1 rs174546 T/T 1.33 (0.96-1.84) 0.088 
16 CETP rs7205804 A/G 1.19 (0.85-1.65) 0.31 
2 IRS1 rs2943645 C/T 1.42 (1.00-2.00) 0.049 
6 HLA rs2247056 T/C 1.12 (0.77-1.62) 0.55 
1 GALNT2 rs1321257 G/G 1.03 (0.74-1.43) 0.87 
5 MAP3K1 rs9686661 T/T 0.97 (0.66-1.44) 0.90 
15 LIPC rs261342 G/G 0.86 (0.59-1.27) 0.45 
15 CAPN3 rs2412710 A/A 0.90 (0.32-2.55) 0.84 
2 COBLL1 rs10195252 C/T 1.42 (1.02-1.99) 0.039 
12 LRP1 rs11613352 T/C 1.02 (0.69-1.50) 0.92 
7 TYW1B rs13238203 T/C 1.64 (0.40-6.69) 0.49 
8 NAT2 rs1495743 G/G 1.11 (0.76-1.62) 0.61 
3 MSL2L1 rs645040 G/T 1.31 (0.88-1.96) 0.18 
16 CTF1 rs11649653 G/C 1.33 (0.95-1.86) 0.097 
20 PLTP rs4810479 C/C 0.96 (0.65-1.42) 0.85 
19 APOE rs439401 T/C 1.00 (0.66-1.54) 0.98 
22 PLA2G6 rs5756931 C/T 1.06 (0.77-1.47) 0.71 
12 ZNF664 rs12310367 G/A 0.91 (0.66-1.26) 0.58 
15 FRMD5 rs2929282 T/T 0.68 (0.29-1.55) 0.35 
10 JMJD1C rs10761731 T/A 0.98 (0.71-1.35) 0.89 
8 PINX1 rs11776767 C/C 0.95 (0.68-1.33) 0.77 
CHR, chromosome; CI, confidence interval; HLP, hyperlipoproteinemia; HTG, hypertriglyceridemia; Mb, 
megabases; NC, not calculated; OR, odds ratio; SNP, single nucleotide polymorphism; T2D, type 2 
diabetes mellitus; TG, plasma triglyceride. The modeled allele is the TG-raising allele in the combined 
HTG cohort.  
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Table 4.2d. Replication of TG-associated loci in patients with HLP type 3. 
 
CHR Gene SNP 
Minor allele/ 
modeled allele 
HLP type 3 (n=37) 
OR (95% CI) P-value 
11 APOA5 rs964184 G/G 5.02 (2.51-10.1) 5.3X10
-6
 
2 GCKR rs1260326 T/T 0.66 (0.35-1.22) 0.18 
8 LPL rs12678919 G/A 1.34 (0.45-3.99) 0.60 
8 TRIB1 rs2954029 T/A 1.60 (0.89-2.85) 0.12 
1 ANGPTL3 rs2131925 G/T 1.16 (0.63-2.17) 0.63 
7 MLXIPL rs7811265 G/A 0.82 (0.40-1.68) 0.59 
4 KLHL8 rs442177 G/T 1.86 (0.99-3.49) 0.052 
10 CYP26A1 rs2068888 A/G 0.96 (0.53-1.74) 0.89 
19 CILP2 rs10401969 C/T 2.94 (0.78-11.1) 0.11 
2 APOB rs1042034 C/T 1.92 (0.83-4.46) 0.13 
5 TIMD4 rs1553318 G/C 1.07 (0.60-1.92) 0.82 
11 FADS1 rs174546 T/T 1.08 (0.59-1.98) 0.80 
16 CETP rs7205804 A/G 1.04 (0.56-1.90) 0.91 
2 IRS1 rs2943645 C/T 1.07 (0.59-1.95) 0.83 
6 HLA rs2247056 T/C 0.86 (0.45-1.66) 0.66 
1 GALNT2 rs1321257 G/G 1.07 (0.59-1.93) 0.82 
5 MAP3K1 rs9686661 T/T 1.68 (0.88-3.21) 0.12 
15 LIPC rs261342 G/G 1.26 (0.68-2.33) 0.46 
15 CAPN3 rs2412710 A/A 0.83 (0.11-6.27) 0.86 
2 COBLL1 rs10195252 C/T 1.89 (1.00-3.56) 0.049 
12 LRP1 rs11613352 T/C 0.97 (0.49-1.92) 0.93 
7 TYW1B rs13238203 T/C NC NC 
8 NAT2 rs1495743 G/G 2.16 (1.18-3.93) 0.012 
3 MSL2L1 rs645040 G/T 1.22 (0.62-2.42) 0.56 
16 CTF1 rs11649653 G/C 1.47 (0.81-2.64) 0.20 
20 PLTP rs4810479 C/C 1.15 (0.57-2.32) 0.70 
19 APOE rs439401 T/C 2.07 (0.96-4.43) 0.062 
22 PLA2G6 rs5756931 C/T 0.77 (0.44-1.38) 0.38 
12 ZNF664 rs12310367 G/A 1.45 (0.80-2.62) 0.22 
15 FRMD5 rs2929282 T/T NC NC 
10 JMJD1C rs10761731 T/A 1.23 (0.67-2.24) 0.51 
8 PINX1 rs11776767 C/C 1.38 (0.77-2.48) 0.28 
CHR, chromosome; CI, confidence interval; HLP, hyperlipoproteinemia; HTG, hypertriglyceridemia; Mb, 
megabases; NC, not calculated; OR, odds ratio; SNP, single nucleotide polymorphism; T2D, type 2 
diabetes mellitus; TG, plasma triglyceride. The modeled allele is the TG-raising allele in the combined 
HTG cohort. 
1
Variant is monomorphic in HTG cases. 
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Table 4.2e. Replication of TG-associated loci in patients with HLP type 2B. 
CHR Gene SNP 
Minor allele/ 
modeled allele 
HLP type 2B (n=159) 
OR (95% CI) P-value 
11 APOA5 rs964184 G/G 2.57 (1.82-3.63) 8.2X10
-8
 
2 GCKR rs1260326 T/T 1.87 (1.41-2.47) 1.3X10
-5
 
8 LPL rs12678919 G/A 1.48 (0.90-2.43) 0.12 
8 TRIB1 rs2954029 T/A 1.60 (1.20-2.12) 1.2X10
-3
 
1 ANGPTL3 rs2131925 G/T 1.63 (1.19-2.24) 2.3X10
-3
 
7 MLXIPL rs7811265 G/A 1.42 (0.97-2.08) 0.073 
4 KLHL8 rs442177 G/T 1.47 (1.11-1.96) 7.6X10
-3
 
10 CYP26A1 rs2068888 A/G 1.27 (0.96-1.68) 0.093 
19 CILP2 rs10401969 C/T 2.07 (1.13-3.79) 0.018 
2 APOB rs1042034 C/T 1.60 (1.11-2.31) 0.01 
5 TIMD4 rs1553318 G/C 1.38 (1.03-1.84) 0.032 
11 FADS1 rs174546 T/T 1.16 (0.88-1.53) 0.29 
16 CETP rs7205804 A/G 1.17 (0.88-1.55) 0.28 
2 IRS1 rs2943645 C/T 1.16 (0.87-1.53) 0.32 
6 HLA rs2247056 T/C 1.30 (0.95-1.77) 0.099 
1 GALNT2 rs1321257 G/G 1.07 (0.81-1.42) 0.63 
5 MAP3K1 rs9686661 T/T 1.40 (1.01-1.93) 0.041 
15 LIPC rs261342 G/G 0.8 (0.57-1.12) 0.19 
15 CAPN3 rs2412710 A/A 1.37 (0.60-3.10) 0.46 
2 COBLL1 rs10195252 C/T 0.95 (0.72-1.26) 0.73 
12 LRP1 rs11613352 T/C 1.09 (0.78-1.53) 0.60 
7 TYW1B rs13238203 T/C 1.22 (0.41-3.62) 0.72 
8 NAT2 rs1495743 G/G 0.93 (0.67-1.29) 0.65 
3 MSL2L1 rs645040 G/T 1.23 (0.87-1.73) 0.24 
16 CTF1 rs11649653 G/C 1.01 (0.77-1.33) 0.95 
20 PLTP rs4810479 C/C 0.95 (0.67-1.34) 0.77 
19 APOE rs439401 T/C 0.87 (0.60-1.24) 0.44 
22 PLA2G6 rs5756931 C/T 1.00 (0.76-1.31) 0.98 
12 ZNF664 rs12310367 G/A 0.85 (0.64-1.12) 0.24 
15 FRMD5 rs2929282 T/T 1.38 (0.77-2.47) 0.28 
10 JMJD1C rs10761731 T/A 1.13 (0.85-1.49) 0.40 
8 PINX1 rs11776767 C/C 1.14 (0.86-1.52) 0.35 
CHR, chromosome; CI, confidence interval; HLP, hyperlipoproteinemia; HTG, hypertriglyceridemia; Mb, 
megabases; NC, not calculated; OR, odds ratio; SNP, single nucleotide polymorphism; T2D, type 2 
diabetes mellitus; TG, plasma triglyceride. The modeled allele is the TG-raising allele in the combined 
HTG cohort. 
1
Variant is monomorphic in HTG cases. 
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common variants in TG-associated loci increase susceptibility to HTG and the HLP 
phenotypes. 
 
For HDL-C-associated loci (Table 4.3 a-e), we replicated associations at four loci 
with HTG. The replicated loci were predominantly jointly associated with plasma TG as 
the lead trait, including MLXIPL, TRIB1, and FADS1, but we also replicated the HDL-C 
associated IRS1 locus. Generally, there was a trend towards association at additional loci 
as 31/47 loci had directions of effect concordant with estimates from GLGC (P=0.01). 
Few loci were replicated among individual HLP-HTG types, although concordant 
directions of effect were over-represented among HLP types 4 and 5 (P=0.005 and 
P=0.05, respectively), but not HLP types 2B and 3 (P=0.11 and P=0.11, respectively). 
Together, these data suggest that common variants in some HDL-C-associated loci 
contribute to the phenotypic spectrum within HTG. 
 
For LDL-C-associated loci (Table 4.4 a-e), we replicated associations at nine loci 
with HTG. The strongest association was at the DNAH11 locus, while remaining loci had 
similarly large effects (OR=1.2-1.4) but with marginal statistical significance. Generally, 
there was a trend towards association at additional loci as 25/37 loci had directions of 
effect concordant with estimates from GLGC (P=0.01). Among HLP-HTG phenotypes, 
few loci were replicated in phenotypes other than HLP type 2B; however concordant 
directions of effect were over-represented among HLP types 2B, 4 and 5 (P=0.0009, 
P=0.04, P=0.02, respectively). Together, these data suggest that common variants in 
some LDL-associated loci also contribute to the phenotypic spectrum within HTG.
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Table 4.3a. Replication of HDL-associated loci in patients with polygenic HTG. 
CHR Gene SNP 
Minor allele/ 
modeled allele 
All HTG (n=504) 
OR (95% CI) P-value 
7 MLXIPL rs17145738 T/C 2.28 (1.63-3.19) 1.5X10
-6
 
8 TRIB1 rs10808546 T/C 1.46 (1.21-1.77) 1.0X10
-4
 
2 IRS1 rs1515100 C/A 1.28 (1.05-1.55) 0.015 
11 FADS1 rs174601 T/T 1.25 (1.04-1.50) 0.019 
19 APOE rs4420638 G/G 0.62 (0.4-0.95) 0.029 
16 CETP rs3764261 A/C 1.23 (1.00-1.50) 0.051 
6 CITED2 rs605066 C/C 1.20 (1.00-1.45) 0.052 
1 GALNT2 rs4846914 G/G 1.21 (1.00-1.45) 0.052 
9 TTC39B rs643531 C/C 0.77 (0.59-1.01) 0.059 
6 LPA rs1084651 A/A 0.83 (0.64-1.07) 0.16 
19 ANGPTL4 rs7255436 C/C 1.15 (0.94-1.40) 0.18 
20 PLTP rs6065906 C/C 1.17 (0.92-1.48) 0.20 
1 ZNF648 rs1689800 G/G 1.13 (0.93-1.37) 0.21 
12 MVK rs7134594 C/C 0.90 (0.75-1.08) 0.24 
12 LRP1 rs3741414 T/C 1.14 (0.91-1.43) 0.25 
11 UBASH3B rs7115089 G/C 1.12 (0.93-1.34) 0.25 
20 HNF4A rs1800961 T/T 0.75 (0.44-1.28) 0.29 
7 KLF14 rs4731702 T/C 0.91 (0.76-1.09) 0.31 
8 PPP1R3B rs9987289 A/A 1.17 (0.84-1.64) 0.35 
22 UBE2L3 rs181362 T/T 0.90 (0.71-1.14) 0.39 
18 LIPG rs7241918 G/G 0.90 (0.71-1.15) 0.40 
12 SBNO1 rs4759375 T/C 1.16 (0.78-1.72) 0.47 
17 PGS1 rs4082919 G/G 1.07 (0.89-1.28) 0.47 
15 LIPC rs1532085 A/G 1.07 (0.89-1.29) 0.49 
4 SLC39A8 rs13107325 T/T 0.89 (0.64-1.25) 0.49 
15 LACTB rs2652834 A/A 0.93 (0.73-1.19) 0.56 
18 MC4R rs12967135 A/A 0.94 (0.76-1.18) 0.61 
5 ARL15 rs6450176 A/A 0.95 (0.77-1.17) 0.61 
2 COBLL1 rs12328675 C/T 1.07 (0.81-1.40) 0.64 
11 LRP4 rs3136441 C/T 0.94 (0.73-1.23) 0.67 
19 LOC55908 rs737337 C/C 1.06 (0.77-1.45) 0.72 
16 LCAT rs16942887 A/G 1.05 (0.80-1.38) 0.73 
6 C6orf106 rs2814944 A/A 1.05 (0.80-1.38) 0.73 
1 PABPC4 rs4660293 G/G 1.04 (0.84-1.28) 0.74 
12 SCARB1 rs838880 C/T 1.02 (0.84-1.24) 0.82 
11 AMPD3 rs2923084 G/G 1.02 (0.81-1.28) 0.86 
17 STARD3 rs881844 C/C 1.02 (0.84-1.23) 0.86 
16 CMIP rs2925979 T/T 0.99 (0.81-1.21) 0.91 
8 TRPS1 rs2293889 T/T 0.99 (0.83-1.19) 0.92 
12 PDE3A rs7134375 A/C 0.99 (0.83-1.19) 0.95 
12 ZNF664 rs4765127 T/G 1.00 (0.82-1.20) 0.96 
17 ABCA8 rs4148008 G/G 1.00 (0.82-1.21) 0.97 
9 ABCA1 rs1883025 T/T 1.00 (0.81-1.22) 0.98 
19 LILRA3 rs386000 C/G 1.00 (0.80-1.25) 1.00 
CHR, chromosome; CI, confidence interval; HLP, hyperlipoproteinemia; HTG, hypertriglyceridemia; Mb, 
megabases; NC, not calculated; OR, odds ratio; SNP, single nucleotide polymorphism; T2D, type 2 
diabetes mellitus; TG, plasma triglyceride. The modeled allele is the HDL-lowering allele in the combined 
HTG cohort.  
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Table 4.3b. Replication of HDL-associated loci in patients with HLP type 5. 
CHR Gene SNP 
Minor allele/ 
modeled allele 
HLP type 5 (n=180) 
OR (95% CI) P-value 
7 MLXIPL rs17145738 T/C 1.93 (1.16-3.19) 0.011 
8 TRIB1 rs10808546 T/C 1.32 (0.98-1.77) 0.07 
2 IRS1 rs1515100 C/A 1.22 (0.90-1.65) 0.20 
11 FADS1 rs174601 T/T 1.21 (0.91-1.62) 0.20 
19 APOE rs4420638 G/G 0.73 (0.38-1.38) 0.33 
16 CETP rs3764261 A/C 1.26 (0.91-1.73) 0.16 
6 CITED2 rs605066 C/C 1.13 (0.85-1.50) 0.41 
1 GALNT2 rs4846914 G/G 1.29 (0.97-1.73) 0.084 
9 TTC39B rs643531 C/C 1.05 (0.70-1.56) 0.82 
6 LPA rs1084651 A/A 0.82 (0.54-1.23) 0.33 
19 ANGPTL4 rs7255436 C/C 0.93 (0.68-1.26) 0.63 
20 PLTP rs6065906 C/C 1.38 (0.96-1.97) 0.082 
1 ZNF648 rs1689800 G/G 1.05 (0.77-1.43) 0.76 
12 MVK rs7134594 C/C 0.87 (0.66-1.16) 0.35 
12 LRP1 rs3741414 T/C 1.44 (1.00-2.07) 0.051 
11 UBASH3B rs7115089 G/C 1.24 (0.92-1.67) 0.16 
20 HNF4A rs1800961 T/T 0.42 (0.14-1.21) 0.11 
7 KLF14 rs4731702 T/C 1.00 (0.75-1.33) 0.99 
8 PPP1R3B rs9987289 A/A 1.09 (0.65-1.83) 0.76 
22 UBE2L3 rs181362 T/T 0.85 (0.59-1.23) 0.38 
18 LIPG rs7241918 G/G 1.02 (0.70-1.48) 0.91 
12 SBNO1 rs4759375 T/C 1.50 (0.75-3.01) 0.25 
17 PGS1 rs4082919 G/G 1.17 (0.89-1.55) 0.26 
15 LIPC rs1532085 A/G 0.99 (0.74-1.32) 0.95 
4 SLC39A8 rs13107325 T/T 0.60 (0.33-1.09) 0.093 
15 LACTB rs2652834 A/A 0.90 (0.60-1.33) 0.59 
18 MC4R rs12967135 A/A 0.91 (0.64-1.28) 0.58 
5 ARL15 rs6450176 A/A 0.86 (0.61-1.21) 0.38 
2 COBLL1 rs12328675 C/T 1.47 (0.93-2.34) 0.10 
11 LRP4 rs3136441 C/T 1.26 (0.81-1.95) 0.30 
19 LOC55908 rs737337 C/C 0.93 (0.55-1.56) 0.78 
16 LCAT rs16942887 A/G 1.10 (0.71-1.72) 0.66 
6 C6orf106 rs2814944 A/A 1.11 (0.73-1.69) 0.63 
1 PABPC4 rs4660293 G/G 1.18 (0.85-1.63) 0.32 
12 SCARB1 rs838880 C/T 0.92 (0.68-1.23) 0.56 
11 AMPD3 rs2923084 G/G 1.04 (0.72-1.49) 0.85 
17 STARD3 rs881844 C/C 0.84 (0.61-1.14) 0.26 
16 CMIP rs2925979 T/T 1.12 (0.83-1.51) 0.47 
8 TRPS1 rs2293889 T/T 0.99 (0.75-1.31) 0.94 
12 PDE3A rs7134375 A/C 0.88 (0.66-1.18) 0.40 
12 ZNF664 rs4765127 T/G 1.16 (0.86-1.58) 0.34 
17 ABCA8 rs4148008 G/G 0.92 (0.68-1.26) 0.61 
9 ABCA1 rs1883025 T/T 0.86 (0.62-1.21) 0.39 
19 LILRA3 rs386000 C/G 1.02 (0.72-1.44) 0.90 
CHR, chromosome; CI, confidence interval; HLP, hyperlipoproteinemia; HTG, hypertriglyceridemia; Mb, 
megabases; NC, not calculated; OR, odds ratio; SNP, single nucleotide polymorphism; T2D, type 2 
diabetes mellitus; TG, plasma triglyceride. The modeled allele is the HDL-lowering allele in the combined 
HTG cohort.  
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Table 4.3c. Replication of HDL-associated loci in patients with HLP type 4. 
CHR Gene SNP 
Minor allele/ 
modeled allele 
HLP type 4 (n=128) 
OR (95% CI) P-value 
7 MLXIPL rs17145738 T/C 3.63 (1.75-7.54) 5.4X10
-4
 
8 TRIB1 rs10808546 T/C 1.43 (1.03-1.98) 0.032 
2 IRS1 rs1515100 C/A 1.53 (1.07-2.18) 0.018 
11 FADS1 rs174601 T/T 1.46 (1.05-2.01) 0.023 
19 APOE rs4420638 G/G 0.50 (0.22-1.14) 0.10 
16 CETP rs3764261 A/C 1.26 (0.89-1.80) 0.20 
6 CITED2 rs605066 C/C 1.21 (0.87-1.66) 0.25 
1 GALNT2 rs4846914 G/G 1.14 (0.82-1.58) 0.45 
9 TTC39B rs643531 C/C 0.68 (0.41-1.12) 0.13 
6 LPA rs1084651 A/A 1.03 (0.67-1.58) 0.91 
19 ANGPTL4 rs7255436 C/C 1.20 (0.85-1.69) 0.31 
20 PLTP rs6065906 C/C 1.10 (0.72-1.67) 0.66 
1 ZNF648 rs1689800 G/G 0.96 (0.68-1.36) 0.81 
12 MVK rs7134594 C/C 1.08 (0.79-1.48) 0.64 
12 LRP1 rs3741414 T/C 0.99 (0.68-1.44) 0.97 
11 UBASH3B rs7115089 G/C 1.26 (0.90-1.76) 0.17 
20 HNF4A rs1800961 T/T 1.52 (0.70-3.29) 0.28 
7 KLF14 rs4731702 T/C 0.80 (0.59-1.10) 0.17 
8 PPP1R3B rs9987289 A/A 1.03 (0.58-1.83) 0.92 
22 UBE2L3 rs181362 T/T 1.15 (0.77-1.69) 0.50 
18 LIPG rs7241918 G/G 0.90 (0.58-1.37) 0.61 
12 SBNO1 rs4759375 T/C 1.71 (0.78-3.77) 0.18 
17 PGS1 rs4082919 G/G 1.22 (0.90-1.67) 0.20 
15 LIPC rs1532085 A/G 1.51 (1.08-2.11) 0.016 
4 SLC39A8 rs13107325 T/T 1.15 (0.67-1.99) 0.61 
15 LACTB rs2652834 A/A 1.18 (0.79-1.76) 0.43 
18 MC4R rs12967135 A/A 1.11 (0.76-1.62) 0.59 
5 ARL15 rs6450176 A/A 1.00 (0.70-1.42) 0.99 
2 COBLL1 rs12328675 C/T 0.93 (0.60-1.45) 0.76 
11 LRP4 rs3136441 C/T 0.58 (0.38-0.87) 8.0X10
-3
 
19 LOC55908 rs737337 C/C 0.64 (0.34-1.22) 0.17 
16 LCAT rs16942887 A/G 1.15 (0.71-1.88) 0.57 
6 C6orf106 rs2814944 A/A 0.95 (0.57-1.56) 0.83 
1 PABPC4 rs4660293 G/G 0.96 (0.67-1.39) 0.83 
12 SCARB1 rs838880 C/T 1.01 (0.72-1.41) 0.97 
11 AMPD3 rs2923084 G/G 1.05 (0.71-1.57) 0.81 
17 STARD3 rs881844 C/C 1.26 (0.91-1.74) 0.17 
16 CMIP rs2925979 T/T 1.13 (0.80-1.59) 0.50 
8 TRPS1 rs2293889 T/T 0.97 (0.71-1.32) 0.85 
12 PDE3A rs7134375 A/C 1.26 (0.91-1.76) 0.17 
12 ZNF664 rs4765127 T/G 0.91 (0.66-1.26) 0.57 
17 ABCA8 rs4148008 G/G 0.99 (0.70-1.39) 0.96 
9 ABCA1 rs1883025 T/T 1.20 (0.85-1.69) 0.30 
19 LILRA3 rs386000 C/G 1.11 (0.74-1.65) 0.62 
CHR, chromosome; CI, confidence interval; HLP, hyperlipoproteinemia; HTG, hypertriglyceridemia; Mb, 
megabases; NC, not calculated; OR, odds ratio; SNP, single nucleotide polymorphism; T2D, type 2 
diabetes mellitus; TG, plasma triglyceride. The modeled allele is the HDL-lowering in the combined HTG 
cohort.  
199
  
 
Table 4.3d. Replication of HDL-associated loci in patients with HLP type 3. 
CHR Gene SNP 
Minor allele/ 
modeled allele 
HLP type 3 (n=37) 
OR (95% CI) P-value 
7 MLXIPL rs17145738 T/C 1.38 (0.55-3.49) 0.49 
8 TRIB1 rs10808546 T/C 1.56 (0.87-2.79) 0.14 
2 IRS1 rs1515100 C/A 0.98 (0.54-1.79) 0.95 
11 FADS1 rs174601 T/T 1.16 (0.64-2.12) 0.63 
19 APOE rs4420638 G/G 0.58 (0.13-2.52) 0.47 
16 CETP rs3764261 A/C 0.82 (0.44-1.52) 0.52 
6 CITED2 rs605066 C/C 1.50 (0.84-2.67) 0.17 
1 GALNT2 rs4846914 G/G 1.16 (0.64-2.09) 0.63 
9 TTC39B rs643531 C/C 0.49 (0.17-1.41) 0.19 
6 LPA rs1084651 A/A 0.57 (0.23-1.40) 0.22 
19 ANGPTL4 rs7255436 C/C 1.32 (0.71-2.49) 0.38 
20 PLTP rs6065906 C/C 0.62 (0.25-1.56) 0.31 
1 ZNF648 rs1689800 G/G 1.30 (0.71-2.39) 0.39 
12 MVK rs7134594 C/C 1.10 (0.63-1.91) 0.75 
12 LRP1 rs3741414 T/C 1.12 (0.56-2.26) 0.75 
11 UBASH3B rs7115089 G/C 1.23 (0.70-2.17) 0.48 
20 HNF4A rs1800961 T/T 0.56 (0.07-4.33) 0.58 
7 KLF14 rs4731702 T/C 0.76 (0.43-1.33) 0.34 
8 PPP1R3B rs9987289 A/A 2.59 (1.18-5.68) 0.018 
22 UBE2L3 rs181362 T/T 0.57 (0.25-1.29) 0.18 
18 LIPG rs7241918 G/G 0.68 (0.29-1.57) 0.36 
12 SBNO1 rs4759375 T/C 0.48 (0.18-1.27) 0.14 
17 PGS1 rs4082919 G/G 0.82 (0.46-1.45) 0.49 
15 LIPC rs1532085 A/G 0.78 (0.45-1.35) 0.37 
4 SLC39A8 rs13107325 T/T 0.75 (0.25-2.24) 0.60 
15 LACTB rs2652834 A/A 0.77 (0.35-1.68) 0.51 
18 MC4R rs12967135 A/A 1.85 (0.99-3.48) 0.054 
5 ARL15 rs6450176 A/A 0.73 (0.36-1.49) 0.38 
2 COBLL1 rs12328675 C/T 1.13 (0.47-2.68) 0.79 
11 LRP4 rs3136441 C/T 1.08 (0.45-2.57) 0.87 
19 LOC55908 rs737337 C/C 1.87 (0.86-4.07) 0.12 
16 LCAT rs16942887 A/G 0.67 (0.31-1.44) 0.30 
6 C6orf106 rs2814944 A/A 0.83 (0.34-2.03) 0.68 
1 PABPC4 rs4660293 G/G 0.56 (0.27-1.18) 0.13 
12 SCARB1 rs838880 C/T 1.11 (0.62-1.99) 0.73 
11 AMPD3 rs2923084 G/G 2.20 (1.17-4.12) 0.014 
17 STARD3 rs881844 C/C 1.02 (0.55-1.89) 0.96 
16 CMIP rs2925979 T/T 0.62 (0.31-1.24) 0.17 
8 TRPS1 rs2293889 T/T 1.21 (0.68-2.15) 0.51 
12 PDE3A rs7134375 A/C 0.98 (0.55-1.76) 0.95 
12 ZNF664 rs4765127 T/G 1.44 (0.79-2.63) 0.24 
17 ABCA8 rs4148008 G/G 1.58 (0.90-2.78) 0.11 
9 ABCA1 rs1883025 T/T 0.61 (0.29-1.27) 0.18 
19 LILRA3 rs386000 C/G 0.92 (0.47-1.79) 0.80 
CHR, chromosome; CI, confidence interval; HLP, hyperlipoproteinemia; HTG, hypertriglyceridemia; Mb, 
megabases; NC, not calculated; OR, odds ratio; SNP, single nucleotide polymorphism; T2D, type 2 
diabetes mellitus; TG, plasma triglyceride. The modeled allele is the HDL-lowering allele in the combined 
HTG cohort.  
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Table 4.3e. Replication of HDL-associated loci in patients with HLP type 2B. 
CHR Gene SNP 
Minor allele/ 
modeled allele 
HLP type 2B (n=159) 
OR (95% CI) P-value 
7 MLXIPL rs17145738 T/C 2.17 (1.32-3.57) 2.3X10
-3
 
8 TRIB1 rs10808546 T/C 1.57 (1.18-2.09) 1.9X10
-3
 
2 IRS1 rs1515100 C/A 1.26 (0.95-1.68) 0.11 
11 FADS1 rs174601 T/T 1.17 (0.89-1.54) 0.27 
19 APOE rs4420638 G/G 0.65 (0.34-1.23) 0.19 
16 CETP rs3764261 A/C 1.36 (1.00-1.85) 0.050 
6 CITED2 rs605066 C/C 1.25 (0.95-1.64) 0.11 
1 GALNT2 rs4846914 G/G 1.09 (0.83-1.45) 0.53 
9 TTC39B rs643531 C/C 0.78 (0.52-1.18) 0.25 
6 LPA rs1084651 A/A 0.81 (0.55-1.19) 0.28 
19 ANGPTL4 rs7255436 C/C 1.25 (0.93-1.69) 0.14 
20 PLTP rs6065906 C/C 1.14 (0.80-1.64) 0.47 
1 ZNF648 rs1689800 G/G 1.42 (1.07-1.90) 0.017 
12 MVK rs7134594 C/C 0.83 (0.63-1.09) 0.19 
12 LRP1 rs3741414 T/C 1.15 (0.82-1.60) 0.42 
11 UBASH3B rs7115089 G/C 0.88 (0.67-1.15) 0.35 
20 HNF4A rs1800961 T/T 0.83 (0.38-1.78) 0.62 
7 KLF14 rs4731702 T/C 0.98 (0.75-1.28) 0.83 
8 PPP1R3B rs9987289 A/A 0.86 (0.50-1.48) 0.57 
22 UBE2L3 rs181362 T/T 0.80 (0.55-1.15) 0.23 
18 LIPG rs7241918 G/G 0.90 (0.63-1.29) 0.58 
12 SBNO1 rs4759375 T/C 0.71 (0.42-1.19) 0.19 
17 PGS1 rs4082919 G/G 1.00 (0.76-1.31) 1.00 
15 LIPC rs1532085 A/G 1.05 (0.80-1.38) 0.74 
4 SLC39A8 rs13107325 T/T 1.00 (0.62-1.64) 0.99 
15 LACTB rs2652834 A/A 0.78 (0.53-1.14) 0.20 
18 MC4R rs12967135 A/A 0.86 (0.61-1.21) 0.38 
5 ARL15 rs6450176 A/A 0.93 (0.68-1.26) 0.64 
2 COBLL1 rs12328675 C/T 0.96 (0.65-1.41) 0.82 
11 LRP4 rs3136441 C/T 1.02 (0.69-1.49) 0.94 
19 LOC55908 rs737337 C/C 1.21 (0.78-1.87) 0.40 
16 LCAT rs16942887 A/G 1.06 (0.71-1.59) 0.76 
6 C6orf106 rs2814944 A/A 1.06 (0.71-1.60) 0.76 
1 PABPC4 rs4660293 G/G 0.96 (0.70-1.33) 0.82 
12 SCARB1 rs838880 C/T 1.15 (0.86-1.55) 0.34 
11 AMPD3 rs2923084 G/G 0.95 (0.67-1.35) 0.77 
17 STARD3 rs881844 C/C 1.12 (0.84-1.48) 0.44 
16 CMIP rs2925979 T/T 1.02 (0.76-1.38) 0.89 
8 TRPS1 rs2293889 T/T 1.10 (0.84-1.44) 0.50 
12 PDE3A rs7134375 A/C 0.87 (0.66-1.14) 0.31 
12 ZNF664 rs4765127 T/G 0.88 (0.67-1.17) 0.38 
17 ABCA8 rs4148008 G/G 0.96 (0.71-1.28) 0.77 
9 ABCA1 rs1883025 T/T 1.15 (0.85-1.55) 0.36 
19 LILRA3 rs386000 C/G 0.98 (0.71-1.35) 0.90 
CHR, chromosome; CI, confidence interval; HLP, hyperlipoproteinemia; HTG, hypertriglyceridemia; Mb, 
megabases; NC, not calculated; OR, odds ratio; SNP, single nucleotide polymorphism; T2D, type 2 
diabetes mellitus; TG, plasma triglyceride. The modeled allele is the HDL-lowering allele in the combined 
HTG cohort.  
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Table 4.4a. Replication of LDL-associated loci in patients with polygenic HTG.  
CHR Gene SNP 
Minor allele/ 
modeled allele 
All HTG (n=504) 
OR (95% CI) P-value 
8 TRIB1 rs2954022 A/C 1.48 (1.23-1.8) 5.3X10
-5
 
1 ANGPTL3 rs3850634 G/T 1.49 (1.21-1.83) 1.7X10
-4
 
7 DNAH11 rs12670798 C/C 1.39 (1.13-1.70) 1.7X10
-3
 
2 ABCG5/8 rs4299376 G/G 1.33 (1.07-1.65) 0.011 
19 LDLR rs6511720 T/G 1.84 (1.12-3.03) 0.017 
9 ABO rs649129 T/T 1.27 (1.04-1.56) 0.021 
5 HMGCR rs12916 C/C 1.23 (1.02-1.48) 0.028 
11 FADS1 rs174583 T/C 0.81 (0.68-0.98) 0.029 
19 APOE rs4420638 G/G 0.62 (0.4-0.95) 0.029 
16 CETP rs247616 T/C 1.24 (1.01-1.51) 0.041 
1 PCSK9 rs2479409 G/G 1.21 (1.00-1.45) 0.045 
5 TIMD4 rs6882076 T/C 1.21 (1.00-1.46) 0.051 
1 SORT1 rs629301 G/T 1.18 (0.94-1.49) 0.16 
7 NPC1L1 rs217386 A/G 1.13 (0.94-1.35) 0.19 
1 IRF2BP2 rs514230 A/T 1.13 (0.94-1.35) 0.20 
6 LPA rs1564348 C/C 1.15 (0.90-1.47) 0.27 
6 HLA rs3177928 A/A 0.87 (0.68-1.13) 0.30 
6 MYLIP rs3757354 T/C 0.90 (0.72-1.13) 0.36 
14 NYNRIN rs2332328 T/T 0.92 (0.76-1.11) 0.36 
8 CYP7A1 rs1030431 A/A 1.09 (0.90-1.32) 0.38 
6 HFE rs1800562 A/G 1.19 (0.81-1.75) 0.38 
2 APOB rs1367117 A/A 1.09 (0.90-1.32) 0.39 
8 PLEC1 rs11136341 G/G 1.09 (0.90-1.31) 0.40 
6 FRK rs11153594 T/C 1.08 (0.90-1.29) 0.42 
10 GPAM rs1129555 A/A 1.08 (0.88-1.32) 0.45 
12 HNF1A rs1169288 C/C 1.07 (0.88-1.31) 0.50 
17 OSBPL7 rs7225700 T/C 0.94 (0.78-1.14) 0.55 
8 PPP1R3B rs2126259 T/C 0.92 (0.67-1.26) 0.61 
1 LDLRAP1 rs12027135 A/T 0.95 (0.79-1.14) 0.61 
16 HPR rs2000999 A/A 1.06 (0.85-1.32) 0.62 
12 BRAP rs11065987 G/A 0.96 (0.80-1.15) 0.65 
1 MOSC1 rs2807834 T/G 0.96 (0.79-1.16) 0.66 
11 ST3GAL4 rs11220462 A/A 0.97 (0.75-1.27) 0.84 
20 MAFB rs2902941 G/A 0.98 (0.81-1.19) 0.86 
20 TOP1 rs909802 T/T 1.00 (0.84-1.20) 0.98 
CHR, chromosome; CI, confidence interval; HLP, hyperlipoproteinemia; HTG, hypertriglyceridemia; Mb, 
megabases; NC, not calculated; OR, odds ratio; SNP, single nucleotide polymorphism; T2D, type 2 
diabetes mellitus; TG, plasma triglyceride. The modeled allele is the LDL-raising allele in the combined 
HTG cohort.  
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Table 4.4b. Replication of LDL-associated loci in patients with HLP type 5. 
CHR Gene SNP 
Minor allele/ 
modeled allele 
HLP type 5 (n=180) 
OR (95% CI) P-value 
8 TRIB1 rs2954022 A/C 1.41 (1.05-1.89) 0.024 
1 ANGPTL3 rs3850634 G/T 1.77 (1.26-2.49) 1.1X10
-3
 
7 DNAH11 rs12670798 C/C 1.26 (0.92-1.74) 0.15 
2 ABCG5/8 rs4299376 G/G 1.18 (0.84-1.67) 0.34 
19 LDLR rs6511720 T/G 1.56 (0.75-3.24) 0.23 
9 ABO rs649129 T/T 1.34 (0.96-1.85) 0.082 
5 HMGCR rs12916 C/C 1.12 (0.84-1.50) 0.44 
11 FADS1 rs174583 T/C 0.84 (0.62-1.12) 0.23 
19 APOE rs4420638 G/G 0.73 (0.38-1.38) 0.33 
16 CETP rs247616 T/C 1.23 (0.89-1.68) 0.21 
1 PCSK9 rs2479409 G/G 1.14 (0.85-1.53) 0.38 
5 TIMD4 rs6882076 T/C 1.17 (0.87-1.58) 0.30 
1 SORT1 rs629301 G/T 0.93 (0.65-1.31) 0.66 
7 NPC1L1 rs217386 A/G 1.02 (0.77-1.34) 0.91 
1 IRF2BP2 rs514230 A/T 1.26 (0.94-1.67) 0.12 
6 LPA rs1564348 C/C 1.11 (0.76-1.63) 0.59 
6 HLA rs3177928 A/A 1.02 (0.69-1.50) 0.93 
6 MYLIP rs3757354 T/C 0.89 (0.64-1.26) 0.52 
14 NYNRIN rs2332328 T/T 0.9 (0.67-1.21) 0.48 
8 CYP7A1 rs1030431 A/A 1.11 (0.82-1.50) 0.51 
6 HFE rs1800562 A/G 1.21 (0.66-2.23) 0.54 
2 APOB rs1367117 A/A 1.08 (0.80-1.47) 0.60 
8 PLEC1 rs11136341 G/G 0.94 (0.70-1.27) 0.71 
6 FRK rs11153594 T/C 0.89 (0.67-1.18) 0.41 
10 GPAM rs1129555 A/A 0.92 (0.67-1.27) 0.62 
12 HNF1A rs1169288 C/C 0.99 (0.72-1.35) 0.94 
17 OSBPL7 rs7225700 T/C 1.25 (0.92-1.69) 0.15 
8 PPP1R3B rs2126259 T/C 1.02 (0.61-1.68) 0.95 
1 LDLRAP1 rs12027135 A/T 1.28 (0.95-1.72) 0.10 
16 HPR rs2000999 A/A 1.13 (0.81-1.58) 0.48 
12 BRAP rs11065987 G/A 0.96 (0.72-1.27) 0.76 
1 MOSC1 rs2807834 T/G 1.16 (0.84-1.60) 0.38 
11 ST3GAL4 rs11220462 A/A 0.85 (0.55-1.30) 0.44 
20 MAFB rs2902941 G/A 0.97 (0.72-1.31) 0.84 
20 TOP1 rs909802 T/T 0.99 (0.74-1.32) 0.95 
CHR, chromosome; CI, confidence interval; HLP, hyperlipoproteinemia; HTG, hypertriglyceridemia; Mb, 
megabases; NC, not calculated; OR, odds ratio; SNP, single nucleotide polymorphism; T2D, type 2 
diabetes mellitus; TG, plasma triglyceride. The modeled allele is the LDL-raising allele in the combined 
HTG cohort. 
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Table 4.4c. Replication of LDL-associated loci in patients with HLP type 4. 
CHR Gene SNP 
Minor allele/ 
modeled allele 
HLP type 4 (n=128) 
OR (95% CI) P-value 
8 TRIB1 rs2954022 A/C 1.36 (0.98-1.88) 0.064 
1 ANGPTL3 rs3850634 G/T 0.97 (0.69-1.37) 0.87 
7 DNAH11 rs12670798 C/C 1.41 (0.98-2.02) 0.062 
2 ABCG5/8 rs4299376 G/G 1.50 (1.04-2.17) 0.032 
19 LDLR rs6511720 T/G 4.35 (1.30-14.6) 0.017 
9 ABO rs649129 T/T 1.14 (0.79-1.65) 0.49 
5 HMGCR rs12916 C/C 1.27 (0.93-1.74) 0.14 
11 FADS1 rs174583 T/C 0.72 (0.52-0.99) 0.046 
19 APOE rs4420638 G/G 0.50 (0.22-1.14) 0.10 
16 CETP rs247616 T/C 1.28 (0.90-1.83) 0.17 
1 PCSK9 rs2479409 G/G 1.38 (1.00-1.90) 0.052 
5 TIMD4 rs6882076 T/C 1.15 (0.83-1.59) 0.40 
1 SORT1 rs629301 G/T 1.05 (0.71-1.55) 0.80 
7 NPC1L1 rs217386 A/G 1.12 (0.83-1.53) 0.46 
1 IRF2BP2 rs514230 A/T 1.08 (0.80-1.46) 0.63 
6 LPA rs1564348 C/C 1.15 (0.75-1.75) 0.53 
6 HLA rs3177928 A/A 0.79 (0.50-1.23) 0.30 
6 MYLIP rs3757354 T/C 0.65 (0.45-0.93) 0.017 
14 NYNRIN rs2332328 T/T 1.00 (0.73-1.38) 0.99 
8 CYP7A1 rs1030431 A/A 1.46 (1.06-2.02) 0.02 
6 HFE rs1800562 A/G 1.54 (0.73-3.24) 0.25 
2 APOB rs1367117 A/A 0.88 (0.62-1.24) 0.45 
8 PLEC1 rs11136341 G/G 1.19 (0.86-1.64) 0.29 
6 FRK rs11153594 T/C 1.27 (0.93-1.74) 0.14 
10 GPAM rs1129555 A/A 0.94 (0.66-1.34) 0.74 
12 HNF1A rs1169288 C/C 1.06 (0.76-1.50) 0.72 
17 OSBPL7 rs7225700 T/C 1.01 (0.72-1.42) 0.95 
8 PPP1R3B rs2126259 T/C 1.04 (0.60-1.82) 0.88 
1 LDLRAP1 rs12027135 A/T 0.91 (0.66-1.26) 0.57 
16 HPR rs2000999 A/A 0.94 (0.63-1.40) 0.74 
12 BRAP rs11065987 G/A 0.97 (0.71-1.32) 0.84 
1 MOSC1 rs2807834 T/G 0.90 (0.64-1.25) 0.52 
11 ST3GAL4 rs11220462 A/A 0.82 (0.51-1.34) 0.43 
20 MAFB rs2902941 G/A 0.80 (0.58-1.11) 0.19 
20 TOP1 rs909802 T/T 0.91 (0.66-1.25) 0.56 
CHR, chromosome; CI, confidence interval; HLP, hyperlipoproteinemia; HTG, hypertriglyceridemia; Mb, 
megabases; NC, not calculated; OR, odds ratio; SNP, single nucleotide polymorphism; T2D, type 2 
diabetes mellitus; TG, plasma triglyceride. The modeled allele is the LDL-raising allele in the combined 
HTG cohort. 
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Table 4.4d. Replication of LDL-associated loci in patients with HLP type 3. 
CHR, chromosome; CI, confidence interval; HLP, hyperlipoproteinemia; HTG, hypertriglyceridemia; Mb, 
megabases; NC, not calculated; OR, odds ratio; SNP, single nucleotide polymorphism; T2D, type 2 
diabetes mellitus; TG, plasma triglyceride. The modeled allele is the LDL-raising allele in the combined 
HTG cohort.
 1
Variant is monomorphic in HTG cases. 
CHR Gene SNP 
Minor allele/ 
modeled allele 
HLP type 3 (n=37) 
OR (95% CI) P-value 
8 TRIB1 rs2954022 A/C 1.59 (0.89-2.84) 0.12 
1 ANGPTL3 rs3850634 G/T 1.24 (0.66-2.32) 0.50 
7 DNAH11 rs12670798 C/C 1.30 (0.70-2.43) 0.41 
2 ABCG5/8 rs4299376 G/G 1.14 (0.59-2.21) 0.69 
19 LDLR rs6511720 T/G NC
1
 NC
1
 
9 ABO rs649129 T/T 1.26 (0.66-2.40) 0.49 
5 HMGCR rs12916 C/C 1.35 (0.78-2.34) 0.29 
11 FADS1 rs174583 T/C 0.78 (0.43-1.41) 0.41 
19 APOE rs4420638 G/G 0.58 (0.13-2.52) 0.47 
16 CETP rs247616 T/C 0.79 (0.42-1.47) 0.46 
1 PCSK9 rs2479409 G/G 1.32 (0.74-2.37) 0.35 
5 TIMD4 rs6882076 T/C 0.88 (0.50-1.55) 0.66 
1 SORT1 rs629301 G/T 1.33 (0.63-2.82) 0.45 
7 NPC1L1 rs217386 A/G 0.62 (0.35-1.07) 0.087 
1 IRF2BP2 rs514230 A/T 1.32 (0.74-2.35) 0.34 
6 LPA rs1564348 C/C 1.36 (0.67-2.76) 0.40 
6 HLA rs3177928 A/A 1.49 (0.72-3.07) 0.28 
6 MYLIP rs3757354 T/C 0.96 (0.48-1.91) 0.90 
14 NYNRIN rs2332328 T/T 1.50 (0.80-2.82) 0.21 
8 CYP7A1 rs1030431 A/A 1.22 (0.68-2.18) 0.51 
6 HFE rs1800562 A/G 0.36 (0.15-0.85) 0.019 
2 APOB rs1367117 A/A 0.77 (0.41-1.46) 0.42 
8 PLEC1 rs11136341 G/G 1.20 (0.66-2.17) 0.55 
6 FRK rs11153594 T/C 0.74 (0.43-1.29) 0.29 
10 GPAM rs1129555 A/A 1.50 (0.84-2.67) 0.17 
12 HNF1A rs1169288 C/C 1.30 (0.71-2.38) 0.39 
17 OSBPL7 rs7225700 T/C 0.61 (0.35-1.07) 0.083 
8 PPP1R3B rs2126259 T/C 0.49 (0.23-1.05) 0.066 
1 LDLRAP1 rs12027135 A/T 0.88 (0.50-1.55) 0.65 
16 HPR rs2000999 A/A 1.12 (0.57-2.17) 0.74 
12 BRAP rs11065987 G/A 1.16 (0.65-2.05) 0.62 
1 MOSC1 rs2807834 T/G 0.99 (0.53-1.85) 0.98 
11 ST3GAL4 rs11220462 A/A 0.77 (0.31-1.90) 0.57 
20 MAFB rs2902941 G/A 1.08 (0.58-2.01) 0.80 
20 TOP1 rs909802 T/T 1.00 (0.57-1.76) 0.99 
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Table 4.4e. Replication of LDL-associated loci in patients with HLP type 2B. 
CHR, chromosome; CI, confidence interval; HLP, hyperlipoproteinemia; HTG, hypertriglyceridemia; Mb, 
megabases; NC, not calculated; OR, odds ratio; SNP, single nucleotide polymorphism; T2D, type 2 
diabetes mellitus; TG, plasma triglyceride. The modeled allele is the LDL-raising allele in the combined 
HTG cohort. 
CHR Gene SNP 
Minor allele/ 
modeled allele 
HLP type 2B (n=159) 
OR (95% CI) P-value 
8 TRIB1 rs2954022 A/C 1.58 (1.19-2.10) 1.5X10
-3
 
1 ANGPTL3 rs3850634 G/T 1.61 (1.17-2.20) 3. X10
-3
 
7 DNAH11 rs12670798 C/C 1.32 (0.97-1.78) 0.076 
2 ABCG5/8 rs4299376 G/G 1.47 (1.07-2.02) 0.019 
19 LDLR rs6511720 T/G 1.46 (0.74-2.88) 0.27 
9 ABO rs649129 T/T 1.53 (1.13-2.07) 5.7X10
-3
 
5 HMGCR rs12916 C/C 1.16 (0.88-1.52) 0.29 
11 FADS1 rs174583 T/C 0.87 (0.66-1.15) 0.33 
19 APOE rs4420638 G/G 0.65 (0.34-1.23) 0.19 
16 CETP rs247616 T/C 1.36 (1.00-1.85) 0.049 
1 PCSK9 rs2479409 G/G 1.22 (0.92-1.60) 0.17 
5 TIMD4 rs6882076 T/C 1.59 (1.18-2.14) 2.4X10
-3
 
1 SORT1 rs629301 G/T 1.43 (0.99-2.06) 0.059 
7 NPC1L1 rs217386 A/G 1.39 (1.06-1.82) 0.017 
1 IRF2BP2 rs514230 A/T 1.03 (0.79-1.35) 0.81 
6 LPA rs1564348 C/C 1.16 (0.80-1.67) 0.43 
6 HLA rs3177928 A/A 0.79 (0.54-1.17) 0.24 
6 MYLIP rs3757354 T/C 1.30 (0.92-1.85) 0.14 
14 NYNRIN rs2332328 T/T 0.98 (0.74-1.30) 0.91 
8 CYP7A1 rs1030431 A/A 0.92 (0.69-1.23) 0.57 
6 HFE rs1800562 A/G 1.46 (0.79-2.68) 0.22 
2 APOB rs1367117 A/A 1.38 (1.04-1.84) 0.026 
8 PLEC1 rs11136341 G/G 1.18 (0.89-1.56) 0.26 
6 FRK rs11153594 T/C 1.21 (0.92-1.59) 0.18 
10 GPAM rs1129555 A/A 1.17 (0.87-1.58) 0.30 
12 HNF1A rs1169288 C/C 1.07 (0.79-1.45) 0.66 
17 OSBPL7 rs7225700 T/C 0.71 (0.54-0.93) 0.014 
8 PPP1R3B rs2126259 T/C 1.04 (0.64-1.68) 0.88 
1 LDLRAP1 rs12027135 A/T 0.89 (0.68-1.18) 0.42 
16 HPR rs2000999 A/A 1.00 (0.72-1.39) 1.00 
12 BRAP rs11065987 G/A 0.93 (0.71-1.23) 0.61 
1 MOSC1 rs2807834 T/G 0.87 (0.65-1.16) 0.35 
11 ST3GAL4 rs11220462 A/A 1.28 (0.89-1.85) 0.18 
20 MAFB rs2902941 G/A 1.05 (0.79-1.40) 0.73 
20 TOP1 rs909802 T/T 1.05 (0.80-1.38) 0.72 
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4.3.3. Genetic risk scores in HTG and the HLP-HTG phenotypes 
Next, we constructed weighted allelic risk scores to assess the accumulation of lipid-
associated risk alleles in the study sample (Figure 4.1). Consistent with our previous 
report in a smaller sample (Teslovich et al., 2010), weighted TG risk scores were 
significantly increased in HTG patients versus controls (Figure 4.1, top). The relative 
frequency distribution was clearly shifted towards increased scores in HTG patients 
versus controls: 0.982±0.004 mmol/L versus 0.896±0.003 mmol/L (P=1.6X10
-53
); 
unweighted risk scores were similarly increased in HTG patients (Figure 4.2). Weighted 
TG risk scores were associated with increased HTG susceptibility (Ptrend<0.001), as 
subjects in the highest risk score bin were 4.15 (95% CI: 2.84-6.09) times more likely to 
be HTG cases than healthy controls compared to the median risk score bin (P=8.56X10
-
14
). Subjects in the highest risk score bin were 23.0 (95% CI: 12.86-41.14) times more 
likely to be HTG cases than healthy controls compared with subjects in the lowest risk 
score bin as the referent group (P=3.51X10
-40
). 
 
Weighted HDL-C risk scores were also significantly increased in HTG patients 
versus controls (Figure 4.1, middle). The relative frequency distribution of HDL-C risk 
scores was modestly shifted towards less favorable scores in HTG patients versus 
controls, corresponding to a highly significant difference between HTG cases and 
controls of -0.449±0.002 mmol/L versus -0.431±0.001 mmol/L, respectively (P=1.3X10
-
12
). Incremental increases in HDL-C risk score also corresponded to increased HTG 
susceptibility (Ptrend<0.001), as subjects in the highest risk score bin were 1.50 (95% CI: 
1.02-2.12) times more likely to be HTG cases than healthy controls compared to the
207
  
 
 
 
 
 
 
 
 
Figure 4.1. Weighted allelic risk scores are increased in polygenic HTG patients 
versus controls. Left: relative frequency distribution of weighted risk scores in HTG 
patients and controls. Right: forest plot demonstrating incremental increases in HTG 
susceptibility or protection as weighted risk scores deviate from the median. P-values 
represent Cochrane-Armitage test for trend. CI, confidence interval; HTG, 
hypertriglyceridemia; TG, triglyceride. 
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median risk score bin (P=0.05). Subjects in the highest risk score bin were 3.14 (95% CI: 
2.09-4.72) times more likely to be HTG cases than healthy controls compared to the 
lowest risk score bin as the referent group (P=2.87X10
-8
).  
 
Weighted LDL-C risk scores were less dramatically increased in HTG patients 
versus controls (Figure 4.1, bottom). A modest shift towards higher weighted risk scores 
was observed in HTG patients, corresponding to a mean risk score of 1.04±0.005 mmol/L 
in HTG patients versus 1.00±0.003 mmol/L in controls (P=6.9X10
-12
). Incremental 
increases in LDL-C risk score were marginally associated with increased HTG 
susceptibility (Ptrend<0.001), as subjects in the highest risk score bin were 1.57 (95% CI: 
1.09-2.27) times more likely to be HTG cases than healthy controls compared to the 
median risk score bin (P=0.02). Subjects in the highest risk score bin were 3.39 (95% CI: 
2.25-5.11) times more likely to be HTG cases than healthy controls compared to the 
lowest risk score bin as the referent group (P=3.03X10
-9
). 
 
We hypothesized that the increased HDL-C and LDL-C risk scores observed in 
HTG patients were mediated by the pleiotropic effect of 15/47 (32%) HDL-C or 10/37 
(27%) LDL-C variants that were jointly associated with plasma TG concentration 
(Teslovich et al., 2010). Accordingly, we constructed HDL-C and LDL-C risk scores 
composed of either (1) variants associated exclusively with HDL-C or LDL-C, or (2) 
pleiotropic variants jointly associated with plasma TG concentration in addition to HDL-
C or LDL-C (Figure 4.3). For HDL-C, risk scores composed exclusively of HDL-C-
associated variants were not different between HTG patients and healthy controls
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(P=0.72); however, risk scores composed of pleiotropic HDL-C-associated variants were 
increased in HTG patients versus controls (P=1.7X10
-18
) (Figure 4.3; top). For LDL-C, 
risk scores composed exclusively of LDL-C-associated variants were slightly increased in 
HTG patients versus controls (P=0.0001); however, risk scores composed of pleiotropic 
LDL-C-associated variants were greatly increased in HTG patients versus controls 
(P=8.8X10
-11
) (Figure 4.3; bottom). We considered the possibility that the large effect 
sizes of many pleiotropic variants could have inflated the observed variant accumulation; 
however this is unlikely because parallel analyses using unweighted risk scores were 
similarly increased in HTG patients (Figure 4.4). 
 
Finally, we tested whether the accumulation of lipid-associated risk alleles 
observed in HTG patients was consistent across the different HLP-HTG phenotypes 
(Figure 4.5). We hypothesized that weighted TG risk scores would be equal among HLP-
HTG phenotypes, whereas weighted HDL-C and LDL-C risk scores might differ among 
HTG patients and phenotypes. For TG risk scores, all HLP-HTG phenotypes had risk 
scores elevated above controls, with HLP type 5 patients having risk scores further 
increased over other phenotypes, suggesting an accumulation of common variants with 
larger effects in these more severely affected patients. For HDL-C risk scores, only HLP 
types 4 and 5 had scores increased above controls, consistent with the excess of HDL-C-
associated variants with directions of effect concordant with GLGC estimates. For LDL-
C risk scores, HLP phenotypes 2B and 5 had risk scores increased above controls, also 
consistent with the excess of LDL-C-associated variants with directions of effect 
concordant with GLGC estimates. Although the greatest differences in risk scores
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Figure 4.5. Weighted allelic risk scores differ among polygenic HLP-HTG 
phenotypes. Mean risk score in all HTG patients is provided as a reference only; it was 
not included in statistical comparisons. Values are mean ± standard error; means sharing 
letters are not statistically different. 
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between HLP phenotypes and controls were attributed to pleiotropic variants, the 
contribution of both pleiotropic and lipid-specific variants likely contribute to the overall 
phenotypic heterogeneity among HLP-HTG phenotypes (Figure 4.6). These data 
collectively suggest that common variants associated with plasma lipid concentrations 
accumulate in HTG patients: TG-associated variants accumulate in all HLP-HTG 
phenotypes, whereas HDL-C and LDL-C associated variants preferentially accumulate in 
an HLP-HTG phenotype-dependent manner.  
 
4.3.4. Rare variants in TG-associated genes among HLP-HTG phenotypes 
We previously demonstrated that a significant excess of rare variants is present in 
GWAS-identified genes associated with HTG, including APOA5, GCKR, LPL and 
APOB, in HTG patients compared to controls (Johansen et al., 2010). Rare variants 
identified in this previous study were often found in multiple subjects, however we could 
not identify any trends between genes, variant or HLP-HTG phenotype. Here, we tested 
whether this excess of rare variants extended to the HLP phenotypes in subjects with 
available sequencing data. Carriers and non-carriers were compared in this analysis, as 
some subjects carried >1 rare variant. Indeed, a significant excess of rare variants was 
observed across all HLP-HTG phenotypes (Figure 4.7). Comparison of rare variants 
between each HLP-HTG phenotype and healthy controls using Fisher’s exact test 
revealed that carriers were 1.8-2.6 times more likely to have HLP-HTG case status than 
control status. There were no differences in number of rare variant carriers or non-carriers 
among the 4 phenotypes (P=0.59), nor were there differences in distribution of rare 
variants among genes in each phenotype (P=0.69), as assessed using contingency table 
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analysis. We also found no differences in TG risk scores among carriers and non-carriers 
of rare variants in HTG patients and controls (Figure 4.8). These data suggest that the 
distribution of rare variants in HTG-associated genes occurs non-preferentially across all 
HLP-HTG phenotypes in several TG-associated genes, on top of an accumulation of 
lipid-associated common variants. 
 
4.3.5. Variation explained by clinical and genetic variables in HLP-HTG patients 
Given the limitations associated with calculating explained variation from logistic 
regression models, we measured changes in model goodness-of-fit (pseudo-R
2
) attributed 
to different clinical and genetic variables in a logistic regression model discriminating 
between HLP-HTG phenotypes and healthy controls as a surrogate metric for explained 
variation (Figure 4.9; see Methods). Within HTG patients, the total proportion of 
variation explained by the model was 42.0%, very similar to our previous estimates 
(Johansen et al., 2010). Clinical variables explained 21.2%, common variants explained 
17.4%, and rare variants explained 1.4%. In this analysis, APOE genotype was also 
included due to its historical importance in HLP type 3, which explained an additional 
2% of variation among HTG cases. Among the HLP-HTG phenotypes, the proportion of 
variation attributable to these variables differed significantly. In HLP type 3, APOE ɛ2 
genotype explained 34.6% of variation; common variation from GWAS-identified genes 
only explained an additional 1.5% variation. Conversely, common genetic variants 
explained 20-24% of variation among remaining phenotypes. APOA5, GCKR, MLXIPL 
and CILP2 explained the majority of this variation, although LPL explained additional 
variation in HLP type 4, TRIB1 explained additional variation in HLP type 2B, and 
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Figure 4.8. TG risk scores are similar between carriers and non-carriers of rare 
variants. Differences among TG risk scores were assessed using ANOVA and post hoc 
pairwise comparisons using Tukey’s test (P<0.05). Values are mean ± standard error; 
means sharing letters are not statistically different. HTG, hypertriglyceridemia. 
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Figure 4.9. Comparison of variation attributable to clinical and genetic variables 
among polygenic HLP-HTG phenotypes within our cohort. The proportion of 
variation explained was calculated from changes in model fit (R
2
) from multiple logistic 
regression entering clinical and genetic variables using forward modeling. Common 
variants included risk alleles (0, 1 or 2 alleles) from multiple TG-associated loci selected 
by the model. APOE genotype was coded as copies of the APOE E2 or E4 genotype. 
BMI, body mass index; HLP, hyperlipoproteinemia; HTG, hypertriglyceridemia; T2D, 
type 2 diabetes; TG, triglyceride. 
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ANGPTL3 explained additional variation in HLP types 2B and 5. Rare genetic variants in 
the 4 genes also explained 1.2-2.6% of variation among HLP types 2B, 4 and 5. Finally, 
APOE genotype explained ~2.2% of variation among HLP type 5 patients, but did not 
explain additional variation among remaining phenotypes. Thus, the contribution of 
common and rare variants to the model was relatively similar among HLP phenotypes 
2B, 4 and 5, whereas APOE genotype was the best predictor of HLP type 3 case status.  
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4.4. Discussion 
The principal finding of this chapter is that many common lipid-associated variants in 
loci associated with TG, HDL-C and LDL-C underlie multiple biochemically-defined 
HLP-HTG phenotypes, and contribute to the phenotypic spectrum within HTG. Weighted 
TG risk scores were distinctly increased across all HLP-HTG phenotypes compared to 
controls, whereas weighted HDL-C and LDL-C risk scores were also increased, albeit 
less pronounced, in some HLP-HTG phenotypes compared to controls. Interestingly, 
decomposition of HDL-C and LDL-C risk scores revealed that pleiotropic variants (those 
jointly associated with TG) accounted for the greatest difference in HDL-C and LDL-C 
risk scores among HLP-HTG phenotypes. However, rare variants in 4 genes also 
accumulated equally among HLP-HTG phenotypes. Thus, HTG susceptibility and 
phenotypic heterogeneity appear to be influenced in part by the accumulation of common 
and rare lipid-associated variants. Taken together, these findings provide a more 
complete accounting of the genetic architecture of HTG susceptibility and the basis of the 
phenotypic heterogeneity in HTG. 
 
Earlier preliminary studies provided a first approximation of the genetic 
architecture of HTG and the HLP-HTG phenotypes (Hegele et al., 2009, Wang et al., 
2008a, Wang et al., 2008b), while the novelty of the current study lies in the 
comprehensive nature of our analysis, which included all recently identified lipid-
associated variants from the GLGC (Teslovich et al., 2010). We have confirmed the 
hypothesis that a common genetic architecture of many common and rare TG-associated 
variants underlies predisposition to HTG (Johansen et al., 2011), and demonstrated that 
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pleiotropic variants and accumulation of additional lipid-associated variants may partly 
explain an origin for the phenotypic heterogeneity among HTG patients.  
 
Our interpretation of these results is that a genetic burden of deleterious variants 
may predispose some subjects to HTG. Common and rare variants accumulate more often 
in HTG patients, suggesting that risk alleles may incrementally contribute to HTG 
susceptibility. However, it appears that no single variant or accumulation of variants is 
sufficient to cause HTG or any particular HLP-HTG phenotype. Despite seemingly 
strong phenotype-specific associations, risk alleles at associated loci are overrepresented 
in multiple HLP-HTG phenotypes compared to controls. Similarly, rare HTG-associated 
variants also accumulate comparably across the HLP-HTG phenotypes, in addition to an 
elevated background of common risk variants, again suggesting that rare variants are not 
sufficient for HTG causation. Ultimately, the significant overlap of risk alleles among 
HTG patients and controls suggests that – as with most complex traits – genetic variants 
only account for a portion of variation in HTG case status.  
 
 Our evolving model of polygenic HTG is that accumulation of common and rare 
TG-associated risk alleles gradually increases HTG susceptibility. Furthermore, the 
accumulation of pleiotropic risk alleles in addition to lipid-associated risk alleles may 
contribute to the phenotypic heterogeneity characteristic of the classical HLP-HTG 
phenotypes. However, we do not exclude the possibility that HTG susceptibility in some 
patients can be independent of risk allele accumulation. In our sample, we observe that 
HLP type 2B appears to be associated preferentially with common variants in pleiotropic 
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and exclusively LDL-C-associated loci; HLP type 4 appears to be associated with 
common variants in pleiotropic HDL-C-associated loci; and the most severe phenotype 
HLP type 5 is associated with large effect common TG-associated risk alleles, with 
additional contributions from both pleiotropic LDL-C- and HDL-C-associated loci. The 
contribution of risk alleles from APOA5, GCKR, MLXIPL, and CILP2 appeared to 
contribute relatively equally among these phenotypes, with additional smaller 
contributions from other TG-associated variants in each HLP-HTG phenotype.  
 
HLP type 3 is unique compared to other HLP-HTG phenotypes as it is 
predominantly explained by the classical APOE ε2/ε2 isoform (APOE E2/E2 genotype). 
However, even APOE ε2/ε2 is individually insufficient to cause HLP type 3. HLP type 3 
is defined by the accumulation of intermediate density lipoproteins (IDL) visible as β-
VLDL (or a broad beta band) on electrophoresis, resulting in a high ratio of VLDL 
cholesterol to TG. Many HLP type 3 patients have APOE ε2/ε2, although some HLP type 
5 patients that are clinically defined by fasting chylomicronemia and pancreatitis in our 
sample also have APOE ε2/ε2 genotype; many healthy controls in the general population 
also have APOE ε2/ε2 genotype. Variants such as APOA5 that are strongly associated 
with HLP type 3, in addition to other TG-raising risk alleles, likely contribute 
additionally to HLP type 3 susceptibility. 
 
Our conclusions must be interpreted in the context of important limitations of our 
study. First, our sample size and statistical power were limited despite having the largest 
cohort of HTG patients reported to date. Accordingly, our sample was insufficient to 
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replicate most small effect variants identified by the GLGC (Teslovich et al., 2010). This 
was compounded by the need for subgroup analyses, which prevented replication of 
many variants in the HLP-HTG phenotypes, even those associated with HTG at P<0.05, 
but was unavoidable because of insufficient numbers. To compensate for this, we have 
used additional analyses including risk score analyses and estimates of directionality of 
effect to overcome this limitation.  
 
Second, the analysis of GWAS lead SNPs is likely insufficient to demonstrate the 
full spectrum of genetic heterogeneity within the HLP-HTG phenotypes. We genotyped 
tagSNPs that serve as surrogates for functional variants at each locus, not truly querying 
the specific functional variants that increase HTG susceptibility. Direct genotyping of 
functional variants, such as the APOA5 -1131T>C promoter variant and the S19W 
variant, which are both strongly associated with HTG (Hegele et al., 2009, Wang et al., 
2008a, Wang et al., 2008b) but are each in relatively weak LD with the APOA5 tag-SNP 
rs964184 (r
2
=0.29 and r
2
=0.34 in sample subsets) may improve the resolution of our risk 
scores, and thus ability to detect differences between phenotypes. This might be expected 
given that APOE genotype at functional variants rs7412 and rs429358 (encoding the 
APOE E2/E3/E4 isoforms) contributed significantly more information to HLP type 3 
case status than the APOE tagSNP.  
 
Third, only 4 HTG-associated genes were selected for resequencing. This limited 
view of rare variant accumulation may preclude our ability to detect genetic 
heterogeneity in other genes that could mediate phenotypic heterogeneity within the 
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HLP-HTG phenotypes. Furthermore, functional data is necessary to separate deleterious 
from benign variants, which may also introduce noise into this analysis preventing 
detection of heterogeneity. However, many variants in these genes were identified across 
multiple HLP-HTG phenotypes. For example, the loss-of-function variant LPL G188E 
(Emi et al., 1990) which completely attenuates LPL function was identified as a 
heterozygous mutation in HLP types 3, 4, and 5. This suggests that rare variants in these 
genes have a general effect on HTG susceptibility, without predisposing subjects to a 
specific HLP-HTG phenotype. Ultimately, the combination of low power arising from a 
limited sample size with an incomplete survey of functional genetic variants in all HTG-
associated genes may hide some of the genetic heterogeneity initially expected to 
underlie the HLP-HTG phenotypes. However, our results based on GWAS tagSNPs and 
4 HTG-associated genes provide evidence for a common overlapping genetic etiology for 
the phenotypic spectrum of HLP-HTG phenotypes. 
 
Future studies will require exhaustive resequencing of TG-associated genes to 
identify additional genetic variants involved in HTG susceptibility. These will include 
both common functional variants that underlie GWAS signals and large effect rare 
variants that mediate significant HTG predisposition in their carriers. Together, these 
variants will likely explain additional variation in HTG case status and may provide a 
better explanation for the genetic basis of the phenotypic heterogeneity among HLP-HTG 
patients. Consideration of these determinants in the context of multiplicative or 
synergistic effects between genes, variants, and metabolic and environmental exposures, 
may contribute additionally to the unexplained variation among HTG patients.  
235
  
 
Evaluation of remaining unexplored variables may eventually lead to improved 
detection of subjects with increased HTG susceptibility. For example, genetic risk scores 
composed of functional HTG-associated variants may facilitate presymptomatic 
identification of clinic patients at increased risk for development of HTG. Common 
variants in genes such as APOA5, LPL, TRIB1 and CILP2, are strong determinants of 
HTG but also CVD, and could further be integrated into risk prediction algorithms such 
as the Framingham risk score as individual variants or genetic risk scores to help predict 
subjects at increased risk of CVD. The clinical utility of HTG-associated variants in the 
prediction of HTG or CVD susceptibility has not been evaluated, but could be used in the 
future to direct evidence-based treatments or lifestyle interventions at those with highest 
HTG susceptibility.  
 
In summary, we demonstrated that a spectrum of common and rare genetic 
variants in lipid-associated loci underlies the biochemically-defined HLP phenotypes 
characterized by HTG. We confirm that an accumulation of common TG-associated risk 
alleles is observed in HTG patients, and provide new evidence supporting the 
accumulation of pleiotropic TG-, HDL-C and LDL-C-associated risk alleles as possible 
determinants of HTG phenotypic heterogeneity. The significant overlap of risk alleles 
among multiple HLP-HTG phenotypes indicates a shared, yet complex and 
heterogeneous genetic HTG susceptibility. Ongoing discovery of additional TG-
associated alleles and elucidation of specific functional variants contributing to HTG 
pathophysiology will be required in the context of normal and perturbed metabolic and 
environmental conditions.  
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 CHAPTER 5 
 
DISCUSSION AND CONCLUSIONS 
 
The work in this chapter originates from sections of the following publications: (1) 
Johansen CT, Wang J, and Hegele RA. (2011). Bias due to selection of rare variants 
using frequency in controls. Nat Genet 43(5):394-395; (2) Johansen CT, Kathiresan S, 
and Hegele RA. (2011). Genetic determinants of plasma triglycerides. J Lipid Res 52(2): 
189-206; (3) Johansen CT and Hegele RA. (2011). Genetic bases of 
hypertriglyceridemic phenotypes. Curr Opin Lidiol 22(4): 247-53; and (4) Johansen CT 
and Hegele RA. (2011). Allelic and phenotypic spectrum of plasma TG. Biochim Biophys 
Acta. Submitted.   
 
5.1. The genetic architecture of HTG 
Hypertriglyceridemia (HTG) is a complex, polygenic, adult-onset disorder defined by 
fasting plasma triglyceride (TG) concentrations >95
th
 percentile (Yuan et al., 2007). Prior 
to the work in this thesis, the genetic architecture of HTG was poorly defined. Few 
common and rare genetic variants were associated with HTG, and the vast majority of 
phenotypic variation was unattributed (Hegele, 2009). However, the experiments 
described here have greatly enhanced our understanding of HTG. Our comprehensive 
evaluation of common and rare genetic variation in the largest HTG cohort assembled to 
date has expanded the number of possible genes implicated in HTG susceptibility to ~35, 
and provided a refined estimate of variation attributable to genetic and clinical variables. 
240
 Furthermore, we have provided a model for HTG susceptibility and phenotypic 
heterogeneity, speculating that all genes and variants that are associated with plasma TG 
concentration similarly increase HTG susceptibility. Ultimately, the research described in 
this thesis has contributed significantly to understanding the genetic determinants of HTG 
susceptibility, while providing hypothesis-generating proof-of-principle experiments 
applicable to the genetic architecture of complex diseases. This chapter will summarize 
the novelty of our experiments and conceptual advances.  
 
5.1.1. Common genetic variation in HTG 
We have described the first genome-wide association study (GWAS) ever conducted on 
an extreme complex lipid phenotype. Using an unbiased approach, we demonstrated that 
common variation in known and novel genes, including APOA5, GCKR, LPL, and APOB, 
is strongly associated with HTG. We demonstrated that GCKR is a novel gene involved 
in HTG susceptibility, despite no prior functional involvement in lipoprotein metabolism. 
Similarly, we demonstrated that APOB has a role in modulating HTG susceptibility, in 
addition to extreme phenotypes of high and low plasma low-density lipoprotein (LDL) 
concentration. Finally, we demonstrated that common variation in known loci including 
LPL and APOA5 are the strongest HTG-associated variants. 
 
Importantly, we have demonstrated that common genetic determinants of plasma 
TG concentration are also determinants of HTG susceptibility. We directly replicated 
associations with TG-associated loci including MLXIPL, ANGPTL3, TRIB1, and provided 
some evidence for association with NCAN and FADS1-FADS2-FADS3, implicating TG-
241
 associated genes in HTG susceptibility. Not surprisingly, common variants with 
individually small effect sizes only detectable by epidemiologically-sized samples were 
not replicated in our cohort, however virtually every TG-associated locus identified by 
the Global Lipids Genetics Consortium (GLGC) that was estimated to increase plasma 
TG concentration had a concordant direction of effect on HTG susceptibility. 
Furthermore, our efforts demonstrated that TG-raising alleles associated with population-
based plasma TG concentration accumulated in HTG patients. Interestingly, the effect 
sizes of single nucleotide polymorphisms (SNPs) found in common between studies of 
HTG and population-based TG concentration suggest that increases in plasma TG are 
proportional to increases in HTG susceptibility (Figure 5.1; Table 5.1). For example, 
each copy of the APOA5 risk allele (rs964184) increases HTG susceptibility by 3.3-fold, 
whereas this allele is only estimated to increase TG concentration by ~0.2 mmol/L. 
However, common TG-associated variants only explain ~10% of variation within the 
population (Teslovich et al., 2010), whereas they explain ~21% of variation in HTG 
diagnoses, perhaps indicative of underlying gene-gene or gene-environment interactions 
that contribute to HTG susceptibility in patients. Ultimately, these experiments have 
firmly established that a genetic background of TG-raising alleles is one component of 
HTG susceptibility. 
 
5.1.2. Rare genetic variation in HTG 
We have demonstrated that rare variation in HTG-associated genes contributes 
significantly to HTG susceptibility. We demonstrated that GWAS-identified genes  
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Figure 5.1. The effect sizes of TG-associated risk alleles on plasma TG concentration 
is correlated with the effect on HTG susceptibility. Effect sizes of TG-associated loci 
on plasma TG concentration (Teslovich et al., 2010) were compared against effect sizes 
on HTG susceptibility . The dotted line represents a reference trendline between 0 effect 
on plasma TG or HTG susceptibility and the maximal effect of the APOA5 variant (~17 
mg/dL; OR=3.3). The solid line represents a trendline fitted to all data points. 
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 APOA5, GCKR, LPL, and APOB harbour together a significant excess of heterozygous 
rare variants in HTG patients versus healthy controls. Similarly, we demonstrated that 
non-GWAS candidate genes APOC2, LMF1, GPIHBP1, CREB3L3, and ZHX3 also 
harbour together a significant excess of heterozygous rare variants in HTG patients 
versus healthy controls. Taken together, our data show that all genes known to cause 
Mendelian pediatric HTG phenotypes resulting from inherited homozygous (or 
compound heterozygous) mutations, including LPL, APOC2, APOA5, LMF1, and 
GPIHBP1, also harbour rare heterozygous loss-of-function variants that increase 
susceptibility to polygenic, adult-onset HTG. We have also established that genes 
recently implicated in TG metabolism by GWAS and other complementary experimental 
approaches, including GCKR, CREB3L3, and APOB also harbour rare variants associated 
with HTG susceptibility. We estimate that rare variation incrementally contributes ~1% 
of the unattributed variation in HTG diagnoses, however the size of this estimate is likely 
to increase with functional characterization using in vitro and in vivo models, as we 
predict that the true effect sizes of penetrant rare variants will approximate those of well 
appreciated markers of polygenic HTG such as the APOA5 S19W common variant. 
 
From a methodological perspective, we have contributed several conceptually 
novel proof-of-principle experiments. First, we demonstrated the proof-of-principle that 
GWAS-identified genes containing common variation associated with a complex disease 
also harbour rare variants that incrementally contribute to the unattributed variation in 
disease susceptibility. Second, we have demonstrated the utility of hypothesis-driven 
resequencing studies, implementing the first head-to-head comparison of gene-centric 
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 permutation-based statistical analyses to implicate specific genes in disease 
pathophysiology. Third, we have demonstrated that genomic techniques complementary 
to GWAS will be important to fully elucidate the genetic determinants of complex 
phenotypes. Our resequencing experiments have additionally contributed to the 
development of consensus regarding methodological considerations for rare variant 
accumulation analyses, including experimental design, rare variant definition, and 
analysis approach. Ultimately, these experiments have provided a framework for the 
imminent tsunami of whole exome and whole genome resequencing studies involving 
complex phenotypes and diseases. 
 
5.1.3. Phenotypic heterogeneity in HTG 
We have proposed that a shared genetic architecture of lipid-associated risk alleles 
underlies the biochemically-defined Fredrickson hyperlipoproteinemia (HLP) 
phenotypes. We conducted the most comprehensive analysis of genetic variation in the 
HLP-HTG phenotypes known to date, by including all common GWAS-identified 
variants associated with plasma lipid phenotypes by the GLGC, and integrating a 
comparison of rare variants in 4 HTG-associated genes among HLP-HTG phenotypes. 
We demonstrated that common and rare TG-associated variants accumulate equally 
among HLP-HTG phenotypes, whereas common high-density lipoprotein (HDL)- and 
LDL-associated variants accumulate in an HLP phenotype-dependent manner. Common 
and rare variants contributed equally to unattributed variation among HLP phenotypes 
2B, 4 and 5, whereas HLP type 3 was defined primarily by the functional APOE E2/E2 
alleles. Interestingly, we demonstrated that pleiotropic effects of genes jointly associated 
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 with TG and HDL or LDL may contribute mechanistically to the phenotypic 
heterogeneity among HTG patients. Finally, we demonstrated that common TG-raising 
alleles accumulated equally among carriers and non-carriers of rare variants, suggesting 
that an overall accumulation of genetic variation contributes to HTG susceptibility. These 
analyses have greatly expanded to our understanding of the genetic architecture of HTG 
and the phenotypic heterogeneity therein. 
 
5.1.4. Emerging model of HTG susceptibility 
The genes and variants that contribute to the modulation of plasma TG concentration are 
better understood than those underlying most complex traits. We have demonstrated that 
there is a significant overlap between genes and variants that predispose subjects to one 
of a broad spectrum of TG-related phenotypes. This has led to our working model that the 
allelic spectrum of plasma TG, consisting of common and rare variation of either small or 
large effect that collectively determine a subject’s specific plasma TG concentration, is 
intricately related to the phenotypic spectrum of plasma TG concentrations (Figure 5.2.). 
Common variation may subtly improve or impair TG metabolism, whereas rare variation 
may have much more dramatic metabolic consequences. Importantly, it is unlikely that 
any single common or rare variant will be individually sufficient to cause HTG; 
additional gene-gene and gene-environment interactions are integral to lipoprotein 
metabolism and will likely be further required to produce a penetrant phenotype. Thus, 
our emerging opinion is that multiple common and rare variants in multiple genes with 
different functions contribute jointly to a given phenotype, such that extreme polygenic  
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Figure 5.2. The allelic and phenotypic spectrum of plasma TG concentration. A) 
Monogenic hypoTG is caused by rare homozygous loss-of-function (LOF) variants in 
genes required for lipoprotein secretion or inhibition of TG-rich lipoprotein catabolism, 
including MTP, APOB, and ANGPTL3. B) Polygenic hypoTG is likely caused by an 
absence of common deleterious variants (or an accumulation of common protective 
variants), and rare heterozygous variants with relatively large effects in APOC3, 
ANGPTL3, ANGPTL4, and APOB. C) Normal plasma TG concentrations likely arise 
from a balance of protective and deleterious common variants, with possible 
contributions of rare heterozygous small effect variants. D) Polygenic HTG is caused by 
an accumulation of common deleterious variants (or an absence of common protective 
variants) and rare heterozygous variants with relatively large effects in APOA5, GCKR, 
LPL, APOB, APOE, CREBH, GPIHBP1. E) Monogenic HTG is caused by rare 
homozygous LOF variants in genes essential for lipoprotein metabolism, including LPL, 
APOC2, APOA5, LMF1, and GPIHBP1. Dotted red lines illustrate 5
th
 and 95
th
 percentiles 
of plasma TG concentration. HTG, hypertriglyceridemia; hypoTG, hypotriglyceridemia; 
LOF, loss-of-function; TG, triglyceride. 
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 phenotypes of plasma TG manifest as a result of a genetic burden in TG-associated 
genes.  
 
We speculate that elevated plasma TG concentration results from a genetic burden 
of deleterious TG-raising alleles (or absence of protective alleles) in TG-associated 
genes. Conversely, low plasma TG concentration likely indicates accumulation of 
protective TG-lowering alleles (or absence of deleterious alleles) in TG-associated genes. 
Subjects near the middle of the plasma TG concentration distribution likely have a 
balance of protective and deleterious small effect common variation, while those at either 
extreme of plasma TG have an accumulation of deleterious or protective alleles plus 
incremental contributions of large effect heterozygous rare variants. Patients with the 
most extreme phenotypes may express these phenotypes as the result of highly penetrant 
homozygous loss-of-function mutations.  
 
Furthermore, the accumulation of pleiotropic TG and other lipid-associated risk 
alleles may contribute to phenotypic heterogeneity among HTG patients defined by the 
classical Fredrickson HLP phenotypes. We suggest that genetic susceptibility to HTG 
requires a minimal burden (‘quorum’) of common and rare variants predisposing to HTG. 
The additional ‘stacking’ of risk alleles on top of the background ‘quorum’ of HTG 
drives the phenotypic spectrum of HTG. HLP type 2B appears to be associated 
preferentially with common variants in pleiotropic and exclusively LDL cholesterol-
associated loci; HLP type 4 appears to be associated with common variants in pleiotropic 
HDL cholesterol-associated loci; HLP type 3 is classically explained by the APOE E2/E2 
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 isoform in addition to other TG-raising risk alleles; and the most severe phenotype HLP 
type 5 is associated with large effect common TG-associated risk alleles, with additional 
contributions from both pleiotropic LDL- and HDL-associated loci. However, there is 
ultimately significant overlap between lipid-associated variants and multiple HLP-HTG 
patients, such that the biochemically-defined HLP-HTG phenotypes are virtually 
indistinguishable at the level of genetic variation.  
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 5.2. Methodological considerations for rare variant association studies 
High-throughput resequencing technologies and rare variant accumulation studies are 
relatively novel genetic analyses that have not yet become commonplace. Methodological 
considerations affecting standards for appropriate design, quality control, statistical 
analysis and interpretation are not yet established. The experiments described in this 
dissertation involving rare variant accumulation are among the first of their kind. 
Accordingly, we have contributed to development of methodological consensus and 
established an analysis framework for rare variant data.  
 
One important issue that directly influences design of re-sequencing studies is 
how best to define rare variants. In our resequencing study of genes identified by GWAS 
of HTG, we defined rare variants using a frequency threshold of <1% in healthy controls 
to eliminate variants with a low probability of deleterious effects. This identified a 
significant excess of rare nonsynonymous variants in TG-associated genes gleaned from 
GWAS of patients with HTG. However, contributing to the dialogue of how best to 
define a “rare variant” were two recent analyses using simulated data, which suggested 
that defining rare variants based on control-only frequency might over-estimate the extent 
of accumulation in cases (Lemire, 2011, Pearson, 2011). We addressed this issue with 
real data, using post hoc analyses to demonstrate that the proposed selection criteria, 
either defining rare variants by their frequency in the combined cohort or by their 
frequency in either cases or controls, do not affect our results or interpretation (Table 
5.2) (Johansen et al., 2011). We believe these differences are probably due to certain 
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 properties of simulated and real biological datasets, in addition to essential hypotheses 
underlying our study design. 
 
Both simulations appear to be sensitive to the underlying frequency distribution of 
simulated variants. For instance, over-estimation of variant counts and allele frequencies 
introduces selection bias into permutation-based analyses when variant frequencies are 
recalculated after each permutation.  Variants with multiple occurrences are more prone 
to frequency changes, since more variants are available for permutation among cases and 
controls, leading to variant inclusion when their frequencies are <1% in controls but 
exclusion when their frequencies are >1% in controls.  Higher frequency variants are 
more likely to introduce such bias, whereas singleton variants are immune to such bias.  
Indeed, Pearson’s analysis shows minimal bias is introduced when the variant frequency 
distribution is nearly identical to our sample, while increasing variant frequencies 
systematically introduce more bias (Pearson, 2011).  Similarly, Lemire’s analysis shows 
that selection bias is exaggerated with increasing numbers of rare variants, since more 
variants are available for permutation, and smaller sample sizes, where simulated variant 
frequencies are more liable to deviate from ‘true’ population frequency (Lemire, 2011).  
These instances of selection bias are only problematic when a restriction is placed upon 
rare variant inclusion in cases or controls alone; whereas a combined frequency threshold 
imposing no restriction upon either group protects against potential inflation of test 
statistics. 
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 Despite our particular definition of rare variants, our findings resist such selection 
bias because the majority of variants in our combined sample have frequencies <1%. We 
identified 94 variants across our entire sample; 80 were designated as rare with 
frequencies <1% in controls. Only 2 variants were affected by alternate selection criteria: 
1) LPL N291S (2.7% in cases and 0.8% in controls) would have been removed from our 
analysis using a frequency <1% in cases and controls combined; and 2) GCKR R540Q 
(0.9% in cases and 1.2% in controls) would have been additionally included in our 
analysis using the definition of a frequency <1% in either cases or controls, although it 
would have been excluded under a combined frequency threshold <1%. Furthermore, 
most variants in our cohort were singletons: 44 (47%) in patients but only 10 (11%) in 
normolipidemic controls. Thus, we observe a true excess of rare variants seen in our 
cases, in contrast to the distribution of some simulated frequency ratios from either 
Pearson or Lemire. 
 
While a frequency threshold in the combined sample is statistically robust to rare 
variant selection bias, a further consideration is the biological relevance of different rare 
variant definitions in the context of the specific study design, since not all definitions 
would necessarily lend themselves to appropriate hypothesis testing.  Our approach to 
rare variant accumulation was appropriate for our study design.  First, we hypothesized 
that rare large-effect variants involved in HTG pathophysiology would essentially be 
absent from controls.  We also assumed that an excess of protective rare variants would 
only be expected in controls drawn from a low extreme of plasma TG concentration when 
a gene product can affect both extreme phenotypes (e.g. “supernormal” controls <5th 
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 percentile of TG concentration); accordingly controls were drawn from the middle of the 
distribution of TG concentration. Thus, the upper bound on controls could only exclude 
or minimize benign rare variants that accumulated both in cases and controls, but were 
not pathogenic in the high extreme. Second, we surmised that variants with modest 
effects on HTG should have been more frequent in our cohort (Manolio et al., 2009).  
Excluding variants with frequency >1% in the total sample would have selected against 
variants with modest effects on HTG (Plomin et al., 2009).  For instance, the LPL N291S 
variant would have been so excluded, despite its proven functional compromise (Reymer 
et al., 1995). These specific examples show potential pitfalls of study designs with 
doctrinaire adherence to any particular definition of a rare variant.   
 
In re-sequencing studies, power to detect associations between complex 
phenotypes and rare variants – individually or even cumulatively within a particular gene 
– is limited.  Factors such as sample size, case-control ratio, ethnicity and gene size can 
all influence the number of identified variants.  Therefore, methodologies that reduce 
noise from benign variants and maximize the ability to detect potentially causal variants 
are required.  Aggregation of rare variants across multiple loci is suggested as one 
method to improve statistical power in re-sequencing studies (Bansal et al., 2010).  Future 
analyses may additionally require: 1) greatly increased sample sizes to more accurately 
reflect ‘true’ variant frequencies in each group separately and in the combined dataset, 
preferably by increasing the number of controls especially when cases are limited; 2) 
selecting controls from the middle of the distribution of a quantitative trait to minimize 
the chance of including protective variants (depending on the underlying biology of the 
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 gene product); and 3) reducing noise contributed by benign variants by using weighted 
effect sizes, such as inverse allele frequencies or by using in silico predictions of 
deleterious effect. Population-scale re-sequencing efforts, including the 1000 Genomes 
Project (Durbin et al., 2010), plus in vitro and in vivo characterization of variants in 
GWAS-identified genes, will also help define variant frequency and effect.  We 
anticipate that no single study design or definition, including the arguably arbitrary 
threshold frequency of 1%, will apply uniformly across studies of rare variant 
accumulation. 
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 5.3. Future directions in the analysis of complex disease phenotypes 
Therefore, experiments described in this dissertation have greatly contributed to our 
understanding of the genetic architecture of HTG. Furthermore, they have provided 
insight into the allelic and phenotypic spectrum of plasma TG. However, genetic 
variation identified to date – especially from GWAS - does not completely explain the 
unattributed variation in plasma TG concentration or HTG susceptibility. Accordingly, 
future investigations must seek to identify remaining TG-associated loci and specific 
functional common and rare variants that modulate of plasma TG (Figure 5.3). This 
section describes future directions that are necessary to explain the unattributed variation 
within complex phenotypes including the phenotypic spectrum of plasma TG and HTG 
susceptibility. 
 
5.3.1. Replication and fine mapping of GWAS loci 
Replication of GWAS-identified loci in additional cohorts is required to confirm true 
associations and establish a priority for fine-mapping and subsequent functional 
characterization of genes at newly associated loci. The statistical methods used in GWAS 
require very large samples to generate sufficient power to robustly identify associated 
loci, without which false positive associations may occur. Replication of associations in 
independent cohorts validates the authenticity of associations which may be artifacts of 
chance association, population stratification or population-specific interactions. 
Replication in non-European samples is also necessary to confirm the involvement of loci 
in other ethnicities, where genomic patterns of linkage disequilibrium (LD) are not 
equivalent to European populations.  
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 Following confirmation of true positive associations, fine mapping of GWAS loci 
is required to identify the precise genomic elements and functional variants that mediate 
the association. The experimental design and statistical analysis is virtually identical to 
GWAS, although using commercially-available high-density targeted microarrays, to 
effectively narrow the region of association to a more specific region within GWAS-
identified loci. This process serves to focus the initial GWAS-associated locus to a region 
ideally containing a single candidate gene or regulatory element that could serve as a 
functional candidate for the association. Following identification of a functional 
candidate gene or locus, deep resequencing is required to identify the specific functional 
variants that underlie each GWAS association. Eventually, cost-effective high-throughput 
sequencing technologies will facilitate simultaneous rapid identification of all functional 
common and rare variation in GWAS-associated loci, expediting the process of fine-
mapping and identification of causal genes and variants.  
 
It is likely that one or more functional variants may underlie each GWAS 
association. As such, the strongest association at any given locus may not represent the 
only functional variant that is causally associated with a complex phenotype or disease. 
Thus, subsequent functional analyses are required to establish all functional variants, 
which will likely explain a significant portion of the unattributed variation in complex 
phenotypes and disease susceptibility. 
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 5.3.2. Attributing causality to GWAS loci 
The identification of specific functional variants mediating GWAS associations will 
permit functional characterization of the biochemical mechanisms by which genomic 
elements contribute to metabolism. Systematic elucidation of newly identified genes will 
reveal their contribution to either novel or existing biological pathways, which will 
expand our understanding of biological networks that contribute to disease susceptibility; 
thus providing novel targets for interventions. The development of a novel treatment 
capable of lowing plasma TG concentration that is traceable to a GWAS-identified 
pathway will be a monumental success for the GWAS approach.  
 
 An emerging framework capable of attributing causality to GWAS-identified loci 
has only been attempted for few loci to date. For instance, the LDL-associated SORT1 
locus is perhaps the best characterized of novel GWAS-identified loci (Musunuru et al., 
2010b). Beginning with expression quantitative trait locus mapping, the functional 
variant at this locus was shown to modulate expression of several genes, but most notably 
SORT1 (encoding the protein product sortilin). A few additional studies have implicated 
SORT1 in modulation of very low-density lipoprotein (VLDL) secretion, although 
controversy stills surrounds the true function of SORT1 and its involvement in 
lipoprotein metabolism (Dube et al., 2011). Strategies for high-throughput functional 
annotation will soon be required to effectively interrogate remaining GWAS-identified 
loci. Analysis strategies may include luciferase assays to map regulatory elements in loci 
associated with transcript concentrations (Jarinova et al., 2009), and murine adenoviral-
based over-expression and knockdown of gene products suspected in lipoprotein 
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 metabolism (Burkhardt et al., 2010). However, such discoveries could take many years to 
be validated, even with a novel straightforward mechanism without inherent biological 
complexities. 
 
5.3.3. Use of complementary experimental approaches 
Although GWAS is an established genomic technique capable of identifying loci strongly 
associated with complex phenotypes, important genes in pathophysiology are not always 
identified by GWAS. There are several possible reasons for this: 1) a locus encodes a 
crucial protein, but there is no structural or functionally relevant genetic variation in 
humans; 2) only very rare functional variants exist at a locus, and these have no 
consistent LD relationship with the common genetic variation that is genotyped on 
microarrays; 3) common functional genetic variation at a locus affects TG metabolism, 
but is not included on the genotyping microarray nor is it in strong LD with surrogate 
markers on microarrays; 4) common functional variation has too small an effect size to be 
significantly associated; 5) GWAS studies that evaluate an additive mode of inheritance 
may miss associations with variants that act through simple dominant or recessive 
models, or non-additive gene-gene or gene-environment interactions, or non-Mendelian 
mechanisms including inheritance of mitochondrial DNA; or 6) common variation is 
present at a biologically important locus, detectable and included on genotyping 
microarrays, but it has no functional consequence. Thus, non-GWAS methodologies such 
as linkage and family-based studies, or analysis of human homologs of animal models 
may help with gene discovery.  
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 5.3.4. Gene-gene and gene-environment interactions 
Genetic variation in concert with gene-gene and gene-environment interactions will likely 
explain additional unattributed variation in complex phenotypes. Gene-gene interactions 
(or epistasis) could lead to additive, multiplicative or synergistic effects that together 
modulate metabolic pathways leading to effects greater than GWAS estimates for 
individual variants alone (Lanktree and Hegele, 2009). Gene-environment interactions 
could explain how the same environmental exposure may contribute disproportionately to 
intermediate traits and disease susceptibility among individuals (Corella and Ordovas, 
2009). Together, the analysis of gene-gene and gene-environment interactions could 
explain a significant portion of missing heritability in complex phenotypes (Manolio et 
al., 2009). However, the statistical methods necessary to analyze gene-gene and gene-
environment interactions are currently very complex and not sufficiently developed for 
high-throughput genetic analyses (Cordell, 2009). Preliminary analyses of gene-gene and 
gene-environment interactions may include: 1) stratification of subjects by genetic 
variants or environmental/metabolic exposures; 2) controlled exposure to environmental 
variables; 3) inclusion of interaction terms in regression models; or 4) assessment of 
covariates in multivariate regression models. However, these suggested analyses are 
highly sensitive to power and multiple testing which severely limits their effectiveness in 
genome-scale experimental designs. Future detailed collection of patient data pertaining 
environmental exposures may also be useful for association studies, as heterogeneity 
among exposures could confound statistical analyses.  
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 5.4. Clinical utility of genetic variation in complex diseases 
The legacy of genetic association studies, including both GWAS and rare variant 
accumulation studies, will be gauged by the number of genetic loci that help to elucidate 
and functionally annotate disease-associated metabolic pathways. However, the greatly 
expanded number of TG-associated genes may challenge our ability to rapidly study their 
functions. Taking full advantage of the new opportunities that have arisen through the 
GWAS discoveries will require analogous technological advances allowing fine-mapping 
of association peaks, deep re-sequencing for functional variants and finally high 
throughput, robust functional validation at all stages: in vitro, in vivo model systems and 
ultimately translational human research, including clinical trials. A more complete 
understanding of the genes and variants that modulate plasma TG will enable 
development of markers for risk prediction, diagnosis, and response to therapies, and 
might help specify new directions for therapeutic interventions. This section will describe 
the potential clinical utility of genetic information gleaned from genetic association 
studies. 
 
5.4.1. Genetic risk prediction 
Genetic information may be useful to estimate a patient’s genetic burden and predict 
disease susceptibility. A widely proposed idea is that genetic variables may be used to 
improve existing risk prediction algorithms for coronary artery disease (CAD) such as the 
Framingham risk score (Wilson et al., 1998). Genetic information could be entered into 
risk prediction equations using a single genetic variant, a genetic risk score composed of 
risk alleles for a single trait, or risk alleles associated with multiple independent traits. 
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 Generally, integration of a single common variant into risk prediction equations has not 
yet been shown to improve discrimination, although risk stratification into low, moderate 
and high risk groups has shown modest improvement (Johansen and Hegele, 2009). 
Perhaps most successfully, a comprehensive lipid risk score composed as a weighted sum 
of multiple lipid-associated risk alleles from early GWAS was strongly associated with 
cardiovascular disease (CVD) risk, and significantly improved risk stratification in 
patients (Kathiresan et al., 2008). The modest improvement of risk prediction provided 
by genetics, while biologically important, appears to be limited due to small effect sizes. 
Therefore, future analyses considering the combined impact of genetic variation, 
including common and rare variants, may improve the performance of genetic 
information in risk prediction algorithms (Kraft and Hunter, 2009). 
 
Genetic information could also permit early identification of subjects at risk for 
developing CVD disease, allowing prompt early lifestyle modification or evidence-based 
pharmacological intervention to reduce risk of clinical end points. Genetic variation in 
PCSK9 that results in decreased lifelong exposure to high circulating LDL-cholesterol 
concentrations substantially improves CAD risk (Cohen et al., 2006, Huang et al., 2009), 
suggesting that lifetime lowering of CVD risk factors has the potential to greatly improve 
outcomes. We have shown that there is a significant difference in mean score of risk 
alleles in HTG patients compared to population-based controls; thus TG risk scoring 
could help identify subjects at risk for developing HTG and who might benefit from early 
intervention. However, while few HTG patients have very low risk allele scores and few 
healthy individuals have very high risk allele scores, there is substantial overlap toward 
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 the centres of the distributions of risk allele scores. Emerging methodologies and future 
analyses that include known common functional variants and rare deleterious or 
protective alleles may help produce more discriminating TG risk scores. 
 
5.4.2. Pharmacogenomics  
Genetic information could also help realize the concept of personalized medicine by 
identifying patient-specific genetic variants for use in personalized therapy. For instance, 
fibrates and niacin are the primary pharmacotherapies for HTG. Inter-individual variation 
in plasma TG response has been reported to differ according to genotype of common 
APOA5 SNPs (Lai et al., 2007) and to the presence of rare loss-of-function variants of 
candidate genes in TG metabolism, including LPL, APOC2, and APOA5 (Wang et al., 
2007). A complete genetic profile related to TG metabolism and possibly plasma TG 
responsiveness, including common and rare variants in TG metabolizing genes or drug 
metabolizing genes, could be used to inform such personalized treatment.  
 
5.4.3. Mendelian randomization 
Genetic information could also be used to investigate whether a causal relationship exists 
between TG-associated loci and CVD risk. The identification of causally associated 
functional variants with CAD susceptibility would identify genes that are ideal 
pharmacological targets. Mendelian randomization (MR) is an emerging methodology 
that utilizes common genetic variation as a surrogate for exposure to different dosages of 
an endogenous disease risk factor (Davey Smith and Ebrahim, 2003). It predicts that if a 
genetic variant is associated with both a biomarker and a clinical endpoint, then the 
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 biomarker would be more likely to play a functional etiological role in the clinical 
outcome (Figure 5.4). MR is suggested to be robust and immune to confounding 
variables encountered in observational studies and to be capable of providing support for 
causality of an intermediate trait on a disease outcome. However, an important 
assumption underlying MR is that pleiotropy and gene-gene or gene-environment 
interactions are not involved in the system. The validity of MR in such scenarios will 
require thorough evaluation. 
 
However, MR may prove effective at implicating plasma TG concentration in 
direct CVD susceptibility. For instance, one recent study has used MR to infer causality 
of plasma TG concentration on CAD susceptibility using genetic variation in the APOA5 
locus, specifically the -1131T>C promoter variant, to demonstrate an association with 
plasma TG concentration that was proportional to increased CAD risk (Sarwar et al., 
2010). Similar analyses would prove useful to confirm whether additional TG associated 
loci are causally associated with CAD. The GLGC recently identified 6 TG-associated 
loci associated with CAD at a stringent threshold of significance (P<0.001), including 
APOA5, LPL, TRIB1, CILP2, NAT2, and IRS1, while 13 TG-associated loci were 
associated with CAD at a more modest threshold (P<0.05). Interestingly, among the 13 
TG- and CAD-associated loci, 7 were independently associated with TG, while 6 were 
jointly associated with either HDL or LDL cholesterol (Table 5.3). By comparison, 
among the 14 LDL- and CAD-associated loci, 9 were independently associated with 
LDL, while 5 were jointly associated with either HDL or TG. The fact that there are 
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Table 5.3. Comparison of lipid-associated loci that increase susceptibility to CAD. 
Traits P<0.001 0.001<P<0.05 P<0.05 
LDL only 5 4 9 
HDL only 1 3 4 
TG only 1 5 6 
LDL + HDL 1 0 1 
LDL + TG 1 0 1 
HDL + TG 2 1 3 
LDL + HDL + TG 2 1 3 
Total P<0.001 0.001<P<0.05 P<0.05 
LDL 9 5 14 
HDL 6 5 11 
TG 6 7 13 
HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglycerides. Associations between TG-
associated loci are shown in Table 1. Results were obtained from Teslovich et al .These tallies include 1 
LDL-associated locus (BRAP; P=1X10
-6
) and 1 TG-associated locus (PINX1; P=0.02) that have apparently 
paradoxical effects on CAD risk, where lipid raising alleles do not correspond to increased CAD risk. 
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 comparable numbers of loci for TG and LDL that are independently associated with CAD 
appears to challenge the widely propagated idea that LDL-associated loci are more 
consistently associated with CAD than are TG-associated loci (or HDL-associated loci 
for that matter). As additional GWAS data accrue, it will become necessary to consider 
and evaluate lipid-associated loci at more modest levels of significance (0.05<P<0.001).  
 
5.4.4. Pharmacological interventions 
The ultimate goal of any GWAS is identification of novel genomic elements involved in 
biological pathways that mediate disease susceptibility. Genes associated with either 
disease risk factors or endpoints represent novel targets for pharmacological 
interventions. Most importantly, genetic variation that reduces gene function yet has a 
favourable effect on metabolism will be most useful for inhibition using small molecule 
inhibitors or siRNA-based therapeutics. For instance, the study of patients with 
monogenic hypoTG syndromes has helped to develop pharmacological inhibitors of key 
genes and gene products in TG metabolism, such as lomitapide, which is a small 
molecule inhibitor of MTP (Samaha et al., 2008), and mipomersen as an RNA 
interference-based inhibitor of APOB (Raal et al., 2010). Future molecular inhibition of 
genes such as ANGPTL3 or APOC3 may also reduce circulating TG-rich lipoproteins, 
potentially without unwanted effects such as hepatosteatosis (Musunuru et al., 2010a). 
 
5.5. Conclusions 
Until recently, the genetic architecture of HTG was poorly understood. Mendelian HTG 
was associated with rare homozygous loss-of-function mutation in LPL, APOC2, APOA5, 
LMF1, and GPIHBP1; whereas polygenic HTG had only confirmed associations with 
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 common functional variants in APOA5 and LPL. Accordingly, we sought to 
comprehensively elucidate the genetic determinants of polygenic HTG using modern 
high-throughput genomic technologies including GWAS and high-throughput 
resequencing. Today, the genetic architecture of HTG is among complex disease traits 
most thoroughly characterized at the genetic level, including common and rare variants in 
>30 genes; a significant portion of this characterization has been conducted by our 
laboratory. We have 1) established the importance of common and rare variation in HTG 
susceptibility; 2) identified novel genes involved in HTG susceptibility; and 3) proposed 
a model for HTG susceptibility and phenotypic heterogeneity. Together with our 
understanding of Mendelian disorder of extreme high and low plasma TG, we have 
greatly contributed to a working model for the allelic and phenotypic spectrum of plasma 
TG. However, these analyses have only explained a modest portion of variation in plasma 
TG concentration. Future analyses including fine-mapping, resequencing, functional 
characterization of genes and variants, and higher order gene-gene and gene-environment 
interactions are necessary to fully explain the variation in plasma TG concentration and 
polygenic HTG diagnoses. Ultimately, elucidation of remaining determinants of HTG 
will serve to identify genes and pathways that could be targeted for pharmacological 
modulation in the hopes of lowering plasma TG concentration and improving CVD risk 
in HTG patients. 
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